3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

FLORENCE, ITALY
14 - 18 APRIL 2012

This meeting is jointly sponsored by the Vanderbilt University School of Medicine and the Schizophrenia International Research Society.
Dear Attendees,

It is our great pleasure to welcome you to the 3rd Biennial Schizophrenia International Research Society (SIRS) Conference. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists internationally. We sincerely appreciate your interest in the Society and in our conference. The second congress in 2010 was a major success for the field attracting more than 1500 attendees from 53 countries. We anticipate an even higher attendance at this congress with most of the best investigators in the world in attendance.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society strives to facilitate international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia. In addition to the Biennial Congress, the Society hosted the first regional meeting in São Paulo, Brazil in August of 2011. The meeting was a great success with over 150 presenters and 400 attendees.

Under the outstanding leadership of Program Committee Chair Jim van Os and Co-Chair Dawn Velligan, we have an exciting scientific program planned for the 3rd Biennial Conference. The Program Committee selected thirty-five outstanding symposia session in addition to seven evening workshops out of 92 submissions. Special sessions including the Family Forum, Italian Symposium and the Basic Science session have been added to the conference schedule. The Program Committee also selected forty-eight superior oral presentations from more than 500 abstracts submitted. Plan to visit the poster sessions during lunch on Sunday, Monday and Tuesday.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy the beautiful city of Florence and its rich history.

Sincerely,

The Organizers
Robin M. Murray, M.D., President
John M. Kane, M.D., President-Elect
Lynn E. DeLisi, M.D., Secretary
René Kahn, M.D., Ph.D., Treasurer
Wolfgang Fleischhacker, Meeting Liaison Chair
Jim van Os, Program Committee Chair
Dawn Velligan, Program Committee Co-Chair
## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Information</td>
<td>6</td>
</tr>
<tr>
<td>Saturday, 14 April</td>
<td>18</td>
</tr>
<tr>
<td>Sunday, 15 April</td>
<td>22</td>
</tr>
<tr>
<td>Monday, 16 April</td>
<td>33</td>
</tr>
<tr>
<td>Tuesday, 17 April</td>
<td>42</td>
</tr>
<tr>
<td>Wednesday, 18 April</td>
<td>54</td>
</tr>
<tr>
<td>Sunday Posters</td>
<td>60</td>
</tr>
<tr>
<td>Monday Posters</td>
<td>82</td>
</tr>
<tr>
<td>Tuesday Posters</td>
<td>104</td>
</tr>
<tr>
<td>Index of Presenters and Authors</td>
<td>126</td>
</tr>
</tbody>
</table>
Acknowledgements

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2011 - 2012 Supporting Corporations.

Platinum

Lilly

Janssen

Otsuka

Silver

Pfizer

Additional Supporters

Hoffman - Intra-cellular Therapies
La Roche

Lundbeck

Sunovion

Hoffman - Intra-cellular Therapies
La Roche

Lundbeck

Sunovion

The Sponsors express appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

AstraZeneca

Eli Lilly & Company

The Junior Travel Award Fellowship Program is sponsored by an R13 grant from the U.S. National Institute of Mental Health to Harvard Medical School (Lynn DeLisi, PI) (Grant ED: R13MH082446).
Schizophrenia International Research Society Officers, Board of Directors and International Advisory Committee

OFFICERS:
Robin M. Murray, President
John M. Kane, President-Elect
Lynn E. DeLisi, Secretary
René Kahn, Treasurer

BOARD OF DIRECTORS (2011 – 2012):
Jean Addington, Canada
Geraldo Busatto, Brazil
Mary Cannon, Ireland
Wolfgang Fleischhacker, Austria
Philip Harvey, USA
Shitij Kapur, UK
Jun Soo Kwon, Republic of Korea
John McGrath, Australia
Stephen Marder, USA
Xin Yu, China
Alison Yung, Australia

INCOMING OFFICERS:
John Kane, USA, President
René Kahn, Netherlands, President-Elect
Lynn E. DeLisi, USA, Secretary
Anthony Grace, USA, Treasurer
Robin M. Murray, UK, Past-President

INCOMING BOARD OF DIRECTORS:
Jean Addington, Canada
Celso Arango, Spain
Geraldo Busatto, Brazil
Jun Soo Kwon, Republic of Korea
Patrick McGorry, Australia
John McGrath, Australia
Stephen Marder, USA
Herbert Meltzer, USA
Xin Yu, China
Alison Yung, Australia

INTERNATIONAL ADVISORY COUNCIL:
Celso Arango, Spain
Francine Benes, USA
David Braff, USA
Mary Cannon, Ireland
William Carpenter, USA
David Castle, Australia
Eric Chen, China
Sioh Ann Chong, Singapore
Christina Dalman, Sweden
Michael Davidson, Israel
J.F.W. Deakin, UK
Robin Emsley, South Africa
Wolfgang Gaebel, Germany
Wagner Gattaz, Brazil
Birte Glenthoj, Denmark
Anthony Grace, USA
Michael Green, USA
Kyung Sue Hong, Korea
Matti Huttunen, Finland
Dan Javitt, USA
Eve Johnstone, UK
Richard Keefe, USA
Veronica Larach Walters, Chile
David Lewis, USA
Mario Maj, Italy
Patrick McGorry, Australia
Paulo Menezes, Brazil
Preben Bo Mortensen, Denmark
Dieter Naber, Germany
Christos Pantelis, Australia
Josef Peuskens, Belgium
Sibylle Schwab, Australia
Cynthia Shannon Weickert, Australia
Iris Sommer, Netherlands
Martha Shenton, USA
Masatoshi Takeda, Japan
Nori Takei, Japan
Carol Tamminga, USA
Rangaswamy Thara, India
Si Tianmei, China
Jim van Os, The Netherlands
Dawn Velligan
Antonio Vita, Italy
John Waddington, Ireland
Mark Weiser, Israel
Til Wykes, UK
2012 Meetings Committees

TRAVEL AWARD SELECTION COMMITTEE
Celso Arango, Spain
Lynn L. DeLisi, USA
Robin Emsley, South Africa
John McGrath, Australia
Dieter Naber, Germany
Sibylle Schwab, Australia
Cyndi Shannon Weickert, Australia

2012 PROGRAM COMMITTEE
Jean Addington, Canada
Köksal Alptekin, Turkey
Alessandro Bertolino, Italy
Geraldo Busatto, Brazil
Mary Cannon, Ireland
Miranda Chakos, USA
Eric Chen, Hong Kong
Siew Ann Chong, Singapore
David Cotter, Ireland
Deepak Cyril D’Souza, USA
Christina Dalman, Sweden
Paola Dazzan, UK
Robin Emsley, South Africa
Anthony Grace, USA
Michael Green, USA
Philip Harvey, USA
Hyung Sue Hong, Korea
Eileen Joyce, UK
Shitij Kapur, UK
Richard Keefe, USA
Tilo Kircher, Germany
Jun Soo Kwon, Korea
John McGrath, Australia
Craig Morgan, UK
Vera Morgan, Australia
Dieter Naber, Germany
Douglas Noordsy, USA
Patricio O’Donnell, USA
Gary Remington, Canada
Dan Rujescu, Germany
Sibylle Schwab, Germany
Martha Shenton, USA
Si Tianmei, China
Antonio Vita, Italy
John Waddington, Ireland

Thomas Weickert, Australia
Mark Weiser, Israel
Stephen Wood, Australia
Til Wykes, UK
Xin Yu, China

CONGRATULATIONS TO THE 2012 TRAVEL FELLOWS:
Bagrat Abazyan, USA
Brandon Abbs, USA
Rashmin Achalia, India
Adegoke Adelufosi, Nigeria
Ahmet Akteker, Turkey
Natalie Beveridge, Australia
Savita Bhakta, USA
Rachael Blackman, USA
Emre Bora, Australia
Min Soo Byun, South Korea
Maurice Cabanis, Germany
Ricardo Carrion, USA
Christina Castellani, Canada
Tze Jen Chow, Malaysia
Monika Dmitrzak-Weglarz, Poland
Charlotte Gayer-Anderson, UK
Felipe Gomes, Brazil
Kristen Haut, USA
Joshua Kantrowitz, USA
Taishiro Kishimoto, USA
Frankie Lee, Canada
Ashleigh Lin, UK
Lena Palaniyappan, UK
Weidan Pu, China
Meina Quan, USA
Maria Rubio USA
Sonia Ruiz de Azúa, Spain
Saddichha Sahoo, India
Gregory Strauss USA
Aleksandra Szcaepankiewicz, Poland
Andrew Thompson, Australia
Antonella Trotta, UK
Laura Tully, USA
Hiroyuki Uchida, Japan
Eva Velthorst, Netherlands
Jared Young, USA
Continuing Medical Education

ACCME:
The 3rd Biennial Schizophrenia International Research Society Conference is jointly sponsored by the Vanderbilt University School of Medicine and SIRS. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vanderbilt University Medical School of Medicine and the SIRS. Vanderbilt University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Vanderbilt University School of Medicine designates this live activity for a maximum of 34.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be a $50.00 USD charge for scientific registrants to obtain CME credits.

To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.schizophreniaconference.org.

Course Objectives:

After participating in this CME Activity, Clinicians should be able to describe and discuss:
• Strategies for determining an approach to manage patients with schizophrenia.
• The status of genetics findings and how they can be incorporated into strategies for managing patients with schizophrenia.
• The use of brain imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia.
• The implications of basic neuroscience findings for managing patients with schizophrenia.

After participating in this CME Activity, Researchers should be able to describe and discuss:
• Approaches to develop novel treatments for schizophrenia.
• Strategies for translating basic neuroscience into knowledge that can be used clinical practice.
• Differences in schizophrenia research across diverse cultures and geographic areas.
• Novel intervention studies that will promote the development of advanced knowledge about schizophrenia.
• Methods to advance the clinical application genetic research in schizophrenia.

Disclosures:
It is the policy of Vanderbilt University School of Medicine and Schizophrenia International Research Society to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. Disclosures for 2012 speakers, plenary, special session, symposia, workshop, oral presentations and poster presenters may be found online at www.schizophreniaconference.org. A copy of the disclosures will be available at the registration desk.
EACCME:
The 3rd Biennial Schizophrenia International Research Society Conference has been granted 24 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians should claim only the credits commensurate with the extent of their participation in the activity. To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.schizophreniaconference.org. There will be a $50.00 USD charge to obtain credit.

Italian Ministry of Health Credits:
Credits will be offered from the Italian Ministry of Health. For more information, please inquire at the Registration Desk in the Palazzo Entrance.

Conference Evaluation:
All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME or EACCME) credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation in the Computer Center or on-line at www.schizophreniaconference.org. All evaluations must be completed by 19 May, 2012.

Videotaping Sessions:
Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

General Information

Registration
Registration for the 3rd Biennial Schizophrenia International Research Society Conference is located at the Main Entrance of Firenze Fiera Congress Center, Piazza Adua.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 14 April</td>
<td>8:30 a.m. - 7:00 p.m.</td>
</tr>
<tr>
<td>Sunday, 15 April</td>
<td>8:00 a.m. - 6:30 p.m.</td>
</tr>
<tr>
<td>Monday, 16 April</td>
<td>8:00 a.m. - 6:30 p.m.</td>
</tr>
<tr>
<td>Tuesday, 17 April</td>
<td>8:00 a.m. - 6:30 p.m.</td>
</tr>
<tr>
<td>Wednesday, 18 April</td>
<td>8:00 a.m. - 4:00 p.m.</td>
</tr>
</tbody>
</table>

Registration Types:
Delegate: Scientific Attendee
Student: Full-time graduate students, medical students or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student’s immediate supervisor verifying his/her student status and relevant field will be required for registration.
Accompanying Guest: Non-scientific attendee who only attends social functions.

Accompanying Guest:
The €200 fee includes all lunches, coffee breaks and welcome reception.

Registration Timeframes:
Regular: Register August 2011 - 14 March 2012
Late: Register 15 March 2012 - onsite
Registration Fees:

<table>
<thead>
<tr>
<th>Category</th>
<th>Up to 14 March 2012</th>
<th>15 March or later</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIRS 2011 and 2012 Member</td>
<td>400.00€</td>
<td>450.00€</td>
</tr>
<tr>
<td>SIRS 2012 New Member</td>
<td>440.00€</td>
<td>490.00€</td>
</tr>
<tr>
<td>SIRS 2011 and 2012 Student Member</td>
<td>150.00€</td>
<td>190.00€</td>
</tr>
<tr>
<td>SIRS 2012 New Student Member</td>
<td>190.00€</td>
<td>240.00€</td>
</tr>
<tr>
<td>Non-Member Delegate</td>
<td>650.00€</td>
<td>700.00€</td>
</tr>
<tr>
<td>Non-Member Student</td>
<td>230.00€</td>
<td>280.00€</td>
</tr>
<tr>
<td>Accompanying Guest</td>
<td>200.00€</td>
<td>200.00€</td>
</tr>
</tbody>
</table>

Abstracts:

Abstracts for all presentations are available online at www.schizophreniaconference.org. Abstracts will be published electronically by Schizophrenia Research and will be available as an electronic flipbook and as a PDF document.

Awards

The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society’s first Honorific Award Winners.

OUTSTANDING BASIC RESEARCH:

John Waddington is Professor of Neuroscience in Molecular & Cellular Therapeutics at the Royal College of Surgeons in Ireland, Dublin. He graduated in Natural Sciences from the University of Cambridge in 1974, where he was enthused for our field by working with Trevor Robbins & Susan Iversen. He received his Ph.D. in Psychopharmacology from the University of London in 1981 for work undertaken with Tim Crow in the Division of Psychiatry, MRC Clinical Research Centre, Northwick Park Hospital, and was awarded DSc in Neuroscience from the same university in 1991. Over a 30-year career, his teams have devoted themselves to basic and clinical research relating to schizophrenia during which they have published more than 400 articles, chapters and books, including articles in Nature, Science, PNAS, Lancet and BMJ. He has been a global ambassador for our field delivering more than 370 invited lectures that include the John Cade Lecture at the University of Melbourne and as Visiting Professor at Nihon University, Tokyo. He was elected to the Royal Irish Academy in 2003 and received the CINP-Lilly Neuroscience Basic Research Award in 2004. He has mentored numerous graduate students, post-docs and clinical fellows, many of whom have evolved to independent standing. Over the past several years, his group has been to the fore in studying mice mutant for genes associated with risk for schizophrenia. In particular, he is currently playing a leading role in the study of gene × environment interactions using mutant mice subjected to a variety of relevant biological and psychosocial insults over their developmental trajectory these studies now extend to the critical issue of identifying and characterizing gene × gene interactions. He has involved himself consistently in additional academic and professional responsibilities to support and advance our field: inter alia, he serves on the Editorial Boards of both SIRS-affiliated journals, Schizophrenia Bulletin and Schizophrenia Research; he...
OUTSTANDING CLINICAL/COMMUNITY RESEARCH

Philip D. Harvey, Ph.D. is a professor of Psychiatry at the University of Miami Miller School of Medicine. He was formerly professor of Psychiatry at Emory University School of Medicine and Mt. Sinai School of Medicine and Chief Psychologist at Mt. Sinai Hospital. Dr. Harvey received his Ph.D. in Clinical Psychology from SUNY at Stony Brook in 1982. Dr. Harvey is the author of over 800 scientific papers and abstracts and he has written over 50 book chapters. He is a widely cited author whose work has been cited more than 500 times per year for the past decade, with over 1500 citations of his work in 2011 alone. Dr. Harvey has given more than 1,800 presentations at scientific conferences and medical education events. He has edited 5 books and written 4 books on topics of psychological assessment, schizophrenia, and aging. He has received a number of awards and is a member of the American Psychological Association, the American College of Neuropsychopharmacology (Fellow), the International College of Neuropsychopharmacology (Fellow), the Society for Research in Psychopathology (Founding Member), the Society for Biological Psychiatry, International Neuropsychological Society, the Schizophrenia International Research Society (Founding Director), and the International Society for Clinical Trials and Methodology (Founding Member).

His research has focused for years on cognition and functioning and he has written extensively on aging in schizophrenia, functional impairments in severe mental illness, the cognitive effects of typical and atypical antipsychotics, as well as studying the effects of cognitive enhancing agents in various conditions, including schizophrenia, dementia, affective disorders, and traumatic brain injury. Dr. Harvey’s past research includes serving as a primary consultant on over 40 pharmacological treatment trials. He directs an annual conference on cognition that is an official satellite of the International Congress on Schizophrenia Research and the Schizophrenia International Research Society.

RISING STAR

Dr. Paolo Fusar Poli, Ph.D. is Senior Lecturer/Associate Professor at the Department of Psychosis Studies, Institute of Psychiatry, London and Consultant at the prodromal OASIS team, South London and Maudsley NHS Trust. Over the past few years he has developed a strong interest into the prodromal phases of psychosis and he has widely employed neuroimaging techniques to address functional, structural and neurochemical correlates of an enhanced clinical risk for the illness. He is particularly interested in the development of multimodal imaging approaches and in conducting large voxel-based meta-analyses in the field of early psychosis. To date, Dr. Fusar-Poli has published over than 150 PubMed papers.
**Scientific Sessions**

**TRAVEL FELLOW ORIENTATION**
Saturday, 14 April, 4:30 p.m. - 5:45 p.m.
Auditorium
Travel Awardees are required to attend.
Four presentations will be given at the Travel Fellow Orientation.

*Successful Manuscript Publication*
Lynn E. DeLisi

*Financial Conflict of Interest*
Stephen Marder

*Career Development and Grant Writing in the American System*
Robert McCarley

*Grant Writing in the European System*
Jim van Os

**KEYNOTE LECTURE**
Saturday, 14 April, 6:00 p.m. - 7:00 p.m.
Auditorium

Philip Campbell
Editor-in-Chief, Nature and the Nature Publishing Group

Dr. Philip Campbell is Editor-in-Chief of Nature and of the Nature Publishing Group. His areas of responsibility include the editorial content and management of Nature, and assuring the long-term quality of all Nature publications. He is based in London. There is a pressing need for continued funding in mental health research to drive new discoveries and find better treatments. Dr. Campbell will describe the processes involved in inaugurating a new major charity to fund mental health research, to be launched later this year. In order to develop sustainable funding in this area of research, a novel strategy is required. He will discuss the options and decision-making concerning a research funding strategy and the ‘proposition’ that can be responsibly offered to donors. These decisions revolve around the potential contributions of diverse disciplines, the tension between short- and long-term accomplishments, and the relevance of stigma. The combination of collaborative, synergistic effort and appropriate funding may pave the way to the development of new science in mental health research.
PLENARY SESSIONS
There will be four plenary sessions covering topics including new genetic advances, psychological and social treatments, models of immunology and experimental medicine and new pharmacologic treatments in the pipeline for schizophrenia.

Sunday, 15 April
Auditorium
8:30 a.m. - 12:00 p.m.  Psychological and Social Treatments Plenary Session
Chair: Dawn Velligan
Co-Chair: Shitij Kapur

Christos Pantelis
Neuroimaging and Cognitive Rehabilitation; A Hypothesis Based on the Evidence for Progressive Brain Changes in Schizophrenia

Steffen Moritz
Metacognitive Training in Schizophrenia Patients (MCT)

Douglas Turkington
Cognitive Behavior Therapy for Positive and Negative Symptoms

Michael Green
Social Cognition Schizophrenia: Rationale and Strategies for Training Intervention

Monday, 16 April
8:30 a.m. – 12:00 p.m.  Genetics Plenary Session
Chair: Jim van Os
Co-Chair: Lynn E. DeLisi

William Byerley
Genetics of Schizophrenia: Past Results and Future Approaches

Maria Karayiorgou
The Genetic Architecture of Schizophrenia: New Mutations and Emerging Paradigms

Robin M. Murray
Gene-Environment Interaction in Psychosis

Inez Myin-Germeys
Reactivity Phenotypes for Genetics Studies
Tuesday, 17 April
8:30 a.m. – 12:00 p.m.  Models from Immunology and Experimental Medicine Plenary Session
Chair: René Kahn
Co-Chair: Carol Tamminga

Preben Bo Mortensen
Epidemiology

Alan Brown
Prenatal Infection, Immune Function and Schizophrenia

Peter McGuffin
What Genetic Studies Tell us about the Involvement of the Immune System in Schizophrenia

Barbara Sperner-Unterweger
Can Affective Disorders and Schizophrenia be Differentiated on an Immunological Basis?

Wednesday, 18 April
8:30 a.m. – 12:00 p.m. New Treatments Plenary Session
Chair: Wolfgang Fleischhacker
Co-Chair: Donald Goff

Donald Goff
Difficulties with Translational Research

John Kane
Methodologic Challenges in Clinical Trials in Schizophrenia

Colleagues in industry will provide brief updates on promising new compounds and strategic approaches to drug development.
Presentation from Pharma:

- Anjana Bose, Forest Pharmaceutical and Gedeon Richter
- Rob Conley, Eli Lilly and Company
- Gerhard Gross, Abbott
- David Hosford, Targacept
- Ron Marcus, Bristol Myers-Squibb
- Daniel Umbricht, Roche
- Kim Vanover, Intracellular Therapies
SPECIAL SESSIONS
Special sessions have been included in the conference program:

- **The Italian Research Experience Concerning First Episode Psychotic Patients**
  Saturday, 14 April, 10:00 a.m. – 12:30 p.m., Sala Verde
  Chair: Paul Fearon, Co-Chair: Alessandro Bertolino
  Simultaneous Translation Provided

- **The Family Forum**
  Saturday, 14 April, 2:00 p.m. – 4:30 p.m., Sala Verde
  Chair: Lynn E. DeLisi, Co-Chair: Alice Mulè
  Simultaneous Translation Provided

- **Basic Science Session**
  Sunday, 15 April, 4:15 p.m. – 6:15 p.m., Palazzo Affari 1st Floor
  Chair: John Waddington

SYMPOSIA SESSIONS
The title and location of each symposium is indicated in the program. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session. Symposia are scheduled:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
</table>
| Sunday, 15 April | 2:00 p.m. – 4:00 p.m.  
               | 4:15 p.m. – 6:15 p.m.  |
| Monday, 16 April | 2:00 p.m. – 4:00 p.m.  
                | 4:15 p.m. – 6:15 p.m.  |
| Tuesday, 17 April | 4:15 p.m. – 6:15 p.m.   |
| Wednesday, 18 April | 1:30 p.m. – 3:30 p.m. |

WORKSHOPS
Seven workshops have been scheduled on Sunday and Tuesday evening. The title and location of each workshop is indicated in the program. The presentations within each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presentation within each workshop. Workshops are scheduled:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 15 April</td>
<td>6:30 p.m. – 8:30 p.m.</td>
</tr>
<tr>
<td>Tuesday, 17 April</td>
<td>6:30 p.m. – 8:30 p.m.</td>
</tr>
</tbody>
</table>
ORAL PRESENTATIONS
Six concurrent oral presentation sessions are scheduled on Tuesday, 17 April from 2:00 p.m. – 4:00 p.m. Within the concurrent sessions, there are 8 individual presentations. Oral sessions scheduled:

- **Genetics and Environment**
  Co-Chairs: John McGrath and Dan Rujescu
  Location: Palazzo Affari, 2nd Floor

- **Neuroimaging**
  Co-Chairs: Paola Dazzan and Jun Soo Kwon
  Location: Palazzo Affari, Ground Floor

- **Neuropathology and Electrophysiology**
  Co-Chairs: Anthony Grace and John Waddington
  Location: Palazzo Affari, Lower Level

- **Neuropsychology and Development**
  Co-Chairs: Eileen Joyce and Richard Keefe
  Location: Sala Verde

- **Psychosocial and Comorbidities**
  Co-Chairs: Michael Green and Til Wykes
  Location: Palazzo Affari, 1st Floor

- **Treatments**
  Co-Chairs: Jean Addington and Robin Emsley
  Location: Auditorium

POSTERS
Three poster sessions have been scheduled. Presenters should put their poster up by 9:30 a.m. and remove the poster by 5:00 p.m. on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in the Cavaniglia located across the street in the Fortezza de Basso. Lunch will be served each day with the poster session. Poster viewing will be open until 5:00 p.m.

<table>
<thead>
<tr>
<th>Date</th>
<th>Poster Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 15 April</td>
<td>Poster Session I</td>
<td>12:00 p.m. – 2:00 p.m.</td>
</tr>
<tr>
<td>Monday, 16 April</td>
<td>Poster Session II</td>
<td>12:00 p.m. – 2:00 p.m.</td>
</tr>
<tr>
<td>Tuesday, 17 April</td>
<td>Poster Session III</td>
<td>12:00 p.m. – 2:00 p.m.</td>
</tr>
</tbody>
</table>
COMPUTER ACCESS
Complimentary wireless internet access is available in the conference center. To access the wireless internet, input “SIRS2012” as the username and “Florence” as the password. Conference attendees may also use the Computer Center located in Limonaia.

The Computer Center is provided this year for the convenience of meeting attendees who wish not to bring a laptop. Computers and printers will be available in the Limonaia for the following: email, internet access and meeting evaluation.

The Computer Center will be open the following hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 14 April</td>
<td>9:00 a.m. – 7:00 p.m.</td>
</tr>
<tr>
<td>Sunday, 15 April</td>
<td>7:30 a.m. – 6:30 p.m.</td>
</tr>
<tr>
<td>Monday, 16 April</td>
<td>7:30 a.m. – 6:30 p.m.</td>
</tr>
<tr>
<td>Tuesday, 17 April</td>
<td>7:30 a.m. – 6:30 p.m.</td>
</tr>
<tr>
<td>Wednesday, 18 April</td>
<td>7:30 a.m. – 4:30 p.m.</td>
</tr>
</tbody>
</table>

SPEAKER READY ROOM
A speaker ready room is available in Sala 103 in the Palazzo Congressi. All presenters are required to come to the speaker ready room to upload your presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 14 April</td>
<td>8:00 a.m. – 7:00 p.m.</td>
</tr>
<tr>
<td>Sunday, 15 April</td>
<td>7:30 a.m. – 7:00 p.m.</td>
</tr>
<tr>
<td>Monday, 16 April</td>
<td>7:30 a.m. – 7:00 p.m.</td>
</tr>
<tr>
<td>Tuesday, 17 April</td>
<td>7:30 a.m. – 7:00 p.m.</td>
</tr>
<tr>
<td>Wednesday, 18 April</td>
<td>7:30 a.m. – 3:30 p.m.</td>
</tr>
</tbody>
</table>
REFRESHMENT BREAKS
Coffee and light pastries are available Sunday - Wednesday at 8:00 a.m. The morning break will be located in the Passi Perduti, located outside the Auditorium. Afternoon breaks will be available Saturday - Wednesday outside the Palazzo Affari meeting rooms, the Auditorium and the Sala Verde.

LUNCHEONS
Buffet lunch will be served Sunday – Tuesday from 12:00 p.m. – 2:00 p.m. in the Cavaniglia during the poster sessions. Buffet lunch will be served on Wednesday from 12:00 p.m. – 1:30 p.m. in the Passi Perduti, located outside the Auditorium.
Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia Pavilion. This is a short 3 to 5 minute walk from the Palazzo de Congressi.

Concurrent Symposia, Oral Presentations and Special Sessions will be held on the Lower Floor, Ground Floor, First Floor, Second Floor of the Palazzo degli Affari.

The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.
Keynote, Plenary Sessions and some Special Sessions, Symposia and Oral Presentations will be held in the Auditorium.

The Speaker Ready Room (Sala 103) and other small meeting rooms for journal meetings and committee meetings will be in the Villa Vittoria Building on the 1st Floor. The Villa Vittoria building is connected to the Auditorium. The Sala Verde room is on the 2nd floor of the Villa Vittoria building. The Italian Symposia Session, Family Forum, Symposia and Oral Presentations will be held in the Sala Verde.
<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Sala Verde</th>
<th>Palazzo Entrance</th>
<th>Sala 103</th>
<th>Limonaia</th>
<th>Palaffari Lawn</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00</td>
<td><strong>Keynote Special Session</strong></td>
<td>9:30-10:00</td>
<td>8:30-7:00</td>
<td>8:00-7:00</td>
<td>9:00-7:00</td>
<td>7:00-9:00</td>
</tr>
<tr>
<td>8:00-9:00</td>
<td><strong>Speaker Ready</strong></td>
<td>10:00-12:30</td>
<td></td>
<td><strong>Registration</strong></td>
<td><strong>Computer Center</strong></td>
<td></td>
</tr>
<tr>
<td>9:00-10:00</td>
<td><strong>Coffee Break</strong></td>
<td>The Italian Research Experience Concerning First Episode Psychotic Patients</td>
<td></td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-11:00</td>
<td></td>
<td></td>
<td></td>
<td><strong>Family Forum</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00-12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-1:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00-2:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00-3:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00-4:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00-5:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00-6:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00-7:00</td>
<td></td>
<td></td>
<td></td>
<td>Workshop <strong>Travel Award</strong></td>
<td><strong>Keynote Lecture</strong></td>
<td></td>
</tr>
<tr>
<td>7:00-8:00</td>
<td><strong>Opening Night Reception</strong></td>
<td>4:30-5:45</td>
<td></td>
<td><strong>Travel Award</strong></td>
<td><strong>Keynote Lecture</strong></td>
<td></td>
</tr>
<tr>
<td>8:00-9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- **Keynote**
- **Special Session**
- **Speaker Ready**
- **Registration**
- **Computer Center**
- **Opening Night Reception**
**Saturday, 14 April, Detailed Schedule of Events**

**Registration**
Palazzo Entrance

8:30 AM - 7:00 PM

**Coffee Available**
Sala Verde

9:30 AM - 12:30 PM

---

**Scientific Sessions**

**SPECIAL SESSION - The Italian Research Experience Concerning First Episode Psychotic Patients**
Sala Verde
Chair: Paul Fearon
Co-Chair: Alessandro Bertolino

Abstract: This symposium will pull together the Italian research experiences on patients with their first episode of psychosis. Dr. Alice Mulè will present her preliminary data on the incidence of psychotic disorders in Palermo, the main city of Sicily, discussing the main incidence differences found compared to those in other European countries. Dr. Sarah Tosato will discuss her findings from the Psychosis Incident Cohort Outcome Study – PICOS-Veneto focusing on social disability and needs for care in patients at their first episode of psychosis according to gender. Dr. Ilaria Tarricone will discuss how migration can impact on psychosis onset. Dr. Marta Di Forti will report her findings on the influence of cannabis consumption on patients affected by a first episode of psychosis.

*Introduction*
Robin M. Murray

*Risk Factors for Psychosis in Migrants in Bologna*
Ilaria Tarricone

*The Influence of Gender on Clinical and Social Characteristics of Patients at Psychosis Onset: A Report from the Psychosis Incident Cohort Outcome Study (PICOS)-Veneto.*
Sarah Tosato

*Incidence of Psychotic Disorders in Palermo: Preliminary Results*
Alice Mulè

*Are Cannabis Users Different from other First Episode Psychotics?*
Marta Di Forti

**Discussant**
Antonio Vita

1:30 PM - 4:30 PM

**Coffee Available**
Sala Verde
Abstract: There often exists a large gap between what researchers know about the illness, schizophrenia, and what patients and their families experience during and by the consequences of this chronic disease. One purpose of the Schizophrenia International Research Society is to foster better communication between researchers and consumers and facilitate the dissemination of knowledge about schizophrenia, both to clinicians who treat it and to individuals who have the disease. This forum will bring together researchers with the families of people who have schizophrenia. Researchers will be present to communicate current knowledge about:

- What factors are relevant to developing schizophrenia
- Advances in early detection and attenuation of its chronic course
- What role genes play in its development
- What latest new treatments can be brought to the clinic

Speakers will include Sir Professor Robin Murray, from London, UK who will give an update on how far we have currently advanced in research; Professor Ilaria Taricone, from Bologna, Italy, who will speak on the role of families in facilitating recovery of their affected relatives; Professor John Kane who will speak on new treatments, and Professor Emmanuelle Peters who will specifically speak on Cognitive Therapy. This, in turn, will be followed by Elyn Saks, someone who has suffered and recovered from the disease, who will give a patient’s perspective. Dr. Muggia will specifically address the Italian family and patient perspective. A panel of other researchers and family members will bring together the audience and speakers to discuss the major current issues and obstacles that exist and the ways in which they can be approached.
SPECIAL SESSION – Travel Fellow Orientation 4:30 PM - 5:45 PM
Auditorium
Chair: Lynn E. DeLisi

The Travel Fellow Orientation has been organized for 2012 Travel Awardees and their mentors, but is open to all junior investigators attending the SIRS Biennial Conference.

Successful Manuscript Publication
Lynn E. DeLisi

Financial Conflict of Interest
Stephen Marder

Career Development and Grant Writing in the American Grant System
Robert McCarley

Grant Writing in the European System
Jim van Os

KEYNOTE LECTURE - Mental Health Research: New Charity, New Strategy, New Science
Auditorium
Philip Campbell, Editor-in-Chief, Nature Magazine and Nature Publishing Group

There is a pressing need for continued funding in mental health research to drive new discoveries and find better treatments. Dr. Campbell will describe the processes involved in inaugurating a new major charity to fund mental health research, to be launched later this year. In order to develop sustainable funding in this area of research, a novel strategy is required. He will discuss the options and decision-making concerning a research funding strategy and the ‘proposition’ that we can responsibly offer to donors. These decisions revolve around the potential contributions of diverse disciplines, the tension between short- and long-term accomplishments, and the relevance of stigma. The combination of collaborative, synergistic effort and appropriate funding may pave the way to the development of new science in mental health research.

OPENING RECEPTION 7:00 PM - 9:00 PM
Palazzo Affari Lawn, Passi Perduti in case of inclement weather
Sunday, 15 April, Detailed Schedule of Events

Registration
Palazzo Entrance
8:00 AM - 6:30 PM

Coffee/Pastries
Passi Perduti – Adjacent to the Auditorium
8:00 AM - 11:00 AM

Scientific Sessions

PLENARY SESSION - Psychological and Social Treatments
Auditorium
Chair: Dawn Velligan
Co-Chair: Shitij Kapur
8:30 AM - 12:00 PM

Abstract: While it is suggested that cognitive deficits are stable throughout all stages of the schizophrenia, the evidence for progressive brain changes identified with neuroimaging would suggest that function might also be affected. If there is evidence of cognitive change with illness progression, this could influence the approach taken to managing these deficits. To date few studies have examined neuroimaging changes associated with cognitive remediation strategies. These studies provide some evidence for positive effects on brain structure and function (e.g. Wykes et al, 2002; Eack et al, 2010; Bor et al, 2011). However, studies have not compared strategies to remediate these deficits versus cognitive adaptation approaches. I will present findings regarding progressive brain structural changes in the early course of the illness involving medial temporal and frontal regions, and relate these findings to results from the Melbourne long-term follow-up studies demonstrating progressive deterioration in relevant neurocognitive domains (associative memory and set-shifting ability), while other domains such as spatial working memory are stable across illness stages (Pantelis et al, 2009). These findings are best understood when placed in the context of brain maturational trajectories for these abilities and may be differentially amenable to alternate intervention strategies (Pantelis et al, 2009a, 2009b). I will suggest that: (i) cognitive remediation approaches should target those abilities that have matured, are relatively unimpaired at psychosis onset, but which show later deterioration; (ii) cognitive adaptation (i.e. an approach that compensates for the deficits through environmental manipulation) (Velligan et al, 2009) would be more appropriate for those abilities that have never fully matured and are impaired at all illness stages. It is hypothesized that the former would have beneficial effects in minimizing or ameliorating progressive brain changes in schizophrenia. Bor, J., Brunelin, J., d’Amato, T., Costes, N., Saoud-Chagny, M. F., Saoud, M., & Poulet, E. (2011). How can cognitive remediation therapy modulate brain activations in schizophrenia? An fMRI study. Psychiatry Research, 192(3), 160-166. Eack, S. M., Hogarty, G. E., Cho, R. Y., Prasad, K. M., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2010). Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Archives of General Psychiatry, 67(7), 674-682. Pantelis, C., Wood, S. J., Proffitt, T. M., Testa, R., Mahony, K., Brewer, W. J., Buchanan, J. A., Velakoulis, D., & McGorry, P. D. (2009a). Attentional set-shifting ability in first-episode and established schizophrenia: Relationship to working memory. Schizophrenia Research, 112(1-3), 104-113. Pantelis, C., Yucel, M., Bora, E., Fornito, A., Testa, R., Brewer, W. J., Velakoulis, D., & Wood, S. J. (2009b). Neurobiological Markers of Illness Onset in Psychosis and Schizophrenia: The Search for a Moving Target. Neuropsychology Reviews, 19, 385-398. Velligan, D. I., Draper, M., Stutes, D., Maples, N., Mintz, J., Tai, S., & Turkington, D. (2009). Multimodal cognitive therapy: combining treatments that bypass cognitive deficits and deal with reasoning and appraisal biases. Schizophrenia Bulletin, 35(5), 884-893. Wykes, T., Brammer, M., Mellers, J., Bray, P., Reeder, C., Williams, C., & Corner, J. (2002). Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. The British Journal of Psychiatry, 181, 144-152.
Presenters:

- Neuroimaging and Cognitive Rehabilitation; A Hypothesis Based on the Evidence for Progressive Brain Changes in Schizophrenia
  Christos Pantelis

- Metacognitive Training in Schizophrenia Patients (MCT)
  Steffen Moritz

- Cognitive Behavior Therapy for Positive and Negative Symptoms
  Douglas Turkington

- Social Cognition Schizophrenia: Rationale and Strategies for Training Intervention
  Michael Green

Travel Awarer and Mentor Lunch
Scherma, Fortezza da Basso

Poster Session #1 and Lunch
Cavaniglia
Buffet Lunch will be served daily at the poster sessions. Please see page 60 - 81 a complete listing of posters.

Coffee Available
Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

CONCURRENT SYMPOSIA

The Abnormal Life of the D2 Receptor in Schizophrenia
Auditorium
Chair: Anissa Abi-Dargham
Co-Chair: Anil Malhotra

  D2 and DA Release in Comorbid Dependence and Schizophrenia
  Anissa Abi-Dargham

  Striatal D2 Receptors regulate Dendritic Morphology of Striatal Neurons via Kir2 Channels
  Christoph Kellendonck

  The Association of DRD2 with Prefrontal Activity as Modulated by Pharmacologic D2 Receptor Stimulation and Genetic Variation of GSK3b
  Alessandro Bertolino

  Dopamine Receptor Genetic Variation and Antipsychotic Drug Response
  Anil Malhotra

Discussant: Robin M. Murray
Immune Response in Schizophrenia: Host-Environment Interactions 2:00 PM - 4:00 PM
Palazzo Affari, Lower Level
Chair: Nicola Cascella
Co-Chair: Akira Sawa

Is Maternal Influenza Specific to Schizophrenia among Offspring Outcomes?
Alan Brown

Antibodies to Retroviruses in Recent Onset Psychosis and Multi-Episode Schizophrenia
Faith Dickerson

DISC1 Is Involved in Innate Immune Response in the Brain
Michael Pletnikov

Microglia and the Complement Cascade: Shaping Neural Circuits in the Developing Brain
Dorothy Schafer

Increased Prevalence of Transglutaminase 6 Antibodies in Sera from Schizophrenia Patients
Nicola Cascella

Discussant: Akira Sawa

Convergent Evidence Linking Advanced Paternal Age and Neurodevelopmental Disorders 2:00 PM - 4:00 PM
Palazzo Affari, Ground Floor
Chair: John J. McGrath
Co-Chair: Dolores Malaspina

Advanced Paternal Age Contributes to a Specific Subtype of Schizophrenia
Dolores Malaspina

Advanced Paternal and Grandpaternal Age as a Risk Factor for Psychiatric Disorders
Christina M. Hultman

Increased De Novo Copy Number Variants in the Offspring of Older Males
John J. McGrath

Paternal Age Effect and Selfish Mutations
Anne Goriely

Discussant: Avi Reichenberg
Long Acting Injectable Antipsychotic Medications in Schizophrenia:
Do Recent Studies Change Our Understanding of Their Role in Our Treatment Armamentarium?
Palazzo Affari, 1st Floor
Chair: Nina R. Schooler
Co-Chair: John Kane

New Results Alter Balance of Evidence in Meta-analysis of Long-Acting Injectables vs. Oral Antipsychotics in Schizophrenia
Taishiro Kishimoto

An Open, Randomized, Controlled Comparison of Long-acting Injectable Risperidone vs. Oral Olanzapine in Schizophrenia & Schizoaffective Disorder
Nicholas A. Keks

Relapse Prevention with Risperidone Long-Acting Injectable vs. Oral Quetiapine. Results of an Open-label RCT
Wolfgang Gaebel

PROACTIVE: Initial Results of an RCT Comparing Long-Acting Injectable Risperidone to 2nd Generation Oral Antipsychotics
Nina R. Schooler

Discussant: Donald C. Goff

Hormonal Influences in Schizophrenia: Key in the Mechanism of Illness or an Illusory Correlation?
Palazzo Affari, 2nd Floor
Chair: Thomas W. Weickert
Co-Chair: Maarten van den Buuse

Oestrogens and Schizophrenia
Anita Reocher-Rossler

The Paradox of Testosterone Signaling in Males with Schizophrenia
Cynthia S. Weickert

Sex Differences and Role of Oestrogen and Testosterone in Animal Models of Schizophrenia: Interaction with NMDA Receptors
Maarten van den Buuse

Genetic and Molecular Mechanisms of Prosocial Neuropeptides in Human Brain – Implications for Schizophrenia Treatment
Andreas Meyer-Lindenberg

Discussant: Sven Mueller
Is Schizophrenia a Unique Illness of the Brain, or the More Severe Part of a Spectrum of Psychopathology?  
Sala Verde  
Chair: Michael Davidson  
Co-Chair: Mark Weiser

- Non-Specificity of Risk Factors for Schizophrenia: Population-Based Studies
  Mark Weiser

- Brain Changes in Schizophrenia and Bipolar Disorder: Is there a Genetic Overlap?
  René Kahn

- Similarities in the Gene and Protein Expression Substrates of Schizophrenia and Bipolar Disorder
  Vahram Haroutunian

- Schizophrenia and Bipolar Disorder Genetics: Overlapping and Distinguishing Features
  Michael O’Donovan

Discussant: Jim Van Os

Coffee Break  
4:00 PM - 4:15 PM
Passi Perduti – Adjacent to the Auditorium  
Palazzo Affari Foyers  
Sala Verde

CONCURRENT SYMPOSIA

Intervening in People At-Risk of Psychosis: What is the Evidence?  
4:15 PM - 6:15 PM
Auditorium  
Chair: Patrick D. McGorry  
Co-Chair: Andreas Bechdolf

- Early Detection and Intervention Evaluation for People At-Risk of Psychosis  
  Anthony P. Morrison

- The Results of a Specific CBT Intervention in Young Help-Seeking Patients with Social Decline and an Ultra-High Risk for Developing a First Episode of Psychosis  
  Mark Van der Gaag

- Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis: 12-Month Outcome  
  Patrick D. McGorry
Rationale and Baseline Characteristics of PREVENT: A Second Generation Intervention Trial in Subjects At-Risk (prodromal) of Developing First Episode Psychosis Evaluating Cognitive Behaviour Therapy, Aripiprazole and Placebo for the Prevention of Psychosis
Andreas Bechdolf

How Effective are Omega-3 Fatty Acids for the Treatment of the Psychosis Prodrome?
Paul G. Amminger

Discussant: Jim van Os

Progressive Changes in Brain Structure and Function in Psychosis 4:15 PM - 6:15 PM
Palazzo Affari, Lower Level
Chair: Philip K. McGuire
Co-Chair: Christos Pantelis

Changes in Brain Structure Before and After the Onset of Psychosis - Evidence from Meta-Analyses and a Proposed New Multi-Centre Longitudinal Study
Matthew J. Kempton

Neurochemical Abnormalities in Schizophrenia and Progressive Changes from the Prodrome to the Onset of the First Psychotic Episode
Oliver D. Howes

Progressive Structural and Functional Brain Changes in Individuals with an At-Risk Mental State of Psychosis
Stefan J. Borgwardt

Progressive Changes in Brain Structure in Schizophrenia – Clinical Outcome, Medication and Heritability
René S. Kahn

Discussant: Lynn E. DeLisi

Cellular Trafficking in Schizophrenia: Is It Important? 4:15 PM - 6:15 PM
Palazzo Affari, Ground Floor
Chair: David R. Cotter
Co-Chair: James Meador-Woodruff

Plastic Modulation of Neurotransmission by Endocytic Sorting of Synaptic Vesicle Proteins
Volker Haucke

Clathrin-Mediated-Endocytosis and Clathrin-Dependent Membrane and Protein Trafficking; Core Pathophysiological Processes in Schizophrenia and Bipolar Disorder?
David R. Cotter

Altered Intracellular Trafficking of NR1 Subunit in Schizophrenia
Chang-Gyu Hahn
Decreased S-Palmitoylation of Proteins as a Potential Mechanism for Abnormal Receptor Trafficking in Frontal Cortex in Schizophrenia
James Meador-Woodruff

Discussant: William G. Honer

Understanding the Path to Better Functioning in Schizophrenia
4:15 PM - 6:15 PM
Palazzo Affari, 2nd Floor
Chair: Stephen R. Marder
Co-Chair: Elyn R. Saks

High Achieving Individuals with Schizophrenia: Techniques Developed to Manage Symptoms
Elyn R. Saks

“Superphrenia”? The Epidemiological, Neuropsychological and Clinical Characteristics of Schizophrenia with Superior Intellectual Functioning
James MacCabe

Maximizing Successful Return to School or Work after an Initial Episode of Schizophrenia
Keith Nuechterlein

Predictors of Good Functional Outcome in Early Psychosis
Jean Addington

Discussant: Shôn Lewis

Psychosis – From Epidemiology to Mechanisms
4:15 PM - 6:15 PM
Sala Verde
Chair: Wim Veling
Co-Chair: Peter Jones

Neural Mechanisms Mediating Urbanicity and Migration Risk
Andreas Meyer-Lindenberg

Virtual Reality in Psychosis: Experiments with Social Risk Environments
Wim Veling

Psychotic Reactivity to Stress: A Combined PET – ESM Approach
Inez Myin-Germeys

Is the Epigenetic Machinery Involved in Mediating the Effects of Stress and Childhood Trauma on Negative Affect and Psychosis?
Bart Rutten

Discussant: John McGrath
SPECIAL SESSION

Basic Science Special Session
Palazzo Affari, 1st Floor
Chair: John Waddington

4:15 PM - 6:15 PM

The Psychobiology of Environmental Enrichment and ‘Brain Reserve’ in Genetic Mouse Models of Schizophrenia
Anthony Hannan

Bridging Epidemiology and Rodent Models: Maternal Inflammation and Psychobiology of Offspring
Urs Meyer

MRI as a Translational Tool in Mouse Models of Neurodevelopmental Disorder
Grainne McAlonan

The Enduring Challenge of Modeling the Negative Symptoms of Schizophrenia in Animals
Jared Young

Coffee Break
Palazzo Affari Foyers

6:15 PM - 6:30 PM

WORKSHOPS

How Early and Late Social Environment Shapes Risk and Onset of Psychotic Disorders
Palazzo Affari, Lower Level
Chair: Marta Di Forti
Co-Chair: Helen L. Fisher

6:30 PM - 8:30 PM

Effect of Childhood Abuse on Cognitive Function in First-Episode Psychosis Patients and Community Controls
Lucia Sideli

Prevalence of Bullying amongst First-Episode Psychosis Patients and Unaffected Controls
Antonella Trotta

Cannabis using First Episode Psychosis (FEP) have Normal Pre-morbid IQ
Laura Ferraro

Cannabis Use and Age of Onset in First Episode of Psychosis: a Gender Issue?
Fabio Allegri

Discussant: Ilaria Tarricone
**Homicide and Schizophrenia**
Palazzo Affari, Ground Floor  
Chair: Anthony W. Harris  
Co-Chair: Vaughan Carr

- **Homicide in First Episode Psychosis**  
  Olav B. Nielssen
- **Homicide in Schizophrenia and Total Homicide**  
  Matthew M. Large
- **Homicide after Discharge from Psychiatric Hospitals**  
  Seena Fazel
- **Homicide Recidivism in Schizophrenia**  
  Matthew M. Large
- **Stranger Homicide in Schizophrenia**  
  Olav B. Nielssen

**Discussant:** John McGrath

---

**Treatment Options for Refractory Positive and Negative Symptoms in Schizophrenia**
Palazzo Affari, 1st Floor  
Chair: Stefan Leucht  
Co-Chair: Georgios Petrides

- **Pharmacological Augmentation Strategies for Schizophrenia Patients with Insufficient Response to Clozapine**  
  Stefan Leucht
- **Cognitive Behavioural Therapy (CBT) for Psychosis - New Developments**  
  Iris Sommer
- **Possibilities and Impossibilities of TMS for the Treatment of Hallucinations**  
  Donald Goff
- **New Approaches with Glutamatergic Agents and Folate**  
  Elizabeth Kuipers
- **Electroconvulsive Therapy (ECT) for Medication Resistant Schizophrenia**  
  Georgios Petrides

**Discussant:** John Kane
Cannabis and Psychosis - The State of the Art  
6:30 PM - 8:30 PM
Palazzo Affari, 2nd Floor
Chair: Philip K. McGuire
Co-Chair: Jim van Os

Cannabis, CNS Rhythms & Positive Psychotic Symptoms  
Paul Morrison

The Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Brain Function in Man  
Sagnik Bhattacharyya

The Paradox of Cannabis Sativa: The Plant that can Induce Psychotic Symptoms and also Treat them  
Jose A. Crippa

A Twin Study on Abnormalities of Endocannabinoid Functioning in Schizophrenia and Bipolar Disorder  
F. Markus Leweke

Discussant: Shitij Kapur
## Monday, 16 April

### Auditorium
- **7:00 - 8:00** Coffee Break
- **8:00 - 10:00** Genetics Plenary: Genetic and Non-Genetic Factors Underlying Sensitivity to Cannabis-Induced Psychosis
- **10:00 - 11:00** Coffee Break
- **11:00 - 13:00** Schizophrenia: A Clinical Disorder being Shattered into Many Molecular Entities?
- **13:00 - 14:00** Coffee Break
- **14:00 - 16:00** Integrating Social and Biological Factors to Predict Early-Onset Psychoses

### Palazzo Affari, Ground Floor
- **8:00 - 10:00** SIRS Business Meeting and Awards Presentation
- **10:00 - 11:00** Coffee Break
- **11:00 - 13:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses
- **13:00 - 14:00** Coffee Break
- **14:00 - 16:00** Integrating Social and Biological Factors to Predict Early-Onset Psychoses

### Palazzo Affari, 1st Floor
- **8:00 - 10:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses
- **10:00 - 11:00** Coffee Break
- **11:00 - 13:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses
- **13:00 - 14:00** Coffee Break
- **14:00 - 16:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses

### Palazzo Affari, 2nd Floor
- **8:00 - 10:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses
- **10:00 - 11:00** Coffee Break
- **11:00 - 13:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses
- **13:00 - 14:00** Coffee Break
- **14:00 - 16:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses

### Sala Verde
- **8:00 - 10:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses
- **10:00 - 11:00** Coffee Break
- **11:00 - 13:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses
- **13:00 - 14:00** Coffee Break
- **14:00 - 16:00** Genetics Plenary: Integrating Social and Biological Factors to Predict Early-Onset Psychoses

### Legenda:
- **Keynote**
- **Special Session**
- **Speaker Ready**
- **Registration**
- **Computer Center**
- **Symposia**
- **Workshop**
- **Poster Session**
Schizophrenia: The Globalization of Research

Monday, 16 April, Detailed Schedule of Events

Registration
Palazzo Entrance 8:00 AM - 6:30 PM

Coffee/Pastries
Passi Perduti – Adjacent to the Auditorium 8:00 AM - 11:00 AM

Scientific Sessions

PLENARY SESSION - Genetics
Auditorium 8:30 AM - 12:00 PM
Chair: Jim van Os
Co-Chair: Lynn E. DeLisi

Abstract: Schizophrenia is a complex neuropsychiatric disorder that afflicts 1% of the world’s population. The global costs of illness are estimated to be over 1 trillion dollars per year. Family, twin and adoption studies conducted over the past half century indicate that hereditary factors account for at least 70% of susceptibility to illness. Genome wide association studies (GWAS) have provided compelling evidence that a handful of common variants underlie a few percent of the genetic inheritance. Another major dividend of GWAS has been the identification of rare susceptibility factors, so called copy number repeats (CNVs) that may explain an additional 2 to 3% of the genetic variance to illness. Most of the remaining heritability (~95%) may be explained by a large number of rare variants, potentially in hundreds to thousands of genes. Next generation sequencing studies are now underway to map additional loci predisposing to schizophrenia.

Panelists:
- Genetics of Schizophrenia: Past Results and Future Approaches
  William Byerley

- The Genetic Architecture of Schizophrenia: New Mutations and Emerging Paradigms
  Maria Karayiorgou

- Gene-Environment Interaction in Psychosis
  Robin M. Murray

- Reactivity Phenotypes for Genetics Studies
  Inez Myin-Germeys

Poster Session #2 and Lunch 12:00 PM - 2:00 PM
Cavaniglia
Buffet Lunch will be served daily at the poster sessions.
Please see page 82 - 103 for a complete listing of posters.

Coffee Available 1:45 PM - 2:15 PM
Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde
CONCURRENT SYMPOSIA

Genetic and Non-Genetic Factors Underlying Sensitivity to Cannabis-Induced Psychosis 2:00 PM - 4:00 PM
Auditorium
Chair: Robin M. Murray
Co-Chair: Deepak Cyril D’Souza

Cannabis and Psychosis: Is the Association Moderated by Environmental Risk Factors?
Rebecca Kuepper

Genetic Moderation of the Psychotomimetic and Amnestic Effects of Delta-9-Tetrahydrocannabinol in the Laboratory
Deepak Cyril D’Souza

The AKT1 (rs2494732) Genotype Moderates the Risk of Psychotic Disorders in Cannabis Users
Marta Di Forti

Combined Effects of COMT and AKT1 Moderate Risk for Cannabis-Induced Psychotic Disorder: Evidence from Two Large, Independent Samples
Ruud van Winkel

Discussant: Paul Morrison

Neural Network Changes in Schizophrenia: Evidence for Dysconnectivity in the Brain 2:00 PM - 4:00 PM
Palazzo Affari, Lower Level
Chair: Hilleke Hulshoff Pol
Co-Chair: Andreas Meyer-Lindenberg

The Human Connectome: A Complex Network
Olaf Sporns

Economical Network Models of the Connectome in Schizophrenia
Edward Bullmore

Imaging Connectomics and Schizophrenia
Alex Fornito

On Brain Networks and Cognition
Martijn Van den Heuvel

Discussant: Andreas Meyer-Lindenberg
Recent Directions in the Treatment of Early-Onset Psychoses

2:00 PM - 4:00 PM

Palazzo Affari, Ground Floor
Chair: Celso Arango
Co-Chair: Christoph Correll

One Year Follow-Up Longitudinal Study with a Large Sample of Antipsychotic-Naïve Children and Adolescents Exposed to Antipsychotics
Celso Arango

Efficacy and Safety of Antipsychotics in Early-Onset Schizophrenia: A Meta-Analysis of Randomized Controlled Trials
Christoph Correll

Safety and Tolerability of Different Antipsychotics and Use of Clozapine in Early Onset Schizophrenia
Sanjiv Kumra

Neuroplasticity-Based Cognitive Training in Ultra-High Risk Adolescents and Recent Onset Patients with Schizophrenia
Sophia Vinogradov

Discussant: Carmen Moreno

Risk Factors and Prevention of Psychosis: New NAPLS 2 Data

2:00 PM - 4:00 PM

Palazzo Affari, 1st Floor
Chair: Barbara A. Cornblatt
Co-Chair: Jean Addington

Altered Functional and Structural Brain Developmental Trajectories in Youth at Clinical Risk for Psychosis
Tyrone D. Cannon

Neuropsychological Abnormalities during Stimulus Processing in Youth at Clinical High Risk for Psychosis: An Interim Analysis of the NAPLS Data
Daniel Mathalon

Neuropsychology of the Prodrome to Psychosis in the NAPLS 2 Consortium: Relationship to Family History and Conversion to Psychosis
Larry J. Seidman

Clinical and Social Risk Factors and Conversion in Young People at Clinical High Risk for Psychosis
Jean Addington

Social and Role Functioning as Predictors of Psychosis and Disability
Barbara A. Cornblatt

Discussant: Stephan Ruhrmann
Dual Process Theory: Automatic and Controlled Processes and their Implications for Psychosocial Treatment Development  
Palazzo Affari, 2nd Floor  
Chair: Dawn I. Velligan  
Co-Chair: Til Wykes

**Automatic and Controlled Processes in Social Cognition Training**  
David Roberts

**Integrated Neurocognitive Therapy (INT): How does the Integration of Automatic and Controlled Approaches Work?**  
Daniel R. Mueller

**Cognitive Behavior Therapy for Positive and Negative Symptoms of Schizophrenia**  
Douglas Turkington

**Cognitive Adaptation Training: Targeted Use of Automatic and Controlled Processes to Improve Functional Outcomes**  
Dawn I. Velligan

**Discussant:** Morris Bell

---

Multimodal Neuroimaging of Prodromal Psychosis  
Sala Verde  
Chair: Paolo Fusar-Poli  
Co-Chair: Stefan Borgwardt

**The Relationship Between Structural, Functional and Effective Connectivity in Subjects of High Genetic Risk in Schizophrenia**  
Stephen Lawrie

**Cortical and Subcortical Function in People at High Clinical Risk of Psychosis: Multimodal Imaging Findings**  
Chris Chaddock

**Elucidating Multimodal Biomarkers of the At-Risk Mental State and the Prodromal Phase of Psychosis Using Pattern Recognition Methods**  
Nikos Koutsouleris

**Thalamic Glutamate Levels as a Predictor of Cortical Response During Executive Functioning in Subjects at High Risk for Psychosis**  
Paolo Fusar-Poli

**Different Duration of At-risk Mental State Associated with Structural and Neurofunctional Abnormalities - A Multimodal Imaging Study**  
Stefan Borgwardt

**Discussant:** Philip McGuire
Coffee Break
Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

CONCURRENT SYMPOSIA

Schizophrenia: A Clinical Disorder being Shattered into Many Molecular Entities?
Auditorium
Chair: Aiden Corvin
Co-Chair: David Porteous

Next Generation Sequencing of the DISC1 Locus in Major Mental Illness and Cognition
David Porteous

Investigating CNVs in Schizophrenia
Dan Rujescu

Family Studies of Cognitive Disorders
Dick McCombie

Exome Sequencing in Schizophrenia to Map Disease Variants, Genes and Networks
Shaun Purcell

Family Based Sequencing of Extended Pedigrees and Trios with Schizophrenia
Shane McCarthy

Discussant: Aiden Corvin

Do Schizophrenia and Bipolar Disorder Have Opposite Associations with Intelligence?
Palazzo Affari, Lower Level
Chair: James MacCabe
Co-Chair: Avi Reichenberg

Premorbid Intellectual Functioning and Social Adjustment and Risk of Developing Schizophrenia, Psychotic or Non-Psychotic Bipolar Disorder: A Population Longitudinal Study
Avi Reichenberg

Neurocognitive Functioning in Twins Discordant for Schizophrenia and Bipolar Disorder
Rachel G. Higier
Intelligence in Bipolar Disorder: Normal, Impaired or Enhanced?
James H. MacCabe

Creativity and Psychosis
Simon Kyaga

Discussant: Mary Cannon

Integrating Social and Biological Factors to Predict the Course and Outcome of Psychosis: Evidence from Two Large Epidemiological First Episode Psychosis Cohorts (AESOP and PICOS)
Palazzo Affari, Ground Floor
Chair: Paola Dazzan
Co-Chair: Mirella Ruggeri

The Impact of Cannabis Use on Age of Onset in First-Episode Psychotic Patients
Sarah Tosato

Predictors of Two-Year Outcomes in First-Episode Psychotic Patients Treated in Community Mental Health Services
Antonello Lasalvia

Biological Predictors of Clinical Outcome after the First Psychotic Episode: Initial Findings from AESOP-10
Paola Dazzan

Ethnicity and the Long-Term Course and Outcome of Psychosis: Initial Findings from AESOP-10
Craig Morgan

Discussant: Mirella Ruggeri

Role for Oxidative Stress, Inflammation, and Misfolded Protein in the Early Pathology of Schizophrenia
Palazzo Affari, 1st Floor
Chair: Akira Sawa
Co-Chair: Carsten Korth

Oxidative Stress and Inflammation in the Pathology of Schizophrenia: Data from Patient Neuron Biology and Brain Imaging
Akira Sawa

Characterization of Molecular Changes in CSF of Patients with Recent Onset Schizophrenia
Jennifer Coughlin

N-Acetylcysteine Normalizes Neurochemical Changes in the Glutathione-Deficient Schizophrenia Mouse Model during Development
Anita Kulak
Systematic Search for Misfolded Proteins in Schizophrenia
Carsten Korth

Misfolding of Risk Factors for Schizophrenia in Frontotemporal Lobar Degeneration
Motomasa Tanaka

**Discussant:** Nicola Cascella

**Personalizing Social and Cognitive Remediation –**
Is the Whole Greater Than the Sum of the Parts?
Palazzo Affari 2nd, Floor
Chair: Anthony W. F. Harris
Co-Chair: Pamela J. Marsh

*Bolstering Work: Potential Benefits of Cognitive and Social Cognitive Interventions to Employment Interventions for People with Early Psychosis*
Kelly Allott

*SoCog: A Novel Social Cognitive Training Program for People with Schizophrenia*
Pamela J. Marsh

*Personalized Skills-training Interventions Combined with Cognitive Remediation enhances Community Outcome*
Alice Medalia

*Implementing Cognitive Remediation Therapy Outside the Ivory Tower: Maintaining Momentum with a New Treatment in a Large Mental Health Service*
Francis Dark

*Social Cognitive Skills Training for Schizophrenia: Initial Efficacy and Ways to Augment the Effects*
William Horan

**Discussant:** Anthony W. F. Harris

**Characteristics of People At-Risk of Psychosis**
Sala Verde
Chair: Andreas Bechdolf
Co-Chair: Mark Weiser

*Adverse Life Events in Help-Seeking and Non-Help-Seeking UHR Individuals*
Lucia Valmaggia

*Basic Self-Disturbance Predicts Psychosis Onset in the Ultra High Risk for Psychosis (‘Prodromal’) Population*
Barnaby Nelson
Axis I and II Comorbidity in People At-Risk of Psychosis in the Early Initial Prodromal State: Correlations with Symptoms, Functioning and Transition to Psychosis
Andreas Bechdolf

The Relationship between Transition to Psychosis, and Functional Outcome in a Group at Ultra High Risk for Psychotic Disorder
Barnaby Nelson

Comparison of Clinical and Sociodemographic Risk Factors between Adult and Early Onset Psychosis
Marco Armando

Discussant: Mark Weiser

Coffee Available 6:00 PM - 6:30 PM
Passi Perduti – Adjacent to the Auditorium

SPECIAL SESSION

SIRS Business Meeting and Awards Presentation 6:15 PM - 7:15 PM
Auditorium
Tuesday, 17 April, Detailed Schedule of Events

Registration
Palazzo Entrance
8:00 AM - 6:30 PM

Coffee/Pastries
Passi Perduti – Adjacent to the Auditorium
8:00 AM - 11:00 AM

Committee Meeting
ICOSR Advisory Board Meeting – by Invitation
Sala 103
7:30 AM - 8:30 AM

Scientific Sessions

PLENARY SESSION- Models from Immunology and Experimental Medicine
8:30 AM - 12:00 PM
Auditorium
Chair: Carol Tamminga
Co-Chair: René Kahn

Abstract: Evidence is growing for the role of immunological factors in schizophrenia. This evidence is based on epidemiological and postmortem data, and covers treatment trials and basic research. This panel will address these various aspects and explain how immune processes may play a role in the pathogenesis of schizophrenia. Epidemiological data will be presented as well as data from trials, more fundamental studies and the panel will start with presentation on the enormous progress that has been made in multiple sclerosis. The model of MS could well present an excellent example of the kind of studies that need to be conducted in schizophrenia. All in all, this symposium will present an opportunity for researchers and clinical psychiatrists to get an update on the newest research on immune factors in schizophrenia thereby providing a new concept and offering hope for the development of new treatments in schizophrenia.

Panelists:

- Epidemiology
  Preben Bo Mortensen

- Prenatal Infection, Immune Function and Schizophrenia
  Alan Brown

- What Genetic Studies Tell us about the Involvement of the Immune System in Schizophrenia
  Peter McGuffin

- Can Affective Disorders and Schizophrenia be Differentiated on an Immunological Basis?
  Barbara Sperner-Unterweger
Poster Session #2 and Lunch 12:00 PM - 2:00 PM
Cavaniglia
Buffet Lunch will be served daily at the poster sessions.
Please see page 104 - 125 for a complete listing of posters.

Coffee Available 1:45 PM - 2:15 PM
Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

ORAL PRESENTATIONS 2:00 PM - 4:00 PM
Treatment
Auditorium
Co-Chairs: Jean Addington and Robin Emsley

2:00 PM  Multiple-treatments Meta-analysis on the Efficacy, Acceptability and Tolerability of 15 Antipsychotic Drugs in Schizophrenia
Stefan Leucht

2:15 PM  Cognitive Remediation Therapy (CRT) Impacts on Functional and Structural Connectivity in Schizophrenia: A Multimodal Imaging Study
Rafael Penadés

2:30 PM  Augmenting Social Skills Training with Cognitive Remediation in Schizophrenia
Matthew Kurtz

2:45 PM  Non-steroidal Anti-inflammatory Drugs in Schizophrenia: Ready for Practice or a Good Start? A Meta-analysis
Iris E. Sommer

3:00 PM  Predictors of Cognitive Improvement and Normalization Under Cognitive Remediation in Patients with Schizophrenia
Antonio Vita

3:15 PM  Treatment of Insight in Psychosis: A Meta-analysis
Marieke Pijnenborg

3:30 PM  Metformin for Treatment of Atypical Antipsychotic-Induced Weight Gain and Endocrinological Side Effects in Patients with First Episode Schizophrenia: Results from Randomized, Double blind, Placebo-Controlled Study
Ren-Rong Wu
3:45 PM  Effects of Benzodiazepine and Other Hypnotic Use on Efficacy Results in placebo Controlled Antipsychotic Trials: Lessons Learned from the NewMeds Repository of RCT Data from AstraZeneca, Janssen, Eli Lilly, Lundbeck, and Pfizer
Jonathan Rabinowitz

Neuropathology and Electrophysiology
Palazzo Affari, Lower Level
Co-Chairs: Anthony Grace and John Waddington

2:00 PM  Aberrant Prediction Error Signalling, Salience Attribution and Presynaptic Dopamine Synthesis in the Prodrome of Psychosis
Christopher A. Chaddock

2:15 PM  Shedding Light on the Molecular Basis for NMDAR Hypofunction in Schizophrenia
Vibeke S. Catts

2:30 PM  Dopamine and Schizophrenia. Do all Roads Lead to Dopamine or is the Start of the Journey? Evidence from Animal Models
Darryl W. Eyles

2:45 PM  Elucidating the Role of Aggregated,Cell-invasive DISC1
Verian Bader

3:00 PM  The Effects of Regular Long-term Cannabis Use on Auditory Mismatch Negativity (MMN)
Lisa-marie Greenwood

3:15 PM  Processing Information from Face and Voice in Schizophrenia
Margaret A. Niznikiewicz

3:30 PM  Startle Reactivity and Prepulse Inhibition in Subjects at Ultra High Risk for Psychosis: Correlation with Striatal D2/3 Receptor binding Following Dopamine Depletion
Mariken B. De Koning

3:45 PM Selective Remediation of Cognitive Deficits in Pharmacological and Neurodevelopmental Animal Models of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator
Francois Gastambide

Neuroimaging
Palazzo Affari, Ground Floor
Co-Chairs: Paola Dazzan and Jun Soo Kwon

2:00 PM  Repeated Observation of Abnormal Gyrification Localized to the Frontoinsular Cortex from Four Independent Samples with Schizophrenia
Lena Palaniyappan

2:15 PM  Decreased White Matter Integrity in Psychotic Disorder: Association with Childhood Trauma?
Machteld Marcelis
2:30 PM | Effects of Eight Weeks of Atypical Anti-psychotic Medication Treatment on Middle Frontal Thickness in Drug-Naïve First Episode Psychosis Patients  
Vina M. Goghari

2:45 PM | Free-Water Imaging Reveals a Global Inflammatory Effect and Local Axonal Degeneration in First Episode Schizophrenia  
Ofer Pasternak

3:00 PM | Biological Basis of Sensitivity to the Effects of cannabis on Psychosis: AKT1 and DAT1 Genotype Modulates the Effects of Delta-9-Tetrahydrocannabinol on Midbrain and Striatal Function  
Sagnik Bhattacharyya

3:15 PM | Alterations of the Brain Reward System in Antipsychotic Nāive Schizophrenia Patients Before and After Antipsychotic Treatment  
Mette Ø. Nielsen

3:30 PM | Alterations in Magnetoencephalographic Gamma Oscillatory Patterns during Resting-State in Patients with Childhood-Onset Schizophrenia, Non-Psychotic Siblings and Healthy Controls  
Nora S. Vyas

3:45 PM | Auditory Cortical Dysfunction as a Basis for Auditory Hallucinations  
Peter W. Woodruff

---

Psychosocial and Comorbidities  
Palazzo Affari, First Floor  
Co-Chairs: Michael Green and Til Wykes

2:00 PM | Cognitive Remediation and Competitive Employment: Differential Benefits for Schizophrenia Patients with Poor Community Function  
Morris D. Bell

2:15 PM | Specialized Addiction Treatment Versus Treatment as Usual for Patients with Cannabis Use Disorder and Psychosis – Results from the CapOpus Randomized, Parallel-group, Observer-blinded Clinical Trial  
Carsten R. Hjorthøj

2:30 PM | Computerized Functional Capacity Assessment in Schizophrenia: Evidence for Convergent Validity  
Philip D. Harvey

2:45 PM | Different Sensitivity to PCP-induced Schizophrenia-like Symptoms in Adult Female Rats Pre-exposed to Δ9-Tetrahydrocannabinol During Adolescence  
Erica Zamberletti
### 3:00 PM
Shining Light on Sleep-wake and Cortical Gamma Oscillations in Schizophrenia: The Role of Parvalbumin GABA Neurons
Robert W. McCarley

### 3:15 PM
Emotion Recognition in Schizophrenia: No Evidence for an Association with Social Functioning
Mayke Janssens

### 3:30 PM
Are Patients with Schizophrenia Happy?
Ofer Agid

### 3:45 PM
Violent Crimes in People with Schizophrenia
Nomi Werbeloff

---

### Genetics and Environment
Palazzo Affari, Second Floor
Co-Chairs: John McGrath and Dan Rujescu

#### 2:00 PM
Common Polygenic Variation Contributing to Schizophrenia Risk Explains Variation in Total Brain Volume
Afke Terwisscha van Scheltinga

#### 2:15 PM
Persistence of the Extended Psychosis Phenotype in Young People: Link Between Vulnerability and Clinical Need
Johanna T. W. Wigman

#### 2:30 PM
Complete Genome Sequence Based Genetic Analysis of Monozygotic Twins Discordant for Schizophrenia
Christina A. Castellani

#### 2:45 PM
Novel Data from a Large Population Prevalence Survey: A Unique Opportunity to Inform Psychosis Research Directions and Mental Health Reform
Vera A. Morgan

#### 3:00 PM
Absolute Risk of Suicide Following First Hospital Contact with Mental Disorder
Merete Nordentoft

#### 3:15 PM
Maternal Antibodies to Infectious Agents and Risk for Non-affective Psychoses in the Offspring – a Case-control Study Using Archived Blood Samples from Neonatal Life
Åsa Blomström

#### 3:30 PM
Structural Elucidation of DISC1 Pathway Proteins Using Electron Microscopy, Chemical Cross-linking and Mass Spectroscopy
Nicholas J. Bradshaw

#### 3:45 PM
Expression and Function of CHRNA7 and Its Partial Duplication, CHRFAM7A, in Schizophrenia
Sherry Leonard
Neuropsychology and Development
Sala Verde
Co-Chairs: Richard Keefe and Eileen Joyce

2:00 PM  Neurocognition in the Extended Psychosis Phenotype: Performance of a Community Sample of Adolescents with Psychotic Experiences on the MATRICS Neurocognitive Battery
Ian Kelleher

2:15 PM  Ontogeny of Cognitive Impairment Following Prenatal Infection
Juliet Richetto

2:30 PM  Interaction Between Childhood Adverse Events, BDNF Val66Met and Impaired Cognition in Patients with Schizophrenia and Affective Psychoses
Monica Aas

2:45 PM  Identifying Neurocognitive Impairments Prior to Psychosis: New Meta-Analyses of Neurocognition in the Psychosis Risk Syndrome and in Youth at Familial Risk for Schizophrenia
Larry J. Seidman

3:00 PM  The Relationship of Subclinical Psychotic Experiences to Internalising and Externalising Psychopathology in Childhood
Kristin R. Laurens

3:15 PM  Prospective Investigation of Cognitive and Affective Pathways from Childhood Trauma to Psychosis-like Experiences in a UK Birth Cohort
Helen L. Fisher

3:30 PM  Childhood and Adolescence Symptoms Predicting First Episode Psychosis in the General Population Based Northern Finland 1986 Birth Cohort
Pirjo H. Mäki

3:45 PM  Hearing and Speech Impairment at Age 4 and Risk of Later Non-affective Psychosis
Annica Fors

Coffee Break
Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

4:00 PM - 4:15 PM
CONCURRENT SYMPOSIA

Physical Exercise in Schizophrenia: Subjective, Symptomatic, Cardiometabolic and Neurobiologic Effects  
4:15 PM - 6:15 PM
Auditorium
Chair: Douglas L. Noordsy
Co-Chair: Frank G. Pajonk

- Effects of Exercise Therapy on Cardiovascular Fitness and the Metabolic Syndrome in Schizophrenia: A Randomized Clinical Trial
  Thomas W. Scheewe

- International Organization of Physical Therapy in Mental Health-Consensus on Physical Activity within Multidisciplinary Rehabilitation Programmes for Minimising Cardio-Metabolic Risk in Patients with Schizophrenia
  Davy Vancampfort

- Voluntary Wheel Running Rescues Cellular and Behavioral Schizophrenic-like Phenotype in Mice
  Susanne A. Wolf

- The Effects of Physical Exercise on Neural Plasticity and Clinical Symptoms in Schizophrenia
  Frank G. Pajonk

Discussant: Douglas L. Noordsy

What Explains the Schizophrenia Epidemic among Immigrants to Europe?  
4:15 PM - 6:15 PM
Palazzo Affari, Lower Level
Chair: Jean-Paul Selten
Co-Chair: Wim Veling

- Age at Migration and Psychotic-Like Experiences: Clues in Childhood to Explain the Increased Risk for Psychosis among Ethnic Minorities
  Wim Veling

- Psychotic Experiences in the General Population and Ethnicity: Findings from the SELCoH Study
  Craig Morgan

- Does a Recently Occurring Vitamin D Deficit Explain the Increased Risk for Schizophrenia and Other Psychoses in First-Generation Black Immigrants?
  Marie-Jose Dealberto
  The Epidemic is Explained in part by Selective Migration
  Carsten Pedersen

- Testing the Social Defeat Hypothesis in Another Minority: Are Psychotic Symptoms more Prevalent in the Non-Heterosexual Population?
  Jean-Paul Selten

Discussant: John McGrath
A Bright Future for Blood Biomarkers in Schizophrenia

4:15 PM - 6:15 PM
Palazzo Affari, Ground Floor
Chair: Cynthia Shannon Weickert
Co-Chair: Marquis P. Vawter

Brain Derived Neurotrophic Factor: Illustrative of a Putative Biomarker for Schizophrenia
Peter F. Buckley

Disease Biomarkers for Schizophrenia - From Laboratory to Patient Bedside
Sabine Bahn

Transcriptional Signatures from Blood and Brain
Marquis P. Vawter

MicroRNA Biomarkers of Schizophrenia in Blood
Murray Cairns

Discussant: Cyndi Shannon Weickert

The Effects of Psychopharmacologic Treatment on the Brain in Schizophrenia

4:15 PM - 6:15 PM
Palazzo Affari, 1st Floor
Chair: Lynn E. DeLisi
Co-Chair: Eva M. Meisenzahl

Effects of Antipsychotics on Functional and Structural Plasticity in the Human Brain
Andreas Meyer-Lindenberg

The Effects Psychopharmacologic Treatment on the Brain in Schizophrenia
Nancy C. Andreassen

Why Antipsychotics are Good for the Brain
Rene S. Kahn

Differential Effects of Neuroleptic Treatment and Clinical Improvement in First-Episode Schizophrenia
Eva M. Meisenzahl

Discussant: Robert McCarley

ICOSR Symposia: Systems Neuroscience Underlying Schizophrenia Models

4:15 PM - 6:15 PM
Palazzo Affari, 2nd Floor
Chair: Carol Tamminga
Co-Chair: Anthony Grace

New Insights into the Pathophysiology, Treatment and Prevention of Schizophrenia Gleaned from Animal Models
Anthony Grace
Alterations in Brain Structure, Function and Chemistry Prior to the Onset of Psychosis  
Philip McGuire

Analysis of CNVs Points to Specific Abnormalities of Synaptic Function in Schizophrenia  
Michael O’Donovan

The Role of the Hippocampal Subfield System in Schizophrenia Psychosis  
Carol Tamminga

Discussant: Charles Schulz

The NMDA Deficiency Hypothesis of Schizophrenia: 4:15 PM - 6:15 PM  
Emerging from Preclinical Concepts to Clinical Evidence  
Sala Verde  
Chair: Marc Laruelle  
Co-Chair: Shitij Kapur

Loss of Prefrontal Cortical Excitation-Inhibition Balance in a Developmental Animal Model of Schizophrenia  
Patricio O’Donnell

Glutamate Receptor Subtypes Mediating Synaptic Activation of Prefrontal Cortex Neurons  
Guillermo Gonzalez-Burgos

Abnormal Neural Synchrony in Schizophrenia: A Translational Perspective  
Peter J. Uhlhaas

A Translational Success Story: Facilitating NMDA Receptor Signaling with the Glycine Reuptake Inhibitor RG1678  
Daniela Alberati

Glutamate-dopamine Interactions in Schizophrenia: Insight from Molecular Imaging Studies  
Marc Laruelle

Discussant: Shitij Kapur

Coffee Break 6:15 PM - 6:30 PM  
Palazzo Affari Foyers

WORKSHOPS

Aerobic Exercise in Schizophrenia: Clinical Consequences and Neurobiological Effects of a Novel Treatment Strategy 6:30 PM - 8:30 PM  
Palazzo Affari, Ground Floor  
Chair: Peter G. Falkai
Effects of Indoor Cycling on Hippocampal Structure, Metabolism and Clinical Features of Schizophrenia
Peter G. Falkai

The Impacts of Yoga and Aerobic Exercise on Neuro-Cognition and Brain Structure in Early Psychosis – A Preliminary Analysis of the Randomized Controlled Clinical Trial
Jingxia Lin

Effects of Physical Exercise on Psychotic Symptoms, Cognition and Brain Structure: Results of a Randomized Clinical Trial in Chronic Schizophrenia
René Kahn

Does Exercise Alter the Metabolic Effects of Olanzapine in an Animal Model?
Alasdair M. Barr

Discussant: William G. Honer

Cardiovascular Risk in Schizophrenia – The Problem and Some Solutions  6:30 PM - 8:30 PM
Palazzo Affari, 1st Floor
Chair: Fiona P. Gaughran
Co-Chair: Shubulade Smith

IMPaCT– Motivating a Change in Health Behaviour
Shubulaide Smith and Fiona P. Gaughran

Systematic Evaluation of Guidelines for Monitoring Cardio-metabolic Risk in Schizophrenia
Marc De Hert

Shared Genetic Risks for Schizophrenia and Cardiovascular Disease
Urban Osby

The Role of Medication in Increasing and Managing Cardiovascular Risk in Psychosis
Azizah Attard

Discussant: Robin M. Murray

Relapse Prevention in Schizophrenia: An Update on Preclinical Data, Pharmacological and Psychotherapeutic Options  6:30 PM - 8:30 PM
Palazzo Affari, 2nd Floor
Chair: Stefan Leucht
Co-Chair: Christoph Correll

Preclinical Data on Relapse Prevention with Antipsychotic Drugs
Shitij Kapur
Meta-analysis on Relapse Prevention with Antipsychotic Drugs compared to Placebo in Schizophrenia
Stefan Leucht

Christoph Correll

Taishiro Kishimoto

The Role of CBT in Relapse Prevention of Schizophrenia
Elizabeth Kuipers

Discussant: John M. Kane
Wednesday, 14-18 April 2012

Wednesday, 17 April, Detailed Schedule of Events

Registration
Palazzo Entrance

Coffee/Pastries
Passi Perduti – Adjacent to Auditorium

Scientific Sessions

PLENARY SESSION – New Treatments
Auditorium
Chair: Wolfgang Fleischhacker
Co-Chair: Don Goff

Main Address:
Don Goff, Difficulties with Translational Research
John Kane, Methodologic Challenges in Clinical Trials in Schizophrenia

Abstract: The New Treatments for Schizophrenia plenary session will feature brief presentations by colleagues in industry to provide updates on promising new compounds and strategic approaches to drug development which will compliment introductory presentations on methodological issues, regulatory hurdles, and new approaches for drug development. The goal of the session is to stimulate discussion by presenting new preclinical or clinical data representing innovative strategies for treating psychosis, negative symptoms or cognitive impairment in schizophrenia. Data that are already familiar to this international audience of clinical scientists will not be presented.

Panelists:
- Anjana Bose, Forest Pharmaceuticals and Gedeon Richter
- Robert Conley, Eli Lilly & Company
- Gerhard Gross, Abbott
- David Hosford, Targacept
- Ron Marcus, Bristol Myers-Squibb
- Daniel Umbricht, Roche
- Kim Vanover, Intracellular Therapies
Lunch  
Palazzo Affari Lawn, Passi Perduti (in case of inclement weather)

Coffee Available  
Passi Perduti – Adjacent to the Auditorium  
Palazzo Affari Foyers  
Sala Verde

CONCURRENT SYMPOSIA

Nature and Nurture in Schizophrenia: Are There Common Underlying Mechanisms?  
1:30 PM – 3:30 PM

Auditorium
Chair: Oliver D. Howes
Co-Chair: Jean Paul Selten

Developmental Disruption and Stress: What Animal Models Tell Us about Schizophrenia  
Anthony Grace

An Experimental Social Defeat Paradigm to Study Environmental Effects in Psychosis  
Jim van Os

The Link between Cannabis and Schizophrenia: Dopaminergic or Cannabinoid System?  
Oliver D. Howes

Neural Mechanisms of Urbanicity and Migration: Social Risk Factors for Schizophrenia?  
Andreas Meyer-Lindenberg

Discussant: Shitij Kapur

Emerging Clinical Evidence on Oxytocin in Schizophrenia  
1:30 PM - 3:30 PM

Palazzo Affari, Lower Level
Chair: Deanna Kelly
Co-Chair: David Feifel

Oxytocin Improves Emotion Recognition in Patients with Schizophrenia  
Bruno Averbeck

Intranasal Oxytocin Reduces Core Symptoms of Schizophrenia  
David Feifel

Oxytocin Treatment Improves Social Cognition, PANSS Social Item Scores and Verbal Learning in Schizophrenia  
Cort Pedersen
Sex-specific Associations Between Peripheral Oxytocin, Symptoms, and Emotion Perception in Schizophrenia
Leah Rubin

Adjunctive Intranasal Oxytocin to Improve Social Cognition and Functioning in Schizophrenia
Mary Lee

Discussant: Deanna Kelly

Affective Dysfunction and Associated Developmental Vulnerabilities 1:30 PM – 3:30 PM
Across the Extended Psychosis Continuum
Palazzo Affari, Ground Floor
Chair: Max Birchwood
Co-Chair: Maria Michail

Subclinical Psychotic Experiences and Affective Dysregulation in Adolescents and Young Adults
Ashleigh Lin

Prevalence of Psychotic-Like Experiences in Young Adults with Social Anxiety Disorder and Correlations with Affective Dysregulation
Marco Armando

An Investigation of Social Anxiety Disorder in People with First-Episode Psychosis and those at Ultra High Risk
Maria Michail

Developmental Vulnerabilities and Affective Dysregulation in Psychosis Continuum
Ruchika Gajwani

Discussant: Emmanuelle Peters

Is the Psychosis Continuum For Real? The Cognitive, Environmental, and Neural Correlates of ‘Real’ Psychotic Experiences in the General Population 1:30 PM – 3:30 PM
Palazzo Affari, 1st Floor
Chair: Emmanuelle Peters
Co-Chair: Iris Sommer

The Route to Psychosis: What Differentiates Individuals with Psychotic Experiences with and without a ‘Need-For-Care’?
Emmanuelle Peters

Childhood Trauma and Auditory Verbal Hallucinations
Kirstin Daalman
What Makes Voices Distressing? A Comparison of Patients Who Hear
Voices and Non-Psychiatric Voice Hearers
Mike Jackson

Auditory Hallucinations Elicit Similar Brain Activation in Psychotic and Non-Psychotic Individuals
Iris Sommer

Dopaminergic Function in the Psychosis Spectrum: An [18F]-DOPA Imaging Study in Healthy Individuals with Auditory Hallucinations
Paul Shotbolt

Discussant: Anthony David

Subclinical Psychotic Experiences – Time to Move beyond Counting. 1:30 PM - 3:30 PM
Advancing Clinical Research into Risk Factors, Associated Psychopathology and Outcomes
Palazzo Affari, 2nd Floor
Chair: Mary Cannon
Co-Chair: James Scott

A Systematic Review and Meta-Analysis of the Psychosis Continuum: Epidemiological Evidence on the Pathway from Proneness to Persistence to Disorder
Richard Linscott

Exposure to Child Maltreatment and Hallucinations during Adolescence: A Prospective Study
James Scott

Childhood Trauma and Subclinical Psychotic Experiences in Young Adulthood: 20-year Longitudinal Analyses of Two Cohort Studies
Cherrie Galletly

Psychotic Symptoms in Adolescence Index Risk for Self Harm and Suicidal Behaviour: Findings from Two Population-Based Case-Control Clinical Interview Studies
Ian Kelleher

The Association between Self-reported Attenuated Psychotic Symptoms and Suicidal Behavior, and Hospitalization for Non-psychotic Psychiatric Disorders
Mark Weiser

Discussant: Peter Jones
Role of Glia in Schizophrenia 1:30 PM - 3:30 PM
Sala Verde
Chair: Natalya A. Uranova
Co-Chair: Mikhail V. Pletnikov

Proteome Analyses of Post-Mortem Brain Tissue from Patients with Schizophrenia Suggest Dysfunction of Oligodendrocytes and Astrocytes and Potential Biomarker Candidates
Daniel Martins-de-Souza

Reduced Oligodendroglial Density in Neocortex and Lack of Insight in Schizophrenia
Natalya A. Uranova

Protective Effects of Haloperidol and Clozapine on Energy-Deprived OLN-93 Oligodendrocytes
Johann Steiner

DISC1 Interacts with Serine Racemase to Modulate D-Serine Production in Astrocytes
Mikhail V. Pletnikov

Discussant: Vahram Haroutunian

Summary and Closing Session 3:45 PM - 4:45 PM
Auditorium
Chair: Jim van Os
3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Posters, Sunday 15 April

12:00 PM - 2:00 PM
Cavaniglia

1. Prevalence and Factors Associated with Tardive Dyskinesia among Indian Patients with Schizophrenia
Rashmin M. Achalia, Santosh K. Chaturvedi, Geetha Desai, Om Prakash

2. Childhood Adversity and Cannabis use in the Development of Positive Psychotic-like Experiences: Moderation Effects of the COMT Gene
Silvia Alemany, Bárbara Arias, Mar Fatjó-Vilas, Mari Aguilera, Helena Villa, Jorge Moya, Manuel I. Ibáñez, Generós Ortet, Lourdes Fañanás

3. Trauma and Psychotic-like Experiences: Mediating Psychological Mechanisms
Neus Barrantes-Vidal, Tamara Sheinbaum, Sergi Ballespí, Erika Bedoya, Agnès Ros, Mercè Mitjavila, Thomas R. Kwapił

4. Relationship between Attachment and Schizotypy Dimensions in Spanish and American Samples
Tamara Sheinbaum, Thomas R. Kwapił, Erika Bedoya, Agnès Ros, Neus Barrantes-Vidal

5. DISC1 and Serine Racemase Interact in Astrocytes to Regulate D-serine Production
Bagrat Abazyan, Ting Martin Ma, Jun Nomura, Sofya Abazyan, Akira Sawa, Solomon H. Snyder, Mikhail V. Pletnikov

Dorota M. Badowska, Magdalena M. Brzozka, Peter Falkai, Moritz J. Rossner

7. Local Changes in Hippocampal Neural Synchronisation in the Maternal Immune Activation Model of Schizophrenia
Amy R. Wolff, Desiree D. Dickerson, David K. Bilkey

8. Non-human Primate Performance on the Dot Pattern Expectancy Task after Ketamine Administration
Rachael K. Blackman, Matthew V. Chafee

Milen Borsoi, Alice Fialho Viana, Camila Boque Antonio, Andressa Braga, Paula Lunardi, Cristiane Batassini, Carlos Alberto Gonçalves, Stela Maris Kuze Rates

10. Magnetic Resonance Imaging Characterization of Early Postnatal Phencyclidine Treatment as a Rat Model of Schizophrenia
Brian V. Broberg, Kristoffer H. Madsen, Niels Plath, Christina K. Olsen, Birte Y. Glenthøj, Olaf B. Paulson, Börje Bjelker, Lise V. Søgaard
11. Housing Conditions Modulate the Cognitive Performance in Transgenic Mice Overexpressing the Schizophrenia Susceptibility Gene Tcf4
Magdalena M. Brzózka, Dorota Badowska, Peter Falkai, Moritz J. Rossner

12. Effects of Repeated Electroconvulsive Shock on Methamphetamine-Induced Behavioral Abnormalities in Mice
Yu-Lin Chao, Hwei-Hsien Chen, Chia-Hsiang Chen

13. Expression and Distribution Profiles of Glutamatergic Receptors in the MAME17 Neurodevelopmental Rat Model of Schizophrenia
Marie-Caroline Cotel, Eva Hradetzky, Sabine Bahn, Mark Tricklebank, Michael J. O’Neill

14. Neural Systems Underlying Schizophrenia-Related Behavioural Phenotypes in Mice
Neil Dawson, David M. Thomson, Brian J. Morris, Judith A. Pratt

Lieve Desbonnet, Colm O’Tuathaigh, Gerard Clarke, Claire Leary, Emilie Petit, Niamh Clarke, Orna Tighe, Donna Lai, Richard Harvey, John F. Cryan, Timothy G. Dinan, John L. Waddington

16. Synergistic Interactions between Prenatal Infection and Pubertal Stress in the Development of Schizophrenia-relevant Abnormalities
Sandra Giovanoli, Joram Feldon, Urs Meyer

17. Transient Neuroinflammation Mediates Pathological Synergisms between Prenatal Infection and Pubertal Stress
Sandra Giovanoli, Juliet Richetto, Harald Engler, Manfred Schedlowski, Marco A. Riva, Urs Meyer

18. Modulations of Neural Circuits by Cognitive Behavioural Therapy in Patients with Schizophrenic Disorders
Maurice Cabanis, Axel Krug, Martin Pyka, Henrik Walter, Georg Winterer, Bernhard Müller, Jutta Herrlich, Georg Wiedemann, Kai Vogeley, Alexander Rapp, Andreas Wittorf, Stefan Klingberg, Tilo Kircher

19. Impaired Cerebellar Functional Connectivity in Schizophrenia Patients and their Healthy Siblings

Fabiana da Silva Alves, Nicole Schmitz, Nico Abeling, Johan van der Meer, Aart Nederveen, Lieve de Haan, Don Linszen, Therese van Amelsvoort

Maria R. Dauvermann, Thomas W. Moorhead, Liana Romaniuk, Heather C. Whalley, Stephen M. Lawrie

22. Hyperactivation in Working Memory Circuits in Siblings of Schizophrenia Patients: an fMRI Study
Max de Leeuw, Matthijs Vink, Bram B. Zandbelt, René S. Kahn
23. The Association Between Self-Reflective Processing and Insight in Psychosis in Schizophrenia Patients: an fMRI Study
Annerieke de Vos, Lisette van der Meer, Marieke Pijnenborg, Willem A. Nolen, Anthony S. David, André Aleman

24. Failure to Deactivate Medial Prefrontal Cortex Associated with Clinical not Genetic Risk for Psychosis
Irina Falkenberg, Chris Chaddock, Gemma Modinos, Matthew Broome, Philip McGuire, Paul Allen

25. A Genetic Variant of the Dopamine D2 Receptor Gene Predicts Prefrontal Activity during Working Memory Retrieval in Humans
Leonardo Fazio, Gianluca Ursini, Tiziana Quarto, Paolo Taurisano, Raffaella Romano, Barbara Gelao, Marina Mancini, Annamaria Pocelli, Annabella Di Giorgio, Apostolos Papazacharias, Grazia Caforio, Antonio Rampino, Annalisa Incampo, Teresa Popolizio, Giuseppe Blasi, Alessandro Bertolino

26. Delineating the Functional Neuroanatomy of Illness Denial or Anosognosia in Schizophrenia
Philip Gerretsen, Ariel Graff-Guerrero, David Mamo, Bruce G. Pollock, Mahesh Menon

27. Aberrant Functional Connectivity of Right Anterior Insula during a Working Memory Task in Schizophrenia
Lena Palaniyappan, Thomas P. White, Peter F. Liddle

28. Neural Correlates of Action Imitation in Relation to Schizotypal Personality
Joel S. Peterman, Katharine N. Thakkar, Sohee Park

29. Exploring Genetic and Environmental Influences on Brain Function in Schizophrenia
Marco M. Picchioni, Timothea Toulopoulou, Andreina Pauli, Isabel Valli, Ulrich Ettinger, Cynthia Fu, Mei Hua-Hall, Fergus Kane, Eugenia Kravariti, Sri Kaladindi, Elvira Bramon, Muriel Walshe, Mick Brammer, Vincent Giampietro, Robin Murray, Philip McGuire

30. Neural Correlates of Irony Comprehension: Decreased Medial Prefrontal BOLD Response in Schizophrenia
Alexander M. Rapp, Karin Langohr, Dorothee E. Mutschler, Michael Erb

31. Changes in Spontaneous Brain Activity Patterns in Antipsychotic Naïve Schizophrenia Patients before and after Antipsychotic Treatment
Egil Rostrup, Mette O. Nielsen, Jaychandra M. Raghava, Birte Glenthøj

32. The Neural Bases of Reversal Learning Deficits in Unmedicated Schizophrenia Patients
Florian Schlagenauf, Quentin Huys, Lorenz Deserno, Michael Rapp, Anne Beck, Andreas Heinz

33. Changes in Resting State Connectivity Following Treatment in First Episode Schizophrenia
S. Charles Schulz, Chen DaChun, Xue-Dong Yang, Thomas Kosten, Xiang Yang Zhang, Kelvin O. Lim

34. Assessment of Positive and Negative Symptoms using an fMRI Reward-paradigm in a Sample of Healthy Subjects with Different Levels of Symptom Expression
Joe J. Simon, Sheila Cordeiro, Hans-Christoph Friederich, Marc-André Weber, Robert C. Wolf, Matthias Weisbrod, Stefan Kaiser
35. Prefrontal Cortex and Goal-Directed Behavior in Schizophrenia: Neural Mechanisms Underlying Inflexibility
Tatiana Sitnikova, Alexandre Gramfort, Robert W. Boyle, Corinne Cather, Oliver Freudenreich, Matti S. Hämäläinen, Bruce R. Rosen, Donald C. Goff

36. Abnormal Relationship between Circulating BDNF Levels and Prefrontal Cortex Activity during Probabilistic Feedback Learning in Schizophrenia
Ashley J. Skilleter, Ans Vercammen, Cyndi S. Weickert, Thomas W. Weickert

37. Association of DRD2 Genetic Variation and Schizotopy with Attentional Processing and D2 Receptors Availability
Paolo Taurisano, Marina Mancini, Raffaella Romano, Gianluca Ursini, Artor N. Asabella, Barbara Gelao, Leonardo Fazio, Luciana Lo Bianco, Annabella Di Giorgio, Rita Maselli, Grazia Caforio, Lorenzo Sinibaldi, Teresa Popolizio, Giuseppe Blasi, Giuseppe Rubini, Alessandro Bertolino

38. Multimodal Emotional Integration Task: An fMRI Paradigm for Emotional Processing in Early Psychosis and Ultra-High Risk State
Huai-Hsuan Tseng, Jonathan Roiser, Bradley Platt, Sunjeev Kamboj, Philip McGuire, Paul Allen

Weidan Pu, Li Li, Huiran Zhang, Jingping Zhao, Baoci Shan, Zhenning Liu

40. Longitudinal Change in Levels of n-acetyl-aspartate in Early Onset Psychosis and Healthy Controls
Marta Rapado-Castro, Santiago Reig, Montse Graell, Josefina Castro-Fornielles, Ana González-Pinto, Soraya Otero, Inmaculada Baeza, Joost Janssen, Mara Parellada, Dolores Moreno, Manuel Desco, Celso Arango

41. Sex Differences in Verbal Memory Circuitry in Schizophrenia: Structural, Functional, and Hormonal Contributors
Brandon R. Abbs, Lichen Liang, Jason S. Bitterman, Nikos Makris, Larry J. Seidman, Jill M. Goldstein

42. Impact of Clozapine Treatment on Regional Brain Volume: A Longitudinal Study of Treatment Resistant Schizophrenia
Mohamed Ahmed, Dara M. Cannon, Laurena Holleran, Heike Schmidt, John McFarland, Camilla Langan, Louise Emsell, Gary McDonald, Cathy Scanlon, Peter McCarthy, Gareth J. Barker, Colm McDonald

43. Negative Symptoms in the Early Stages of Psychosis are Associated with Changes in the Cingulate
Jacqueline Aston, Erich Studerus, Charlotte Rapp, Hilal Bugra, Stefan Borgwardt, Anita Riecher-Rössler

44. Neurological Soft Signs and Gray Matter Changes: A Longitudinal Analysis in First Episode Schizophrenia
Silke Bachmann, Li Kong, Philipp Thomann, Marco Essig, Johannes Schroeder

45. White Matter and Clinical Symptomatology in the Early Stages of Schizophrenia
Khalima A. Bolden, Heline Mirzakhanian, Kristin Cadenhead, Lisa T. Eyler, Gregorgy G. Brown
46. Diffusion Tensor Imaging Demonstrates Reduced White Matter Integrity in Schizophrenia that is Related to Poorer Memory Performance
Amity E. Green, Rodney J. Croft, Jerome J. Maller, Paul B. Fitzgerald

47. DTI-based Study to Analyse White Matter Integrity in Schizophrenia and Bipolar Disorder using Tract-Based Spatial Statistics
Alexandra Hellerbach, Bruno Dietsche, Davide Laneri, Heidelore Backes, Mirjam Stratmann, Tilo Kircher, Axel Krug, Jens Sommer

48. Neurobiological Correlates of Slow Wave Sleep Reduction in First Episode Schizophrenia
Julie Poulin, Konsale M. R. Prasad, Jeffrey A. Nutche, Jean M. Miewald, Debra Montrose, Matcheri S. Keshavan

49. Changes in DLPFC-Striatum Connections in First Episode Schizophrenia: A Cross-Sectional and Longitudinal DTI Study
Meina Quan, Marek Kubicki, Ryan Eckbo, Zora Kikinis, Robert W. McCarley, James J. Levitt, Martha E. Shenton

50. Structural Brain Heterogeneity in Schizophrenia: A Gray Matter Texture Analysis on MR Images
Eugenia Radulescu, Balaji Ganeshan, Nicholas Medford, Sukhwinder S. Shergill, Hugo D. Critchley

51. Cannabis Use and Brain Structural Alterations of Cingulate Cortex and Hippocampus in First Episode Psychosis Patients and at Risk Mental State Subjects
Charlotte Rapp, Hilal Bugra, Corinne Tamagni, Erich Studerus, Anna Walter, Stefan Borgwardt, Anita Riecher-Rössler

52. Duration of Untreated Illness/Psychosis and Cognitive Functioning
Charlotte Rapp, Erich Studerus, Hilal Bugra, Marlon Pflueger, Jacqueline Aston, Corinne Tamagni, Anna Walter, Stefan Borgwardt, Anita Riecher-Rössler

53. Human Cortical Development and Intelligence: a Longitudinal MRI Study in over 1000 Scans
Hugo G. Schnack, Neeltje E. van Haren, Rachel M. Brouwer, Sarah Durston, Alan C. Evans, Dorret I. Boomsma, Rene S. Kahn, Hilleke E. Hulshoff Pol

54. Disrupted White Matter Connectivity is Associated with Reduced Cortical Thickness in the Cingulate Cortex in Schizophrenia
Kathrin Koch, C. Christoph Schultz, Gerd Wagner, Claudia Schachtzabel, Jürgen R. Reichenbach, Heinrich Sauer, Ralf GM Schlösser

Alana M. Shepherd, Sandra L. Matheson, Kristin R. Laurens, Vaughan J. Carr, Melissa J Green

56. Insular Volume Abnormalities Associated with Different Transition Probabilities to Psychosis – A Voxel-based Morphometry Study
Renata Smieskova, Anita Riecher-Rössler, Jacqueline Aston, Andor Simon, Kerstin Bendfeldt, Claudia Lenz, Rolf-Dieter Stieglitz, Paolo Fusar-Poli, Philip McGuire, Stefan J. Borgwardt

57. Self Organizing Map Analysis of Regional Brain Volume Revealed Subgroups in Schizophrenia
Genichi Sugihara, Naoya Oishi, Shinsuke Fujimoto, Jun Miyata, Toshiya Murai
58. Longitudinal Volume Changes of the Pituitary Gland in the Course of Schizophrenia
Tsutomu Takahashi, Michio Suzuki, Shi-Yu Zhou, Kazue Nakamura, Atsushi Furuichi, Mikio Kido, Yasuhiro Kawasaki, Kyo Noguchi, Hikaru Seto, Masayoshi Kurachi

59. Better Theory-of-mind Skills in Children Hearing Voices Mitigate the Risk of Secondary Delusion Formation
Agna A. Bartels-Velthuis, Els M. Blijd-Hoogewys, Jim Van Os

60. Cognitive Reserve as a Predictor of Two Year Neuropsychological Performance in Early Onset First-Episode Schizophrenia
Elena de la Serna, Susana Andrés-Perpiñá, Olga Puig, Inmaculada Baeza, Igor Bombin, David Bartrés-Faz, Celso Arango, Ana Gonzalez-Pinto, Mara Parellada, María Mayoral, Montserrat Graell, Soraya Otero, Josefnia Castro-Fornieles

61. Cytokine Profile in Acutely States of Child and Adolescent Psychiatric Disorders: A Comparison with Healthy Controls; Preliminary data.
Maria Gariup, Tamara Garcia, Gemma Trias, Carles Serra, Astrid Morer

62. Self-perception vs. Peer Reputation of Bullying Victimization in Relation to Non-clinical Psychotic Experiences
Paula M. Gromann, Frits Goosens, Tjeert Olthof, Jeroen Pronk, Lydia Krabbendam

63. Family Load Estimates of Schizophrenia with Different Age at Onset. Findings from a Nation-wide Population Study of Three Generations
Dorte Helenius, Povl Munk-Jørgensen, Hans-Christoph Steinhausen

64. Plasma Clozapine and Norclozapine in Relation to Prescribed Dose and Other Factors in Patients Aged < 18 Years: Data from a Therapeutic Drug Monitoring Service, 1994-2010
Maxine X. Patel, Lewis Couchman, Sally V. J. Bowskill, Simon Handley, Robert J. Flanagan

65. Shared Risk Factors for Mental Health Problems and Cannabis Use in Adolescence
Willemijn A. van Gastel, Clothilde J.E. Bun, Wanda Tempelaar, Christian D. Schubart, Carolien M. Plevier, René S. Kahn, Marco P. M. Boks

66. Covert Recognition of Familiar, Famous and Unfamiliar Faces in Schizophrenia
Aurely Ameller, Laetitia Delbos, Anne-Laure Côte, Pierre Thomas, Delphine Pins

67. Cognitive Exceptionality and Impairment in Schizophrenia
Narmeen Ammari, Walter Heinrichs, Geoffrey Hall, Ashley A. Miles

68. Diagnostic Value of a Simplified Screening Test for Metabolic Syndrome in a Cohort of Patients with Schizophrenia-spectrum Disorders
Salcey G. Amzand, Bert L. Luteijn, Elsje van der Ven, Clazina D. Dogterom, Jan P. Bogers, Jean-Paul Selten

69. Deficit and Nondeficit Schizophrenia: Boundaries Revisited
Clarissa R. Dantas, Bruno R. Barros, Claudio E.M. Banzato
70. Predicting Deficit/Nondeficit Categorization from the Scale for the Assessment of Negative Symptoms (SANS)
Bruno R. Barros, Claudio E. M. Banzato, Clarissa R. Dantas

71. Similarities and Differences between First Episode Schizophrenia and Schizoaffective Disorders
Sue M. Cotton, Martin Lambert, Benno G. Schimmelmann, Andrew Mackinnon, John Gleeson, Michael Berk, Leanne Hides, Andrew Chanen, Patrick D. McGorry, Philippe Conus

72. Autism Spectrum Disorders and Schizophrenia, a Comparative Study
Maria Hallerbäck, Tove Lugnegård, Christopher Gillberg

73. At-Risk Criteria of Psychosis: Reliability between Interview Modes
Chantal Michel, Benno G. Schimmelmann, Stephan Kupferschmid, Marcel Siegwart, Frauke Schultze-Lutter

74. The Impact of Cultural Competency on Reducing Ethnic Disparities in Psychiatric Diagnosis: A Regional Variation Analysis
John E. Zeber, John F. McCarthy, Jodi M. Gonzalez, David S. Greenawalt, Alejandro Interian, Laurel A. Copeland

75. Ictal EEG Fractal Dimension Early in the Course of ECT in Schizophrenia Patients Predicts Clinical Outcome at Two Weeks
H. A. Abhishekh, M. Anusha, J. Thirthalli, V. H. Puthane, K. Muralidharan, B. N. Gangadhar

76. Semantic and Associative Priming in Schizophrenia: Behavioural and Electrophysiological (N400) Differences
Simon T. E. Baker, Rachel A. Batty, Susan L. Rossell, Neil Thomas, Andrew J. P. Francis

77. Positive Affect and Appetitive Motivation in Schizophrenia as Quantified by the Post-Auricular Reflex

78. Robust EEG Biomarkers of Decision-making: A Possible Probe for Dysfunction in Schizophrenia
Amy R. Bland, Alexandre Schaefer, Bill J. F. W. Deakin

79. The Mismatch Negativity in Different Stages of Schizophrenia
Mitja Bodatsch, Anke Brockhaus-Dumke, Frauke Schultze-Lutter, Ralf Müller, Joachim Klosterkötter, Stefan Ruhrmann

80. Disruption of Prefrontal Fast-Spiking Interneurons in the DISC1-DN Mouse Model of Schizophrenia
Ross A. Cardarelli, Akira Sawa, Patricio O'Donnell

81. Genetic Variation in ABCB1 Associated with P300 Amplitude in Schizophrenia
Jeroen Decoster, Marc De Hert, Wolfgang Viechtbauer, Guy Nagels, Inez Myin-Germeys, Joseph Peuskens, Jim van Os, Ruud van Winkel

82. Association of Treatment Delay, Migration and Urbanicity in Psychosis
Nynke Boonstra, Bouke Sterk, Lex Wunderink, Sjoerd Sytema, Lieuwe de Haan, Durk Wiersma
83. Family History of Mental Illnesses in First- and Second-Generation Migrants: Evidence from the AESOP First-Onset Study
François Bourque, Susana Borges, Jane Boydell, Paul Fearon, Gerard Hutchinson, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M Murray, Paola Dazzan, Craig Morgan

84. The Prevalence of Diabetes Mellitus is Increased in Relatives of Patients with a Psychotic Disorder
Hanneke Welie, Eske Derks, Kim Verweij, Harold de Valk, Rene Kahn, Wiepke Cahn

85. The CCC2000 Birth Cohort Study: Theory of Mind in Children at Risk of Psychosis
Lars Clemmensen, Anja Munkholm, Charlotte Eberhardt, Jim van Os, Anne Mette Skovgaard, Pia Jeppesen

86. Premature Aging as a Proposed Explanation for Excess of Death in Schizophrenia
Dan Cohen, Christiane Gasse, Thomas Laursen

87. Effect of Geographical Ancestry and Ethnicity on Tardive Dyskinesia Severity
Vincenzo De Luca, Clement Zai, Gary Remington, James L. Kennedy

88. Childhood Infection and Schizophrenia and Other Psychosis: A Systematic Review and Meta-Analysis of Population-based Studies
Golam M. Khandaker, Glyn Lewis, Christina Dalman, Peter B. Jones

89. Prenatal Maternal Infection, Neurodevelopment and Adult Schizophrenia: A Systematic Review of Population-based Studies
Golam M. Khandaker, Jorge Zimbron, Glyn Lewis, Peter B. Jones

90. AESOP-10: A 10-Year Follow-up Study of First-Episode Psychosis – Rationale, Method, and Preliminary Findings
Craig Morgan

91. Childhood and Adulthood Social Disadvantage in First Episode Psychosis Patients: Is the Latter a Consequence of the Former?
Simona A. Stilo, Marta Di Forti, Alessandra Paparelli, Aurora Falcone, Valeria Mondelli, Paola Dazzan, Anthony David, Robin M. Murray, Craig Morgan

92. Ethnicity, Separation and Psychosis: Exploring the Odds
Simona A. Stilo, Adanna Onyejiaka, Charlotte Gayer-Anderson, Susana Borges, Grant McQueen, Chelsea Gardner, Sophie Sowden, Francois Bourque, Rowena Handley, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Paola Dazzan, Craig Morgan

93. Cancer Mortality in Patients with Psychiatric Diagnoses: A Higher Hazard of Cancer Death does not Lead to a Higher Cumulative Risk of Dying from Cancer
Ng Chong Guan, Fabian Termorshuizen, Wijnand Laan, Hugo M. Smeets, Nor Zuraida Zainal, René S. Kahn, Niek J. de Wit, Marco P. M. Boks

94. Trauma and Risk of Developing Psychosis in a High Clinical Risk Population: Results from a Medium to Long Term Follow-up Study
95. Is Clozapine Treatment Associated with Lower Mortality Rates in Schizophrenia? Preliminary Evidence from a Register Based Study
   Annet H. van Bergen, Fabian Termorshuizen, Hugo M. Smeets, Iris E. Sommer, René S. Kahn, Marco P. M. Boks

96. Comparing the Clinical Presentation of First Episode Psychosis across Different Migrant and Ethnic Minority Groups in Montreal, Canada
   Elsje van der Ven, Francois Bourque, Ridha Jouber, Jean-Paul Selten, Ashok Malla

97. The Curacao Extrapyramidal Syndromes Study, an 18 Year Prospective Study of Inpatients with Severe Mental Illness
   Peter N. van Harten, Hans W. Hoek, Glenn E. Matroos, Jim van Os

98. Hearing in Persons with Schizophrenia – Findings from a Population-based Survey
   Satu Viertiö, Jonna Perälä, Samuli I. Saarni, Seppo Koskinen, Jaana Suvisaari

99. CNR1 and Risk of the Metabolic Syndrome in Patients with Schizophrenia
   Weiping Yu, Marc De Hert, Tim Moons, Stephan J. Claes, Christoph U. Correll, Ruud van Winkel

100. Privacy and Confidentiality: Beliefs, Expectations, and Protections in an Indian Context
    Nagendra N. Mishra, Triptish Bhatia, Vishwajit L. Nimgaonkar, Lisa S. Parker, Smita N. Deshpande

101. Psychological Mechanisms as Potential Endophenotypes for Bipolar Disorder: A Study of Twin and Sibling Pairs
    Stephanie Beards, Manasi Sharma, Anna Georgiades, Fergus Kane, Sridevi Kalidindi, Katja Schulze, Muriel Walshe, Mei-Hua Hall, Irene Rebollo-Mesa, Jan Scott, Robin M. Murray, Fruhling Rijssdijk, Eugenia Kravariti

102. The Association of NRG1, DTNBP1, RGS4, G72/G30, DISC1 and BDNF Candidate Genes with Cognition in Patients with Schizophrenia and Healthy Controls
    János M. Réthelyi, Patrícia Polgár, Judit Benkovits, Kinga Farkas, Attila J. Pulay, Pál Czobor, István Bitter

103. COMT Met158 allele is Associated with Violence in Schizophrenia: A Meta-analysis
    Savita G. Bhakta, Jian-Ping Zhang, Anil K. Malhotra

104. Risk Stratification Incorporating Cognitive Endophenotypes for Schizophrenia (SZ) in India
    Triptish Bhatia, Elizabeth A. Gettig, Jon Berliner, Nagendra N. Mishra, Kapila Garg, Vishwajit L. Nimgaonkar, Smita N. Deshpande

105. Monozygotic Twins Discordant for Bipolar Disorder Show Functional DNA Methylation Changes in Whole Blood and Brain

106. In a Normal Population Sample Schizophrenia Associated Copy Number Variations in Genomic Regions 1q21. 1, 15q11. 2 are more Frequent in Female and are Associated with Lower Socioeconomic Status, Obesity and Higher Cholesterol Levels
    Elemi J. Breetvelt, Maartje F. Aukes, Marco P. Boks, René S. Kahn, Roel A. Ophoff
107. Genetic and Functional Analysis of EGR Family Genes in Schizophrenia  
Min-Chih Cheng, Yang-An Chuang, Shih-Hsin Hsu, Chia-Hsiang Chen

108. Altered Language Network Activity in Young People at Genetic Risk for Schizophrenia  

Dorota Frydecka, Lidia Karabon, Edyta Pawlak, Aleksander Beszlej, Andrzej Klejna

110. Using a Translational Approach to Study Behavioral Disorders’ Pathophysiology: Dopamine System is Affected in a Glutamatergic Animal Model of Psychosis  
Felice Iasevoli, Gianmarco Latte, Livia Avvisati, Carmine Tomasetti, Rodolfo Rossi, Luigi Aloj, Andrea de Bartolomeis

111. Epistatic Interaction of COMT and DTNBP1 Modulates Working Memory Performance in Mice and Related Prefrontal Physiology in Humans  
Francesco Papaleo, Madeline Burdick, Joseph Callicott, Daniel Weinberger

112. Glial-derived Neurotrophic Factor (GDNF) Serum Levels in Schizophrenic Women during 8-weeks of Treatment  
Aleksandra Rajewska-Rager, Maria Skibinska, Pawel Kapelski, Anna Leszczynska-Rodziewicz, Joanna Pawlak, Hauser Joanna

113. Brain-derived Neurotrophic factor (BDNF), Neurotrophin 3 (NTF3), Neurotrophin 4 (NTF4) and Glial-derived Neurotrophic Factor (GDNF) Serum Levels in Schizophrenia  
Anna Leszczynska-Rodziewicz, Maria Skibinska, Pawel Kapelski, Aleksandra Rajewska-Rager, Joanna Pawlak, Joanna Hauser

114. OPEN BOARD

115. An Environmental Analysis of Genes Associated with Schizophrenia: Hypoxia and Vascular Factors as Interacting Elements in the Neurodevelopmental Model  
Bart P. F. Rutten, Jim van Os, Gabriel Esquivel, Harry W. M. Steinbusch, Rainald Schmidt-Kastner

116. Decreased Inhibitory Neurotransmission Markers in the Amygdala of Alzheimer Patients Suffering from Psychosis  
Ana R. Saez, Javier Gilabert-Juan, Jose L. Ivorra, Josep M. Haro, Alfonso Monje, Isidre Ferrer, Juan Nacher, Julio Sanjuan, M. Dolores Moltó

117. Analysis of Candidate Genes Conferring Susceptibility to Schizophrenia in a Sample from Indonesia with 1081 Cases and 1111 Controls Reveals Association with rs1344706 Located in the ZNF804A Gene  
118. Intermediate Phenotype Analysis of Patients, Unaffected Siblings and Healthy Controls Identifies VMAT2 as a Candidate Gene for Psychotic Disorder and Neurocognition
Claudia Simons, Ruud van Winkel

119. Genetic Modulation of the Long-term Effects of Cannabis on Brain Structure, Function and Symptomatology
Nadia Solowij, Francesca Fernandez, Robin Murray, Murat Yücel

120. The Genetics of Language Lateralization and Left-handedness: Linkage Analysis in a Dutch Population Isolate
Metten Somers, Roel A. Ophoff, Rita M. Cantor, Maartje F. Aukes, Kristel van Eijk, Meenakshi Dauwán, Ruben van ‘t Slot, Esther Janson, Marco P. Boks, René S. Kahn, Iris E. Sommer

121. Multilocus Analysis of Candidate Genes Involved in Neurodevelopment with Schizophrenia Susceptibility
Aleksandra Szczepankiewicz, Maria Skibinska, Pawel Kapelski, Monika Wilkosc, Piotr Czerski, Monika Dmitrzak-Weglärz, Joanna Hauser

122. Impact of Positive and Negative Symptoms and Cognitive Impairment on Health Outcomes and Healthcare Resource Utilization in European Patients with Schizophrenia
Namita L. Tundia, Menaka Bhor, Amy M. Duhig, Steven Hass, Richard Perry, Gary Milligan

123. Peripheral Blood Mononuclear Cells CB1 and CB2 Receptor Levels in First Episodes of Psychosis
Miquel Bioqué, Karina MacDowell, Borja Bueno, Ana Meseguer, Bibiana Cabrera, Juan C. Leza, Miguel Bernardo

124. Decreased Hand Blood Flow Correlates with Symptom Severity and is Acutely Increased by Atypical Antipsychotic Medication in Patients with Schizophrenia and Schizoaffective Disorder
Esther Blessing, Linda Kader, Youichirou Ootsuka, William W. Blessing, Christos Pantelis

125. Association of Hyperprolinemia with Schizophrenia: Implications for the Etiology, Clinical Management and Treatment of Schizophrenia Patients
Catherine L. Clelland, Valerie Drouet, Ian Orozco, Alexandra Kelly, Angela Kaon, Li Liu, Raymond Suckow, Laura L. Read, Robert Nadrich, Amit Rajparia, James D. Clelland

126. Dopaminergic Function in Treatment Resistant Schizophrenia: New Evidence from an [18F]-DOPA PET Study
Arsime Djenjaka, Robin Murray, Shitij Kapur, Oliver Howes

127. Analyses of Monoamine Metabolites in the Cerebrospinal Fluid of Patients with Schizophrenia
Kotaro Hattori, Daimei Sasayama, Toshiya Teraishi, Takashi Fujii, Hiroshi Kunugi

128. Nitric Oxide Synthase Activity is Differentially Altered between Acute and Subchronic Phencyclidine Treatments in Discrete Mouse Brain Regions
Graham Lee, David M. Thomson, Allan McVie, Colin J. Suckling, Brian J. Morris, Judith A. Pratt

129. Dynamic Changes in microRNA Expression in the Developing Human Prefrontal Cortex
Natalie J. Beveridge, Danielle M. Santarelli, Paul A. Tooney, Maree J. Webster, Cynthia S. Weickert
130. Prenatal Vitamin D Deficiency Alters Dopamine and Glutamate Metabolism in Rat Brain
Thomas H. Burne, James P. Kesby, Karly Turner, Alexander Suzy, John J. McGrath, Darryl W. Eyles

131. Prediction of Functional Outcome in Individuals at Clinical High-Risk for Psychosis
Ricardo E. Carrion, Danielle McLaughlin, Terry E. Goldberg, Doreen Olvet, Andrea Auther, Barbara A. Cornblatt

132. The Group of Schizophrenias: Evidence for Differential Developmental Trajectories in Schizophrenia and Bipolar Disorder
Nicolas A. Crossley, Mark Weiser, Michael Davidson, Abraham Reichenberg

133. SerumNT3 and NT4 Levels and the Positive and Negative Syndrome Scale (PANSS) Scores – Pilot Study
Monika Dmitrzak-Weglarz, Maria Skibinska, Pawel Kapelski, Aleksandra Szczepankiewicz, Joanna Pawlak, Joanna Hauser

134. Hostility Bias in Healthy Persons: It’s Association with ‘Theory of Mind’ Skills
Suk Kyoon An, Su Young Lee, Imhong Jeon, Kyung Ran Kim, Jin Young Park, Eun Lee, Jun Soo Kwon

135. Myelin Pathology and its Relationship to Iron Homeostasis in Schizophrenia
Lorna A. Farrelly, Melanie Föcking, Jane English, Gerard Cagney, David Cotter

136. Disruption of Cdc42 and Duo/PAK1 Pathway Drives Myosin Light Chain Phosphorylation in Schizophrenia
Maria D. Rubio, Vahram Haroutunian, James H. Meador-Woodruff

137. The Phrenic Component of Acute Schizophrenia – A Name and its Physiological Reality
Karl-Juergen Bär, Steffen Schulz, Sandy Berger, Voss Andreas

138. Semantic Fluency is Impaired but Phonological Fluency is Intact -the Key to Pathophysiology
Timothy J. Crow, Simon L. Collinson, Anthony C. James

139. Study Using Magnetoencephalografy of Spontaneus Neural Activity in a Schizophrenic Patients
Josep Tarragó, Cristina Alonso, Rafal Novack, Oscar Pino, Jose E. Rojo

140. Meta-analysis of Cognitive Deficits in Ultra-High Risk to Psychosis
Emre Bora, Christos Pantelis

141. Theory of Mind Impairment at Risk Conditions to Psychosis and in First-Degree Relatives of Schizophrenia: Systematic Review and Meta-analysis
Emre Bora, Christos Pantelis

142. Social Cognition in Impaired Patients: Which Role for Facial Emotion Recognition and Theory of Mind?
Perrine Brazo, Virginie Beaucousin, Laurent Lecardeur, Sonia Dollfus

143. Visual Backward Masking Deficits in Schizotypy
Celine Cappe, Christine Mohr, Daniela Herzig, Michael Herzog
144. Breaking Down Thinking Speed: Components of Processing Time and their Relationship to Symptoms and other Cognitive Domains in Schizophrenia
Matteo Cella, Til Wykes

145. Impairment in Cognitive Flexibility in Patients with Bipolar Disorder Versus Patients with Schizophrenia

146. Semantic Inhibition Performances in Bipolar Disorders and Schizophrenia: A Meta-analysis of Hayling Sentence Completion Test
Raymond C. Chan, Li L. Song, Kui Wang, Eric F. Cheung, Simon S. Lui, David Shum

147. The Emotional Stroop in First Episode Schizophrenia
Sieds Dieleman, Frederik M. Veen van der, Christian H. Roder

148. IQ Measure: Relation with Refractory Schizophrenia
Graça Maria R. Oliveira, Monica Kayo, Sandra M. K. Iso, Helio Elkis

149. Facial Affective Expressiveness in Patients with Schizophrenia
Helena Fatouros Bergman, Jochen Spang, Jörg Merten, Gunilla Preisler, Andrzej Werbart

150. Goal-representation and Action Control in Patients with Schizophrenia and Predominant Negative Symptoms
Anja Fritzsche, Tania Lincoln

151. Clinical and Neurocognitive Assessment of Schizophrenic Patients who Suffer Repeated Relapse and Hospitalization
Manuela Perez Garcia, Julio Brenlla Gonzalez, Mario Parmo Fernandez, Alfonso Mozos Ansorena, Begoña Portela Traba

152. Further Evidence for an Impaired Discrimination between Imagined and Performed Actions in Schizophrenia
Łukasz Gawęda, Steffen Moritz, Andrzej Kokoszka

153. The Role of DRD2 rs1076560 and AKT1 rs1130233 Variants in the Modulation of Attention in Patients with Schizophrenia and Healthy Subjects
Barbara Gelao, Giuseppe Blasi, Maria Teresa Attrotto, Annamaria Porcelli, Marina Mancini, Paolo Taurisano, Leonardo Fazio, Gianluca Ursini, Antonio Rampino, Rita Masellis, Raffaella Romano, Lucia Colagiovanni, Enrico D’Ambrosio, Annabella Di Giorgio, Grazia Caforio, Alessandro Bertolino

154. Neurocognitive Profiles of Marginalized Persons with Comorbid Psychosis and Polysubstance Abuse
155. **Child Maltreatment, COMT variability and Adult Cognition: Gene-Environment Interaction using a Twin Study**  
Ximena Goldberg, Mar Fatjó-Vilas, Silvia Alemany, Aldo Córdova, Igor Nenadic, Cristobal Gastó, Lourdes Fañanás

156. **Neuropsychological Performance of Individuals at Ultra High Risk or First Episode Psychosis**  
Priscila D. Gonçalves, Paula A. Martins, Pedro Gordon, Mario Louzã

157. **Metacognition in Non-psychotic Help-seeking Adolescents: Associations with Prodromal Symptoms, Distress, and Psychosocial Deterioration**  
Danny Koren, Ravit Scheyer, Noa Reznik, Merav Adres, Alan Apter, Larry J. Seidman

158. **Cognitive Reserve as a Moderator of Outcome in Chronic Schizophrenia**  
Natalia Ojeda, Pedro Sanchez, Javier Peña, Edorta Elizagarate, Jesus Ezcurra, Miguel Gutierrez

159. **Executive Attention Impairment in First Episode of Schizophrenia**  
Gricel P. Orellana, Marcela Pena, Andrea Slachevsky

160. **Hearing Voices; Abnormal Perception of “Biological” Sound in Schizophrenia and Schizotypy**  
Sohee Park, Amanda Cumming, Heathman Nichols

Sunyoung Park, Jae-Jin Kim, Seok-Hyeong Kim, Jung-Hwan Kim, Min-Seong Koo, Il Ho Park

162. **Affect Recognition in People at Clinical High Risk of Psychosis**  
Danijela Piskulic, David Penn, Diana Perkins, Scott Woods, Lu Liu, Jean Addington

163. **Applicability of the MATRICS Consensus Cognitive Battery in Singapore**  
Attilio Rapisarda, Thomas Lim, Matthew Lim, Simon Collinson, Michael Kraus, Richard Keefe

164. **The Cognitive Substrates of Thought Disorder Using Analogue Modeling**  
Susan L. Rossell, Erica Neill, Celia Morgan

165. **An Investigation of a Novel Transdiagnostic Model of Delusions in a Group with Positive Schizotypal Symptoms**  
Susan L. Rossell

166. **Relationship between Cognitive and Psychosocial Functioning in First Psychotic Episodes: 5 Year Follow-Up Study**  
Itxaso González-Ortega, Sara Barbeito, Sonia Ruiz de Azúa, Patricia Vega, Susana Alberich, Ariadna Besga, Ruben González-Oliveros, Ana González-Pinto

167. **A Virtual Reality Investigation of Spontaneous Navigation Strategies in Schizophrenia**  
Leanne K. Wilkins, Todd A. Girard, Jelena King, Matt King, Katie Herdman, Bruce Christensen, Veronique Bohbot
Eduardo J. Aguilar, Gracián Garcia-Martí, Luis Martí-Bonmatí, Douglas Turkington, Mercedes Renovell, Julio Sanjuán

169. COMBIMOD: Interest of a French Integrative Programme in the Improvement of Cognitions among Patients with Schizophrenia: Preliminary Results
Marie-Cécile Bralet, Delphine Catinaud, Abderrahman Jlidi, Christophe Hochard, Corinne Gautier, Thierry Lambert, Sandrine Orrens, Laurence Gerret

170. Assessment and Treatment of Metacognitive Impairment in People with Psychosis
Steven de Jong, Marieke Pijnenborg, André Aleman, Mark van der Gaag, Paul H. Lysaker

171. Yoga as Adjunctive Cognitive Remediation for Schizophrenia in India
Triptish Bhatia, Akhilesh Agrawal, Gyandeepak Shah, Wood Joel, Jan Richards, Raquel E. Gur, Ruben C. Gur, Vishwajit L. Nimgaonkar, Smita N. Deshpande

172. A Multi-centre Randomised Controlled Trial of Cognitive Therapy to Prevent Harmful Compliance with Command Hallucinations
M. Birchwood, E. Peters, T. Wykes, N. Tarrier, S. Lewis, G. Dunn, L. Davies, H. Lester, M. Michail, S. L. Griffiths

173. Group Cognitive-behavioral Therapy for Early Psychosis
Nam-In Kang, Kil-Sang Yoon, Tae-Won Park, Jong-Chul Yang, Keun-Young Oh, Young-Chul Chung

174. Can Prenatal Supplementation of Omega-3 Prevent the Early Prodrome of Schizophrenia in Adolescence in a Mouse Model?
Qi Li, Xiaofan Zhan, Ran Wei, Sylvia Lam, Basil Paul, Pak C. Sham, Siew E. Chua, Grainne M. McAlonan

175. Clozapine Administration in Adolescence Improves the Social Function of the Adult Offspring in an Animal Model of the Schizophrenia
Qi Li, Ran Wei, Kelvin Kwok, Joseph Lau, Siew E. Chua, Grainne M. McAlonan

176. Long-term Effects (up to 4 years) of Aripiprazole on Maintenance Treatment for Schizophrenia or Schizoaffective Disorder: A Pooled Open-label Extension of Two Clinical Trials

177. Is the Dreaming Mentation Directly Influenced by the Psychotic Mental State?
Anna Castelnovo, Rebecca Ranieri, Silvio Scarone

178. Theory of the Mind Skills in Schizophrenia: Exploring Economic Behavior in the Dictator (DG) and in the Ultimatum Game (UG)
Anna Castelnovo, Rebecca Ranieri, Silvio Scarone
179. Proteomic Analysis of the Corpus Callosum Reveals Down-regulation of the Glycolysis Protein Pathway and further Implicates CME in Schizophrenia
Jane A. English, Kieran Wynne, Gerard Cagney, David R. Cotter

180. Vitamin D Deficiency in First Episode Psychosis
Matthieu P. Crews, Poonam Gardner-Sood, Stefania Bonaccorso, Shubulade Smith, Robin M. Murray, Oliver Howes, Fiona Gaughran

181. Ongoing Data Quality Monitoring of Videotaped Patient Interviews in Global Schizophrenia Clinical Trials: Initial Findings
David Daniel, Alan Kott

182. Compulsory Psychiatric Treatment in Canada: 100 Cases
Luc Nicole, Marie Boivin, Kathe Villeneuve, Benedicte Nicole, Christian Desmarais

183. Metabolic Syndrome in Patients with Schizophrenia and Actions from Mental Health Services

184. The EMEA ADHES Survey: Schizophrenia Through the Carers’ Eyes
A. Svettini, B. Johnson, C. Magro, J. Saunders, K. Jones, S. Silk, L. Hargarter, A. Schreiner

185. The EMEA ADHES Survey in Schizophrenia: Nurses’ Perceptions of the Extent and Burden of Partial and Non-adherence to Medication in Patients with Schizophrenia

186. The EMEA ADHES Survey in Schizophrenia: Nurses’ Views on the Treatment Options for Improving Partial or Non-adherence in Patients with Schizophrenia

187. Evaluating Injection Site Pain with Long-acting Atypical Antipsychotics Using Clinical Trial Databases of Subjects with Schizophrenia
Jennifer Kern Sliwa, Srihari Gopal, Dong-Jing Fu, Isaac Nuamah, Larry Alphs

188. Maintenance Treatment with Risperidone Long-Acting Injection vs. Placebo in Subjects Recently Diagnosed with Bipolar Disorder: A Subgroup Analysis
Larry Alphs, Dong-Jing Fu, Jennifer Kern Sliwa, Yi-Wen Ma, Cynthia A. Bossie

189. Prediction of Relapse after a First Episode of Psychosis: A Follow-up Clinical Study
Daniel Berge, Anna Mane, Purificación Salgado, Romina Cortizo, Patricia C. Garnier, Antoni Bulbena

190. Olanzapine Long-acting Injection: Review of First Experiences of Post-injection Delirium/Sedation Syndrome in Routine Clinical Practice
Chris J. Bushe, Chetan C Shatapathy, Ernie Anand, Marta Casillas, Elena Perrin, Holly Detke
191. How well do Psychosis Risk Criteria Predict Psychosis Relative to their Absence? A 10-year Audit of an Early Psychosis Service
Vaughan J. Carr, Terry J. Lewin, Agatha M. Conrad, Sean A. Halpin, Ulrich Schall, Ketrina A. Sly

192. Relationship of Premorbid Functioning with Negative Symptoms and Cognition in First-episode Schizophrenia: A Three-year Prospective Follow-up Study
Wing-Chung Chang, Christy Hui, Jennifer Tang, Gloria Wong, Sherry Chan, Eric Y. H. Chen

193. Baseline Characteristics of First-episode Psychosis Patients in Cape Town
Bonginkosi Chiliza, Laila Asmal, Robin Emsley

194. Functional Status Rating Scales as Predictors of Everyday Functioning in People with Schizophrenia: Global vs. Subscales Ratings
Davide Prestia, Samir Sabbag, Philip D. Harvey

195. Examining Levels of Antipsychotic Adherence to Better Understand Nonadherence in Patients with Schizophrenia
Gagan Fervaha, Celine Teo, Steve Mann, Margaret Hahn, George Foussias, Ofer Agid, Gary Remington

196. FFM Personality Traits and Subclinical Psychotic Symptoms in Patients with Psychotic Disorders, their Siblings and Healthy Subjects: Preliminary Findings
Lindy Boyette, Carin Meijer, Lieuwe de Haan

197. Self Relevance of Patients with Schizophrenia
Kit Wa Chan, Tianyin Liu, Gloria H. Y. Wong, Christy L. M. Hui, Wing Chung Chang, May M. L. Lam, Eric Y. H. Chen

198. Childhood Trauma and Auditory Verbal Hallucinations
Kirstin Daalman, Kelly M. Diederen, Eske M. Derks, Remko van Lutterveld, René S. Kahn, Iris E. Sommer

199. Effect of Medication in Cognition and Insight in Psychotic Patients

200. Splitting the Mind and Body: Disturbances in Body Ownership as a Core Feature of the Schizophrenia Spectrum
Lindsey G McIntosh, Taylor L Benson, Joel S. Peterman, Sohee Park

201. Frequency of Auditory and Visual Hallucinations over the Course of 20-Years in Patients with Schizophrenia, Schizoaffective Disorder, and Bipolar Disorder with Psychosis
Vina M. Goghari, Martin Harrow

202. Comparing the Prodrome of Schizophrenia-spectrum Psychoses and Bipolar Disorders With and Without Psychotic Features
Frauke Schultze-Lutter, Benno G. Schimmelmann, Joachim Klosterkötter, Stephan Ruhrmann

*Ofer Agid, Cynthia O. Siu, Robert B. Zipursky, Gary Remington*

204. *Change in Psychopharmacotherapy of Schizophrenia Patients within a Period of 10 Years*

*Deniz Ceylan, Ahmet Yiğit Aktener, Berna Binnur Akdede Kivrıcık, Köksal Alptekin*

205. *TRIES: An Open, Randomized, Prospective, Multicenter Study, Searching the Best Switch Policy of Sertindole in Patients with Schizophrenia*

*Köksal Alptekin, Berna Akdede, Haldun Soygur, TRIES Study Group*

206. *Lamotrigine Augmentation in Patients with Schizophrenia Who Show Partial Response to Clozapine Treatment*

*Sefa Vayısıoğlu, A. Elif Anıl Yaşçioğlu, Süha Yaşçioğlu, Sevilyan Karahan, Oğuzhan Karci, Can Gürel, M. Kâzım Yazıcı*

207. *Long-term Functional Improvements in the 2-Year Treatment of Schizophrenia Outpatients with Olanzapine Long-acting Injection*

*Haya Ascher-Svanum, Diego Novick, Josep M. Haro, Jordan Bertsch, David McDonnell, Holland Detke*

208. *New Results Alter Balance of Evidence in Meta-analysis of Long-Acting Injectable vs. Oral Antipsychotics in Schizophrenia*

*Taishiro Kishimoto, Alfred Robenzadeh, Stanley Ng, Koichiro Watanabe, Masaru Mimura, Claudia Leucht, Stefan Leucht, John M. Kane, Christoph U. Correll*

209. *Central Glycine Increase in Rats, Monkeys and Healthy Volunteers after Two Glycine Reuptake Inhibitors, RG1678 and RG7118*

*Flavia Pizzagalli, Meret Martin-Facklam, Carsten Hofmann, Christophe Boetsch, Larry Ereshefsky, Alain Patat, Bruno Boutouyrie-Dumont, Joseph G. Wettstein, Daniela Alberati*

210. *Identification of a Putative Serum Biomarker Predicting Response to the Glycine Reuptake Inhibitor RG1678 in Improving Negative Symptoms in Patients with Schizophrenia*

*Anne Vogt, Daniel Umbricht, Daniela Alberati, Jens Robert Wendland, Enrico Domenici, Fabian Model, Johann Karl, Peter Kastner, Giuseppe Palermo, Carsten Horn, Dominique de Quervain, Andreas Papassotiropoulos, Gabriel Vargas, George Garibaldi, Luca Santarelli*

211. *The Behavioral Profile of TP-10 in Rodents and Non-human Primates Supports PDE10A Inhibition as a Novel Treatment Approach for Schizophrenia*


212. *The Influence of the Route of Administration on the Efficacy of Long-term Oral Antipsychotic Treatment in Schizophrenia*

*Rebecca Ranieri, Anna Castelnovo, Silvio Scarone*
213. Trends in the Pharmacological Treatment of Involuntarily Committed Patients with a Schizophrenia, Schizotypal or Delusional Disorder Over an 11 Year Observation Period
Anna-Sophia Rauch, Monika Edlinger, Thomas Wolfinger, Georg Kemmler, Nursen Yalcin, W. Wolfgang Fleischhacker, Alex Hofer

214. Study on the Control of Symptoms and Impact on Functioning in Hospital Intervention during a First Psychotic Episode
Rosa E. Rodriguez-Huesca, Jose M. Manzano

215. Prehypertension, Hypertension, Diabetes, Obesity and Cardiometabolic Changes Associated with Antipsychotic Use in Schizophrenia
Sahoo Saddichha, Sayeed Akhtar

216. Risk of New-onset Diabetes after Long-term Treatment with Clozapine in Comparison to Other Antipsychotics in Patients with Schizophrenia
Peter F. Schulte, Johanna T. Bocxe, Hieronymus J. Doodeman, Ingrid M. van Haelst, Dan Cohen

217. Leptin Reversed the Sensorimotor Gating Disturbance in a Rat Developmental Model of Schizophrenia
Ali Shahbazi, Somayeh Dashti, Nahid Aboutaleb

218. Bayesian Analysis of Weighted-Z Tests in Adaptive Trial Design
Cynthia Siu, Carla Brambilla, Fabrizio Ruggeri

219. Differences Between Patients Undergoing Augmentation or Switching of Antipsychotic Medications During Treatment of Schizophrenia
Virginia L. Stauffer, Haya Ascher-Svanum, Alan J. M. Brnabic, Anthony H. Lawson, Bruce J. Kinon, Peter D. Feldman, Katarina Kelin

220. A Phase 1b Study Investigating the Potential Interaction between LY2140023 and Second Generation Antipsychotics in Subjects with Schizophrenia or Schizoaffective Disorder
Virginia L. Stauffer, Mosun Ayan-Oshodi, Eshetu T. Wondmagegnehu, Jennifer Wilcher, Tong Shen, Eunice Soek Mun Yuen, Ludmila Kryzhanovskaya, Lev Gertsik, David P. Walling

221. Acute and Chronic Administration of Cotinine to DBA/2 Mice Increase Conditioning Amplitude in the Sensory Inhibition Model
Karen E. Stevens, Lijun Zheng, Kevin S. Choo

222. Prediction of Remission in a Sample of Subjects with Schizophrenic Disorder
Paolo Stratta, Alessandro Rossi

223. A Novel Interactive Social Cognition Task Reveals Decreased Adaptation of Verbal Productions as a Function of Interlocutor’s Likely Knowledge in People with Recent-onset Schizophrenia
Amélie M. Achim, Sophie Couture, Marie-Audrey Lavoie, Marion Fossard

224. Improving Functional Outcome Using Compensatory Strategies in Comorbid Intellectual Disability and Psychosis: A Case Study
Kelly A. Allott, Shona M. Francey, Dawn I. Velligan
225. Exploring the Relationship Between Schizotypy and well-being in a Student Population  
David S. Barron, Nina Smyth, Kevin D. Morgan, Tony Towell, Angela Clow

226. Social Cognition Training as an Intervention for Improving Functional Outcome in First Episode Psychosis: A Pilot Study  
Cali F. Bartholomeusz, Kelly Allott, Eoin Killackey, Stephen J. Wood, Andy Thompson

227. Relationships of Object Relations to Empathy and Social Skills Performance in Schizophrenia and Healthy Controls  
Morris D. Bell, Silvia Corbera, Satoru Ikezawa, Bruce E. Wexler

228. Affective Prosody Perception in Remitted Patients with Schizophrenia Compared to Healthy Controls  
Falko Biedermann, Susanne Baumgartner, Alexandra Kaufmann, Christine Hoertnagl, Christian Georg Widschwending, Nursen Yalcin, Wolfgang W. Fleischhacker, Alex Hofer

229. Predictors of Recovery and Social Functioning in Early Psychosis  
Geneviève Bourdeau, Tania Lecomte, Paul H. Lysaker

230. Enhancing Adherence to Antipsychotic Medication: Where are we Going Wrong?  
Ellie Brown, Richard Gray

231. Motivation and Metacognition as Predictors of Occupational Functioning in Remitted Schizophrenia Patients  
Cumhur Tas, Elliot C. Brown, Aysen E. Danaci, Lysaker H. Paul, Martin Brüne

232. How Separable are the Domains of Social Cognitive Deficits in Schizophrenia?  
Elliot C. Brown, Cumhur Tas, Aysen E. Danaci, Martin Brüne

233. An Investigation into Covert Signal Detection and Selective Attention Control in Individuals Diagnosed with Schizophrenia Using a Covert Cueing Paradigm  
Elizabeth Bryant, Mohammed M. Al-Uzri, Maria Dale, Timothy Millward, Vesna Acovski, Chris Stowers Steven S. Shimozaki

234. Social Skills and Social Functioning Related to Type and Severity of Psychiatric Symptoms  
Emma Casas-Anguera, Gemma Prat, Susana Ochoa, Maria Escandell Jose, Ramon Martin Jose, Sonia Vilamala, Mar Garcia-Franco

235. Smoking and Other Cardiovascular Disease Risk Behaviours among People with Severe Mental Disorders  
Amanda Baker, Robyn Richmond, Frances Kay-Lambkin, David Castle, Sacha Filia, Jill Williams, Vanessa Clark

236. Listeners’ Impressions of Speakers with Schizophrenia: Impact for Social Functioning  
Maud Champagne-Lavaux, Anne-Sophie Lienhart, Julie Girer, Hélène Wilquin, Mariapaola D’Imperio
237. Effects of Extended Case Management on Functioning in People with Early Psychosis- Preliminary Findings of the EASY3 Randomised Controlled Study

238. Emotion Recognition and Social Functioning Deficits in Schizophrenia
Cameron M. Clark, Vina M. Goghari, Frédéric Gosselin

239. Family History of Psychosis, Social Risk Factors and Risk of Developing Psychosis
Jacqueline Stowkowy, Jean Addington

240. Subjective Quality of Life of Nigerian Outpatients with Schizophrenia: Sociodemographic and Clinical Correlates
Adegoke O. Adelufosi, Adeboyega Ogunwale, Olukayode Abayomi, Temilola J. Mosanya

241. Social Cognition and Quality of Life in Schizophrenia
Arija Maat, Anne-Kathrin Fett, Eske Derks, GROUP Investigators

242. Recovery Based Practice in Acute Psychosis – The Current State of Play, Future Directions
David Ash, Jonathan Crichton

243. OPEN BOARD

244. Early Psychosis Intervention: Service Model Determines Case Detection Rate but What the Clinician Does Determines 6 to 12 Month Outcomes
Stanley V. Catts, Brian I. O’Toole, Vaughan J. Carr, Terry Lewin, Amanda Neil, Meredith G. Harris

245. Metabolic Monitoring for Black vs White Veterans with Schizophrenia
Laurel A. Copeland, John E. Zeber, Karon L. Phillips, Richard A. Beswick

246. Early Patterns of Symptom Profiles Using the Positive and Negative Syndrome Scale (PANSS) to Inform Decisions on the Expected Response to Treatment during Clinical Trials
Christian Yavorsky, Anzalee Khan, Mark Opler, Guillermo DiClemente, Ashleigh DeFries, Sofija Jovic

247. Neuro-cognitive Presentations of Methamphetamine Abusers with and without Psychosis Compared to Schizophrenics
Chih-Ken Chen, Liang-Jen Wang, Yi-Chih Chen, Ming-Chy Huang, Shih-Ku Lin

248. Intervention in Schizophrenia in an Underserviced Community: Addressing Comorbid Substance Abuse
Leonardo Cortese, Saadia Ahmad, Jeffrey Geml, Giovanni Villella, Corina Velehorschi

Monika Edlinger, Anna-Sophia Rauch, Georg Kemmler, Nursen Yalcin, W.Wolfgang Fleischhcker, Alex Hofer

250. Cannabis Abuse and Psychotic Symptoms in Patients with their First Episode of Psychosis
Miriam Sirianni, Marta Di Forti, Pasquale De Fazio, Simona A. Stilo, Sonia M. Pintore, Craig Morgan, Robin M. Murray
251. Event-related Potentials and Brain Rhythm Oscillations Changes in First-episode Schizophrenia during Working Memory Activation
Pascal Missonnier, Maryse Badan Bâ, Panteleimon Giannakopoulos, Marco Merlo

252. Plasma Ndel1 Activity is Reduced in Patients with Schizophrenia.
Ary Gadelha, Mauricio F. M. Machado, Camila M. Yonamine, João Ricardo Sato, Vitor Oliveira, Rodrigo A. Bressan, Mirian A.F. Hayashi

253. Prediction of Psychosis in Clinical High-risk Patients by Schizotypal PersonalityQuestionnaire
Raimo K. R. Salokangas, Peter Dingemans, Markus Heinimaa, Tanja Svisrskis, SinkkaLuutonen, Joachim Klosterkötter, Stephan Ruhrmann, Georg Juckel, Heinrich Graf von Reventlow5, Don Linszen, Max Birchwood6, Paul Patterson

254. Childhood Adversity and Premorbid Schizotypal Traits: Findings from the AESOP First-episode Psychosis Case-control Study
Tjasa Velikonja, Craig Morgan, Paola Dazzan, Kevin Morgan, Paul Fearon, Gillian Doody, Peter Jones, Robin Murray, Helen L. Fisher

255. Clinical Features of Patients with Schizophrenia who Showed Symptomatic Remission
Yeon Ho Joo, Jung Sun Lee, So Yeon Park

256. Structural Brain Correlates of Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A 6 Year Follow-up Study of Initially Antipsychotic Naive, First-Episode Schizophrenia patients
Trine Bjørg Hammer, William Baaré, Arnold Skimminge, Birte Glenthøj, Bob Oranje

257. Task-dependent Modulation of Cortical Excitability and Intracortical Inhibition in Schizophrenia
Agathe Saby, Pavel G. Lindberg, Benoît Crepon, Marie-Odille Krebs, Raphaël Gaillard, Isabelle Amado

258. Variation in Functional Ratings of Patients with Schizophrenia among Different Types of Informants and the Relationship to Objective Measures of Ability
Sara J. Czaja, David A. Loewenstein, Jonathan E. Sherin, Philip D. Harvey

259. Maternal Antibodies to Dietary Antigens and Risk for Non-affective Psychoses in the Offspring
Susanne Wicks, Håkan Karlsson, ÅsaBlomström, Shuojia Yang, Robert H. Yolken, Christina Dalman

260. The Expression of Pro-inflammatory Cytokines in Patients with Schizophrenia
Kara O’Connell, JoginThak, KumleshDev

261. Severe Weight Gain in Association with Duration of Antipsychotic use; A Meta-analysis of RCT’s between 1999 and 2009
Maarten Bak, Annemarie Fransen, Jim van Os, MarjanDrukker

262. Lexical-semantics and Schizotypy: What Deficits do High Schizotypes have with Word Processing?
Giorgia Wagner, Eric Tan, Susan Rosell

263. Spinocerebellar Ataxia Type 17: a Putative Neurochemical and Behavioural Model of Schizophrenia-like Phenotype Development
Davide Amato, Sally Makady, Fabio Canneva, Stephan von Hörsten, Christian P. Müller

264. Disrupted Functional Connectivity During Memory Encoding and Retrieval in Patients with First-Episode Schizophrenia
Kristen M. Haut, Theo G. Van Erp, Barbara J Knowlton, Keith H. Nuechterlein, Kenneth L. Subotnik, Joseph Ventura, Tyrone D. Cannon

265. Computational Approach to Understanding Cortical Circuit Deficits of Schizophrenia
Peter J. Siekmeier, Tsung-Ung W. Woo
Monday Poster Session and Lunch

1. Insecure Attachment Style Mediates the Association between Childhood Adversity and Subclinical Psychotic Symptoms in a Non-clinical Sample
Tamara Sheinbaum, Thomas R. Kwapił, Agnès Ros, Sergi Ballespí, Mercè Mitjavila, Neus Barrantes-Vidal

2. Sudden, Acute Stress during Early Development Confers the Greatest Risk of Schizophrenia and Bipolar Disorder – A Population-based Study
Mary C. Clarke, Antti Tanskanen, Matti O. Huttunen, Mary Cannon

3. Beyond White Blood Cell Monitoring: Screening in the Initial Phase of Clozapine Therapy
Dan Cohen, Jan P. Bogers, Daniel van Dijk, Bert Bakker, Peter F. Schulte

4. Sex Differences in Plasma Clozapine/Norclozapine and Olanzapine Concentrations in Clinical Practice: Data from a Therapeutic Drug Monitoring Service
Lewis Couchman, Sally V. Bowskill, James H. MacCabe, Maxine X. Patel, Robert J. Flanagan

5. Gender Differences in the Association between Childhood Adversity, Social Support, and Psychosis
Charlotte E. Gayer-Anderson, Helen L. Fisher, Paola Dazzan, Paul Fearon, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M. Murray, Craig Morgan

6. A New Treatment Algorithm for Tardive Dyskinesia or Dystonia
Peter N. van Harten, Charlie L. Mentzel, Diederik E. Tenback, Rob Bakker, Marina Tijssen, Jim Jim

7. Neurochemical Changes in Schizophrenia are Primed by the Synergistic Action of Prenatal Immune Challenge and Restraint Stress
Jessica Deslauriers, Annie Larouche, Philippe Sarret, Sylvain Grignon

8. Suicide-related Behaviors Induced by Social Isolation in a Model of Schizophrenia
Jessica Deslauriers, Karine Belleville, Karyn Kirby, Nicolas Beaudet, Philippe Sarret, Sylvain Grignon

9. Antagonists at N-Methyl-D-Aspartate Receptor (NMDA-R) with Different Clinical Profile Affect Differently the Transcripts of Constitutive and Inducible Early Genes at Postsynaptic Density
Felice Iasevoli, Chiara Sarappa, Anna Eramo, Elisabetta F. Bonaguro, Federica Marmo, Andrea de Bartolomeis

10. Effects of Maternal Immune Activation on Gene Expression Patterns in the Fetal Brain
Krassimira A. Garbett, Elaine Y. Hsiao, Sára Kálmán, Paul H. Patterson, Károly Mirnics

11. The Sp4 Hypomorphic Mouse as a Model Relevant to Schizophrenia
Xianjin Zhou, Mark A. Geyer
12. A Dual Model of Schizophrenia in Rats Reveals Deficiencies in the Structure and Inhibitory Neurotransmission of the Medial Prefrontal Cortex
Javier Gilabert-Juan, Maria Belles, Ana R. Saez, Hector Carceller, Maria D. Molto, Juan Nacher

Melanie D. Guenette, Adria Giacca, Margaret Hahn, Celine Teo, Loretta Lam, Araba F. Chintoh, Tamara Arenovich, Gary Remington

14. How does Maternal Inflammation in the Mouse Result in Alterations in GAD67 and Reelin Expression in the Hippocampus?
Louise Harvey, Nadia Zeramdini, Ridha Joober, Patricia Boksa

15. Sulforaphane as a Potential Therapeutic Drug for Schizophrenia
Kenji Hashimoto, Hongxian Chen, Yuko Fujita, Jichun Zhang, Tamaki Ishima, Yumi Shirai, Jin Wu

16. Cariprazine, a D3/D2 Dopamine Receptor Partial Agonist Antipsychotic, Displays Greater D3 Receptor Occupancy in Vivo Compared with Other Antipsychotics
Bela Kiss, Ferenc Horti, Amrita Bobok

17. Oxygen Restriction of Neonate Rats Elevates HIF-1α, IL-6, NF-κb and Capase-3 Protein Levels: Possible Relationship to Neurodevelopmental Disorders
Sylvia Lam, Qi Li, Ran Wei, Xiaofan Zhang, Siew Chua, Grainne M McAlonan

18. Effects of Direct and Indirect Cannabinoids Agonists on Contextual Fear Conditioning in a New Animal Model of Schizophrenia: The SHR Strain
Raquel Levin, Valéria Almeida, Fernanda Fiel Peres, Neide Derci da Silva, Ana Maria Vendramini, Mariana Bendlin Calzavara, Vanessa Costhek Abílio

19. X-linked Tspyl2deficit Mouse is Associated with a Phenotype of Schizophrenia
Q. Li, Kwun K. Wong, Ran Wei, Sylvia Lam, Xiao F. Zhang, Pak C. Sham, Siew E. Chua, Siu Y. Chan, Grainne M. McAlonan

20. Maternal Immune Activation in the Early or Late Pregnancy Leads to the Different Behavioral Abnormalities of the Adult Offspring Relevant to the Schizophrenia
Qi Li, Ran Wei, Xiao Fan Zhang, Sylvia Lam, Siew E. Chua, Grainne M. McAlonan

21. Functional Hemispheric Lateralization for Language in Patients with Schizophrenia
Mathieu Alary, Annick Razafimandimby, Nicolas Delcroix, Sonia Dollfus

22. Brain Activation to Facial Emotion in Individuals Reporting Psychotic-like Experiences: A fMRI Community-based Twin Study
Silvia Alemany, Alex Mas, Ximena Goldberg, Carles Falcón, Núria Bargalló, Cristobal Gastó, Lourdes Fañanás

23. Interaction between DRD2 Genetic Variation and Bromocriptine Stimulation on Prefrontal Response during Attentional Control in Healthy Individuals
Linda A. Antonucci, Paolo Taurisano, Barbara Gelao, Leonardo Fazio, Pierluigi Selvaggi, Tiziana Quarto, Gianluca Ursini, Antonio Rampino, Raffaella Romano, Apostolos Papazacharias, Annabella Di Giorgio, Grazia Caforio, Teresa Popolizio, Lorenzo Sinibaldi, Giuseppe Blasi, Alessandro Bertolino
24. Defective Joint Action Processing in Schizophrenia  
Bianca Backasch, Farahnaz Klöhn-Saghatolislam, Martin Pyka, Benjamin Straube, Tilo Kircher, Dirk Leube

Heidelore Backes, Bruno Dietsche, Mirjam Stratmann, Carsten Konrad, Tilo Kircher, Axel Krug

26. Effect of Low Frequency rTMS Treatment on Inner Speech Related Activity in Schizophrenia Patients with Auditory Verbal Hallucinations  
Leonie Bais, Ans Vercammen, Marianne Oldehinkel, Rikus Knegtering, André Aleman

27. Neural Correlates of ToM in Schizophrenia: A Meta-analysis of Functional Neuroimaging Studies  
Nadia Baklouti, Annick Razafimandimby, Sonia Dollfus

28. Interaction between COMT Val158Met Polymorphism and Susceptibility for Schizophrenia during Emotion Processing  
Luciana Lo Bianco, Francesca Ferrante, Paolo Taurisano, Annabella Di Giorgio, Barbara Gelao, Leonardo Fazio, Gainluca Ursini, Raffaella Romano, Apostolos Papazacharias, Grazia Caforio, Lorenzo Sinibaldi, Teresa Popolizio, Cesario Bellantuono, Giuseppe Blasi, Alessandro Bertolino

29. Evaluation of Cortex-based Alignment for fMRI Studies of Working Memory in Schizophrenia  
Robert A. Bittner, David E. J. Linden, Wolf Singer, Rainer Goebel, Corinna Haenschel

30. Dopamine Synthesis Capacity in Regular Cannabis Users who Experience Transient Psychotic Symptoms on Cannabis: An [18F]-DOPA PET Imaging Study  
Michael A.P. Bloomfield, Celia J. A. Morgan, Alice Egerton, Shitij Kapur, H. Val Curran, Oliver D. Howes

31. Reduced Connectivity in the Default Mode Network of Schizophrenia Patients with Poor Insight  
Edith J. Liemburg, Lisette Van der Meer, Marte Swart, Branislava Curcic, Richard Bruggeman, Henderikus Knegtering, André Aleman

32. Brain Response to Psychological Stress in Patients with Schizophrenia: Preliminary Results  
Mariana N. Castro, Mirta F. Villarreal, Oscar I. Jáuregui, Fernando Binder, Delfina de Achával, Elsa Y. Costanzo, Karl-Jürgen Bär, Salvador M. Guinjoan

33. Fingerprint of Antipsychotic Drug Action Revealed by Arterial Spin Labeling-based phMRI  
Thomas Mueggler, Celine Risterucci, Andreas Bruns, Basil Kuennecke, Edilio Borroni, Joseph G. Wettstein, Jean-Luc Moreau, Markus von Kienlin

34. Working Memory-related Brain Activity in Antipsychotic-naïve Schizophrenia Patients after Seven Months of Quetiapine Treatment  

35. Studying Episodic Memory Cerebral Network: A Novel Event-related Task for fMRI  
Maria A. Nettis, Annabella Di Giorgio, Enrico D’Ambrosio, Leonardo Fazio, Paolo Taurisano, Tiziana Quarto, Marco Colizzi, Teresa Popolizio, Giuseppe Blasi, Alessandro Bertolino
36. Altered Emotion Processing in Schizophrenia Patients—A Functional Imaging Study
   Anne Pankow, Eva Friedel, Anne Beck, Michael Rapp, Florian Schlagenhauf, Andreas Heinz

   Il Ho Park, Hae-Jeong Park, Min-Seong Koo, Ji-Won Chun, Seok-Hyeong Kim, Jae-Jin Kim

38. Anterior Cingulate Biochemistry Predicts Symptom Severity in Schizophrenia: A Magnetic Resonance Spectroscopy (1H-MRS) Study
   Liv E. Falkenberg, René Westerhausen, Else-Marie Løberg, Rune Kroken, Erik Johnsen, Kasten Specht, Kenneth Hugdahl

39. Striatal Glutamate and the Conversion to Psychosis: A Prospective 1H-MRS Imaging Study
   Camilo de la Fuente-Sandoval, Pablo León-Ortiz, Rafael Favila, Sylvana Stephano, Mariana Azcárraga, Ariel Graff-Guerrero

40. Longitudinal Hemodynamic Changes and Prediction of Functional Outcome in At-risk Mental State and First-episode Psychosis
   Shinsuke Koike, Yoshihiro Satomura, Yukika Nishimura, Yosuke Takano, Norichika Iwashiro, Motomu Suga, Ryu Takizawa, Tsuyoshi Araki, Kiyoto Kasai

41. Comparison of Cerebral Glutamate and GABA in Schizotypal Personality Disorder using Spectral Editing and 2D Correlated Spectroscopy
   Alexander Lin, Hui J. Liao, Ana Cadena, Saadallah Ramadan, Israel Molina, Robert W. McCarley

42. Cannabis Effects on Brain Structure in First-episode Psychosis
   Paulo J. Cunha, Jose A. Crippa, Fabio L. Duran, Marcia Sczufca, Paulo R. Menezes, Robin M. Murray, Geraldo F. Busatto, Maristela S. Schaufelbeger

43. Structural Brain Changes in First-episode Schizophrenia: A 4-5 Year Follow-up Study Using MRI
   Maristela S. Schaufelberger, Pedro G. Rosa, Marcus V. Zanetti, Fabio L. Duran, Paulo R. Menezes, Marcia Sczufca, Robin M. Murray, Geraldo F. Busatto

44. Regional Cortical Thinning in Subjects with High Genetic Loading for Schizophrenia
   Min Soo Byun, June Sic Kim, Wi Hoon Jung, Joon Hwan Jang, Jung-Seok Choi, Sung Nyun Kim, Chi-Hoon Choi, Chun Kee Chung, Suk Kyoong An, Jun Soo Kwon

45. White Matter and Genetic Risk for Schizophrenia: A Twin DTI Study
   Francesco Carletti, Marco Picchioni, Irina Falkenberg, Timothea Toulopoulou, Gareth J. Barker, Philip K. McGuire

46. Grey Matter Density and Cortical Thickness Vary with Different Orbitofrontal Sulcogyral Patterns

47. White Matter Abnormalities in Schizophrenia: a Volume Preserved Warping (VPW) Analysis
   Tiziano Colibazzi, Bruce Wexler, Dongrong Xu, Xuejun Hao, Ravi Bansal, Bradley Peterson
48. Frontostriatal Dependency in Grey Matter Volume is Reduced in Schizophrenia

49. Neuroanatomical Alterations in Regions Mediating Language in Young Adults at High Risk for Inheritance of Schizophrenia (GHR)
Alan N. Francis, Gul A. Jabbar, Heidi W. Thermenos, Larry J. Seidman, Richard Juelich, Ashley Proal, Marek Kubicki, Martha Shenton, Matcheri Keshavan, Lynn E. DeLisi

50. White Matter Integrity in Schizophrenia and Bipolar Disorder in Association with Symptom Severity
Bruno Dietsche, Davide Laneri, Heidelore Backes, Alexandra Hellerbach, Mirjam Stratmann, Tilo Kircher, Jens Sommer, Axel Krug

51. Microstructural White Matter Biomarkers for Psychotic Disorder: A Family-based Diffusion Tensor Imaging Study
Patrick A. E. Domen, Stijn Michielse, Ed Gronenschild, Petra Habets, Alard Roebroeck, Koen Schruers, Jim van Os, Machted Marcelis

52. Grey Matter Correlates of Mismatch Negativity Amplitudes in At-risk Mental State
Tim Ehlkes, Rebekah Atkinson, Philip B. Ward, Georgie Paulik, Jackie Curtis, Patricia T. Michie, Paul E. Rasser, Juanita Todd, Helen Stain, Ulrich Schall

53. Relationship between Working Memory Performance and Prefrontal Volumes in Schizophrenia: A Family Study
Vina M. Goghari, Angus W. MacDonald, Scott R. Sponheim

54. To Trust or not to Trust: The Dynamics of Social Interactions in Early Psychosis
Anne-Kathrin J. Fett, Sukhi S. Shergill, Dan W. Joyce, Paula M. Gromann, Lydia Krabbendam

55. Cortical Thinning Over Two Years following the First Episode of Psychosis: Relationship to Treatment Duration and Cognitive Impairment

56. Classification of Schizophrenia Patients and Healthy Controls from Structural MRI Scans Verified in Two Large Independent Samples
Mireille Nieuwenhuis, Neeltje E. van Haren, Hilleke E. Hulshoff Pol, Wiepke Cahn, René S. Kahn, Hugo G. Schnack

57. Fibre Tractography Reveals Early White Matter Changes in Adolescents Reporting Subclinical Psychotic Symptoms: A Pilot Investigation
Erik O’Hanlon, Sarah Roddy, Lauren Tiedt, Matthew Hosheit, Javeria Tabisch, Ian Kelleher, Thomas Frodl, Mary Cannon

58. Increased Assortativity of Gyrification based Brain Connectome in Schizophrenia
Lena Palaniyappan, Bert Park, Peter F. Liddle
59. Reduced Anterior Cingulate Cognitive Activation is Associated with Prefrontal – Temporal Cortical Thinning in Schizophrenia
C. Christoph Schultz, Kathrin Koch, Gerd Wagner, Igor Nenadic, Claudia Schachtzabel, Daniel Güllmar, Jürgen R. Reichenbach, Heinrich Sauer, Ralf G. Schlösser

60. Psychotic-like Experiences, Psychotic Symptoms and Clinical Correlates in Preadolescent Children in the CCC2000 Birth Cohort Study
Pia Jeppesen, Lars Clemmensen, Anja Munkholm, Charlotte Eberhardt, Else M. Olsen, Hanne Elberling, Charlotte U. Rask, Torben Joergensen, Jim van Os, Anne M. Skovgaard

61. Disturbances of the Basic Self as a Core Marker of Vulnerability to Schizophrenia: Preliminary Results from a 2-year Follow-up Study among Non-psychotic Help-seeking Adolescents
Danny Koren, Noa Reznik, Merav Adres, Ravit Scheyer, Alan Apter, Josef Parnas

62. Disturbances of the Basic Self and Prodromal Symptoms among Non-psychotic Help-seeking Adolescents
Danny Koren, Noa Reznik, Merav Adres, Ravit Scheyer, Tamar Steinberg, Alan Apter, Josef Parnas

63. Changes of Leptin, Adiponectin and Ghrelin in Antipsychotic-naïve Adolescents Taking Second-generation Antipsychotics: Comparative Effects in Patients with Psychotic and Nonpsychotic Disorders
Laura Pina-Camacho, Elena Mérida, Covadonga M. Díaz-Caneja, Cecilia Tapia-Casellas, Pamela Rodríguez-Latorre, Jessica Merchán-Naranjo, David Fraguas, Carmen Moreno, Mara Parellada, Celso Arango

64. Recruitment Status of the TEA Trial: Tolerance and Effect of Antipsychotics in Children and Adolescents with Psychosis: An investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole versus Quetiapine in Children and Adolescents with Psychosis

65. Psychophysiological and Neurocognitive Profiling of Attentional Deficits in Children and Adolescents with Psychosis or ADHD
Jacob Rydkjaer, Jens Richardt Jepsen, Anne Katrine Pagsberg, Birgitte Fagerlund, Birte Y. Glenthøj, Bob Oranje

66. Persistent Positive Symptoms in Persons at High Risk of Psychosis
Mitja Bodalsch, Frauke Schultze-Lutter, Don Linszen, Raimo Salokangas, Max Birchwood, Georg Juckel, Anthony Morrison, Andreas Heinz, Heinrich von Reventlow, Joachim Klosterkötter, Stefan Ruhrmann

67. First-Rank Symptoms in Schizophrenia: Disturbed Dense of Agency vs. Auditory Hallucinations
Jet D. Heering, Neeltje E. M. van Haren, Carin J. Meijer, Lieuwe de Haan

68. Diagnostic Stability of First Episode Psychosis at 10 Year Follow-up – Preliminary Results from the AESOP Cohort
Benjamin A. Lomas, Gillian Doody

69. A Longitudinal Follow-up of Diagnostic Outcomes of Childhood-onset Schizophrenia after Inpatient Evaluation and Medication Washout
Rachel Miller, Tasia Richards, Peter Gochman, Deanna K. Greenstein, Nitin Gogtay, Judith L. Rapoport
70. Coping in Individuals at Clinical High Risk for Psychosis, Schizophrenia Patients and Healthy Control Subjects
Alexandra S.C. Nikolaides, Julia Paruch, Joachim Klosterkoetter, Stephan Ruhrmann

71. Reliability of the Assessment of Subjective Experience and of Mental Status
Julie Nordgaard, Josef Parnas

72. Dissecting the ‘Totality’ of First Episode Psychosis: Do Schizophrenia, Bipolar Disorder and Psychotic Depression Reflect Categorical Distinctions or Dimensional Intersections?
Olabisi Owoeye, Tara Kingston, Patricia A. Baldwin, David Browne, Paul J. Scully, Anthony Kinsella, Vincent Russell, Eadbhard O’ Callaghan, John L. Waddington

73. A New Mobile Assessment Technology for Psychosis: Introducing ClinTouch
Jasper E. Palmier-Claus, Shôn Lewis, Christine Barrowclough, Matt Machin, Graham Dunn, John Ainsworth

74. Can D2/3 Blockade Improve Basic Information Processing in First Episode Schizophrenia?
Signe W. Düring, Birte Glenthøj, Bob Oranje

75. Age Effects on P50 Suppression in Healthy Male Volunteers
Mikkel Erlang, Birte Glenthøj, Bob Oranje

76. Acute Ketamine Infusion in Healthy Volunteers: Effects on Early Visual Processing
Ivan G. Koychev, Andrew Shepherd, Wael El-Deredy, Bill Deakin, Corinna Haenschel

77. Serotonergic Dysfunction of Patients with Schizophrenia and Bipolar Disorder as Assessed by the Loudness Dependence of the Auditory Evoked Potential (LDAEP)
Kyung-Sang Lee, Seung-Hwan Lee, Jung-Seo Yi

78. Preferential Patterns of Gamma Band Activity to Socially-Relevant Stimuli in Schizophrenia Patients
Seung-Hwan Lee, Gewn Hi Park, Sangrae Kim, Ji-Hye Park, Do-Won Kim, Chang-Hwan Im

79. Association between Sensorimotor Gating and Mismatch Negativity
Bob Oranje, Mikkel E. Sørensen, Birte Y. Glenthøj

80. Is there an Overlap between Autism and Schizophrenia: The Search for Shared Psychophysiological Endophenotypes
Gitte F. Madsen, Niels Bilenberg, Bob Oranje

81. The Interactions between Higher-order and Sensory-based Operations during Abnormal Emotional Prosody Processing in Schizophrenia: An Electrophysiological Investigation
Ana P. Pinheiro, Andreia Rauber, Robert W. McCarley, Óscar F. Gonçalves, Margaret Niznikiewicz

82. Genetic Factors and Gene-environment Interactions: A Descriptive Study
Rebecca Ranieri, Anna Castelnovo, Silvio Scarone

83. Are Immigrants to Canada at Increased or Decreased Risk for Schizophrenia?
Marie-Jose Dealberto

84. Longitudinal Association of Stress Measures with Symptoms in Youth at Clinical High Risk for Psychosis
Jordan E. DeVylder, Shelly Ben-David, Scott Schobel, David Kimhy, Cheryl M. Corcoran
85. Paternal Age and Risk of Psychosis in Adoptees  
Mats Ek, Susanne Wicks, Cecilia Magnusson, Christina Dalman

86. Clinical and Social Correlates of Late Onset First-episode Psychosis: Findings from the AESOP Study  
Susana Borges, Helen L. Fisher, Paul Fearon, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M. Murray, Craig Morgan, Paola Dazzan

87. Childhood Adversity and Compulsory Admission during Presentation of First Episode Psychosis  
Jonathan L. Garabette, Grant McQueen, Charlotte Gayer-Anderson, Susana Borges, Adanna Onyejiaka, Monica Charalambides, Chelsea Gardner, Dionne Harleston, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Craig Morgan, Paola Dazzan, Rowena Handley

88. The Impact of Childhood Support on Life Events and Risk of Psychosis  
Chelsea A. Gardener, Charlotte E. Gayer-Anderson, Stephanie F. Beards, Adanna N. Onyejiaka, Susana Borges, Sophie Sowden, Emma Palmer, Kathryn Hubbard, Rowena Handley, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Craig Morgan, Paola Dazzan, Carmine Pariante

89. Improving Participation Rates in Population based Schizophrenia Research by Using Home Interviews  
Marianne Haapea, Erika Jääskeläinen, Juha Veijola, Matti Isohanni, Jouko Miettunen

90. Control Sampling and Selection Bias in Case-control Studies of Psychosis  
Kathryn Hubbard, Emma C. Palmer, Anisa Kurti, Tjasa Velikonja, Simona Stilo, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Paola Dazzan, Rowena Handley, Craig Morgan

Oussama Kebir, Marie-Odile Krebs

92. Childhood Adversity and Suicidal Behaviour in First Episode Psychosis Patients  
Arune Keraite, Rowena Handley, Paul Fearon, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M. Murray, Craig Morgan, Paola Dazzan

93. Cardiovascular Drug Use in Patients with Schizophrenia or Bipolar Disorder  
Thomas M. Laursen, Preben B. Mortensen, James H. MacCabe, Dan Cohen, Christiane Gasse

94. OPEN BOARD

95. Head Injury and Inflammatory Reactions as Risk Factors for Psychiatric Disorders: A Nationwide Register-based Study  
Sonja Orlovska, Michael E. Benros, Preben B. Mortensen, Merete Nordentoft

96. Age of Onset in First Episode Psychosis: The Influence and Interactions of the Environmental Risk Factors  
Brian N. O'Donoghue, John P. Lyne, Eric Roche, Niall Turner, Eadbhard O'Callaghan, Mary Clarke, Abbie Lane

97. Depression, Hopelessness and Suicidality in First Episode Psychosis and the Relationship with the Social Class of Origin  
Brian N. O'Donoghue, John P. Lyne, Felicity Fanning, Niall Turner, Eadbhard O'Callaghan, Mary Clarke, Abbie Lane
98. Validation of Suicide as Cause of Death in Cases of Undetermined Manner of Death in Schizophrenia in Sweden
Eric M. Olsson, Diana Hukic, Lise-Lotte Nilsson, Henrik Druid, Martin Schalling, Urban Ösby

99. Neighbourhood-level Socio-environmental Factors and Incidence of First Episode Psychosis by Place at Onset in Rural Ireland
Sami Omer, James B. Kirkbride, Dennis G. Pringle, Vincent Russell, Eadbhard O’Callaghan, John L. Waddington

100. Severe Trauma and First Episode Psychosis in the UK
Adanna N. Onyejiaka, Helen Fisher, Charlotte E. Gayer-Anderson, Anisa Kurti, Susana Borges, Grant McQueen, Arune Keraite, Dione Harleston, Monica Charalambides, Rowena Handley, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Paola Dazzan, Craig Morgan

101. Mental Health Literacy: Are Psychoses Catching Up with Depression?
Frauke Schultze-Lutter, Chantal Michel, Renata Kulcsarova, Franziska Durstewitz, Nina Schnyder, Benno G. Schimmelmann

102. COMT Genotype Modulates the Effects of Childhood Adversity on Cognition and Symptoms in Schizophrenia
Melissa J. Green, T-Yunn Chia, Murray J. Cairns, Jing Q. Wu, Paul Tooney, Rodney J. Scott, Vaughan J. Carr

103. Interaction between COMT Genotype, Cannabis Use, and BFQ Measures of Sociability
Marco Colizzi, Gianluca Ursini, Annamaria Porcelli, Marina Mancini, Barbara Gelao, Antonio Rampino, Lorenzo Sinibaldi, Maria T. Attrotto, Lucia Colagiglio, Giuseppe Rizzo, Giancarlo Maddalena, Rita Masellis, Annabella Di Giorgio, Grazia Caforio, Giuseppe Blasi, Alessandro Bertolino

104. The Case that Psychosis is Transmitted Epigenetically on an XY Template
Timothy J. Crow

105. The Relevance of the Protocadherin11XY Gene Pair
Timothy J. Crow, Thomas H. Priddle

106. Startle Reactivity and Prepulse Inhibition of the Acoustic Startle Response are Modulated by COMT Val158Met Polymorphism in Adults with 22q11 Deletion Syndrome
Mariken B. De Koning, Erik Boot, Oswald J. N. Bloemen, Esther D. A. Van Duin, Kathryn M. Abel, Lieve De Haan, Don H. Linszen, Thérèse A. M. J. Van Amelsvoort

107. Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions
Jeroen Decoster, Jim van Os, Inez Myin-Germeys, Marc De Hert, Ruud van Winkel

108. Modulatory Effect of the Interleukin -1β Gene on Dorsolateral Prefrontal Cortex Function in Schizophrenia but not in Healthy Subjects: A Genetic Neuroimaging Study
Mar Fatjó-Vilas, Edith Pomarol-Clotet, Raymond Salvador, Gemma C Monté, Jesús J. Gomar, Salvador Sarró, Jordi Ortiz-Gil, Candibel Aguirre, Ramón Landín-Romero, Amalia Guerrero-Pedraza, Sergi Papiol, Josep Blanch, Peter J. McKenna, Lourdes Fañanás
109. Neuritin-1 Gene is Associated with Risk for Schizophrenia-spectrum Disorders and their Age at Onset  
Mar Fatjó-Vilas, Salvador Miret, M. José Muñoz, Bárbara Arias, Manuel Ignacio Ibáñez, Luisa Lázaro, Víctor  
Peralta, Manuel J. Cuesta, Generós Ortet, Lourdes Fañanás

110. No Association between SNAP-25 Gene Polymorphisms and Weight Gain in Antipsychotic Treatment of  
Schizophrenia  
Aziz Ferchiou, Anne Dumaine, Mohamed Lajnef, Christophe Lançon, Pierre Michel Llorca, Stéphane  
Jamain, Marion Leboyer, Alexandre Méary

111. Aberrant Tyrosine Transport across the Fibroblast Membrane in Patients with Schizophrenia –  
Indications of Maternal Inheritance  
Lena Flyckt, Gunnar Edman

112. Immune-Related Differential Expression Profile in Peripheral Blood Mononuclear Cells in Schizophrenia  
Erin J. Gardiner, Murray J. Cairns, Natalie J. Beveridge, Bing Liu, Vaughan Carr, Rodney Scott, Paul Tooney

113. COMT Modulates the Effects of Lifetime Cannabis Use on Cognition and Symptom Profiles in  
Schizophrenia  
Melissa J. Green, T-Yunn Chia, Murray J. Cairns, Paul Tooney, Rodney J. Scott, Vaughan J. Carr

114. Genome-wide Supported Variants (MIR137) Predicts Membership of a Cognitive Subtype of  
Schizophrenia  
Melissa J. Green, Murray J. Cairns, Jin Qin Wu, Milan Dragovic, Assen Jablensky, Paul Tooney, Rodney  
Scott, Vaughan J. Carr

115. Increased Expression of Putative DNA Demethylation Genes in Psychosis  
Alessandro Guidotti, Erbo Dong, David P. Gavin, Dennis R. Grayson

116. ZNF804A and Social Cognition in Patients with Schizophrenia and Healthy Participants  
April Hargreaves, Derek W. Morris, Rose Emma, Michael Gill, Aidan Corvin, Gary Donohoe

Yutaka Mizuki, Manabu Takaki, Yuko Okahisa, Masafumi Kodama, Hiroshi Ujike, Yosuke Uchitomi

118. A Polymorphism in the CNR1 Gene is Associated with Gene Expression and Schizophrenia  
Yuko Okahisa, Hiroshi Ujike, Masafumi Kodama, Manabu Takaki, Yutaka Mizuki, Shinji Sakamoto, Nao  
Imai, Yosuke Uchitomi, Makoto Arai, Masanari Itokawa

119. Candidate Genes for Schizophrenia in a Mixed Brazilian Population Using Pooled DNA  
Vanessa K. Ota, Ary Gadelha, Renata Pellegrino, Fernanda T. Bellucco, Denise M. Christofolini, Marcos  
L. Santoro, Diogo R. Lara, Gustavo L. Ottoni, Ândrea K. Ribeiro-dos-Santos, Sidney Santos, Jair J.  
Mari, Marilza A. Smith, Rodrigo A. Bressan, Maria I. Melaragno, Sintia I. Belangero

120. Long-Term Healthcare Costs and Functional Outcomes Associated with Lack of Remission in  
Schizophrenia  
Virginia S. Haynes, Baojin Zhu, Virginia Stauffer, Bruce J. Kinon, Lei Xu, Haya Ascher-Svanum

121. Protein Profiling of Patients with Acute Psychosis vs. Psychiatric Controls: A Proteomic Approach  
Valentina Mantua, Ginevra Orsolini, Laura Giusti, Mauro Mauri, Antonio Lucacchini
122. Correlations between Clinical Symptoms and Level of Serum Antibodies to Herpes Group Viruses in Paranoid Schizophrenia
Irina I. Mikhailova, Vera A. Orlova, Vitalij L. Minutko

123. BDNF Levels in Schizophrenia – Do Evolution and Type of Schizophrenia Matter?
Cristina V. Oliveira, Alicia Valiente, Ana Meseguer, Clemente Garcia-Rizo, Amalia Lafuente, Miguel Bernardo

124. Relationship between Oxidative Stress/Inflammation and Cognitive Impairment in First Episode Psychosis
Sonia Ruiz de Azua, Patricia Vega, Monica Martinez-Cengotitabengoa, Sara Barbeito, Belen Garcia-Lecumberri, Mahmoud Karim Haidar, Margarita Saenz-Herrero, Ana Gonzalez-Pinto

125. Interleukin-6 Levels in Cerebrospinal Fluid of Patients with Schizophrenia
Daihei Sasayama, Kotaro Hattori, Haruko Tanaka, Hiroaki Hori, Toshiya Teraishi, Miho Ota, Naoji Amano, Hiroshi Kunugi

126. In Vitro and In Vivo Characterization of a New Selective Phosphodiesterase 10 Radioligand
Hervé Schaffhauser, Michael Honer, Jens Uwe Peters, Luca Gobbi, Thomas Hartung, Agnès Nilly, Patricia Glaentzlin, Céline Sutter, Edilio Borroni, Joseph G. Wettstein, Alexander Flohr

127. Clinical and Brain Imaging Correlates of Neurological Soft Signs in Schizophrenia: A Contribution to the Neurodevelopmental Model of Schizophrenia
Olivier Gay, Marion Plaze, Catherine Oppenheim, Sabine Mouchet-Mages, Raphael Gaillard, Jean-Pierre Olie, Marie-Odile Krebs, Arnaud Cachia

128. Neurodevelopmental Liability to Schizophrenia: the Complex Mediating Role of Age at Onset and Premorbid Adjustment
Ximena Goldberg, Mar Fatjó-Vilas, Rafael Penadés, Salvador Miret, María J. Muñoz, Helen Vossen, Lourdes Fañanás

129. A Quantitative Meta-analysis of Population-based Studies of Premorbid Intelligence and Schizophrenia
Golam M. Khandaker, Jennifer H. Barnett, Ian R. White, Peter B. Jones

130. Cortical Gyrification and Neurological Soft Signs in Schizophrenia: Markers of Developmental Load
Marie-Odile Krebs, Olivier Gay, Marion Plaze, Jean Pierre Olié, Catherine Oppenheim, Arnaud Cachia

Antonella Trotta, James H. MacCabe, Robin M. Murray

132. Proteomic Investigation of the Postsynaptic Density in the Brain in Schizophrenia
Melanie Foecking, Patrick Dicker, Jane English, Ger Cagney, David Cotter

133. Alteration of the Expression Balance of hnRNP C1 and C2 Changes the Expression of Myelination- and Schizophrenia-related Genes in the Human Neuroblastoma Cell Line
Keiko Iwata, Hideo Matsuzaki, Nori Takei, Norio Mori

134. A Cross Sectional Study of Novel P300 in Prodromes and First Episode Schizophrenia
Elisabetta C. del Re, Margaret Niznikiewicz, Tracy Petryshen, Robert W. McCarley
135. Neurological Soft Signs and Prepulse Inhibition of the Startle Reflex in Psychosis: A Pilot Study
Elisa Ira, Sarah Tosato, Chiara Bonetto, Martina Zanoni, Rodolfo Mazzoncini, Lisa Martini, Angela Garozzo, Antonio Lasalvia, Michele Tansella, Mirella Ruggeri

136. Computational Models of Hallucinations
Renaud Jardri, Sophie Deneve

137. Effects of High and Low-frequency rTMS on P50: Preliminary results
Clement Nathou, Olivier Etard, Gregory Simon, Annick Razafimandimby, Sonia Dollfus

138. Symptomatic Remission in Schizophrenia: Relation of Cognitive Functions and Clinical Features
Ahmet Yiğit Aktener, Berna Binnur Akdede, Banu Değirmecioğlu, Köksal Alptekin

139. Emotional Prosody Modulates Attention in Schizophrenia Patients with Hallucinations
Lucy Alba-Ferrara, Marco Hirnstein, Susanne Weis, Markus Hausmann

140. Impaired Saccadic Adaptation in Schizophrenic Patients with High Neurological Soft Signs Scores
Isabelle Amado, Anne Le Seac'h, Hernan Picard, Raphael Gaillard, Marie-Odile Krebs, Cecile Beauvillain

141. The Zoo Map Test Reveals Heterogeneity in Action Planning Profiles in Schizophrenia
Alice Rampazzo, Dominique Willard, Aurélie Lagodka, Raphaël Gaillard, Nicolas Franck, Marie-Odile Krebs, Isabelle Amado, Philippe Allain

142. Metacognition of Agency in Patients with Schizophrenia
Elisabeth Bacon, Janet Metcalfe

143. At Risk for Psychosis: The Role of Cognition
Mark A. Colijn, Mariapaola Barbato, Richard S. E. Keefe, Diana O. Perkins, Scott W. Woods, Jean Addington

144. Can Neuropsychological Profile (RBANS) Predict Co-Morbid Traumatic Brain Injury and Psychosis?
Rachel A. Batty, Susan L. Rossell, Neil Thomas, Andrew J. P. Francis, Malcolm Hopwood

145. Enhanced Visuospatial Imagery Manipulation in Schizophrenia
Taylor L. Benson, Sohee Park

146. Are Auditory Processing Deficits a Sensory Substrate of Receptive Prosodic Dysfunction and Auditory Hallucination in Schizophrenia?
Christopher J. Groot, Susan Rossell, Henry J. Jackson

Hee-Yeon Jung, Yeni Kim, Samuel Hwang, Se-Hyun Kim, Jae-Seung Chang

148. Cognitive Reserve: Does it Modify the Effect of Age on Cognitive Remediation Therapy Outcome in Schizophrenia?
Dimitrios Kontis, Vyv Huddy, Clare Reeder, Sabine Landau, Til Wykes
149. **COMT and MTHFR Polymorphisms Interaction on Working Memory in Schizophrenia: An Exploratory Study**

Dimitrios Kontis, Eirini Theochari, Helen Fryssira, Spyridon Kleisas, Christalena Sofocleous, Stamatina Kalogerakou, Angeliki Andreopoulou, Spyridoula Vassilouli, Dimitrios Kypraios, Anthisa Gazi, Lucia Boniatsi, Eleftheria Tsaltas

150. **Crystallized Verbal Skills in Schizophrenia: Relationship to Neurocognition, Symptoms and Functional Status**

Matthew M. Kurtz, Jad Donato, Jennifer Rose

151. **No Evidence for Familial Covariation of Neurocognition and Negative Symptoms in Psychotic Disorders**

Tineke Lataster, Armin Shazad, Cecile Henquet, Piotr Quee, Inez Myin-Germeys, GROUP Investigators

152. **Identifying Social Cognition as a Specific Component of Schizophrenia: The Association of Social Cognitive Capacities between Schizophrenic Patients and their Non-affected Mother**

Marie-Audrey Lavoie, Philip L. Jackson, Amélie M. Achim

153. **Social Cognition in Early-Onset-Schizophrenia, High Functioning Autism and Asperger Syndrome**

Eva Le Gall, Galina Iakimova, Sylvie Serret, Florence Askenazy

154. **The Comparative Strength of Multiple Predictors of Real World Functioning in Patients with Schizophrenia**

David Loewenstein, Sara Czaja, Philip Harvey

155. **Theory of Mindand Context Processing in Schizophrenia: The Role of Social Knowledge**

Maud Champagne-Lavau, Anick Charest, Guy Blouin, Jean-Pierre Rodriguez

156. **Neurocognitive Impairments in Adolescents with At-Risk States of Psychosis**

Chantal M. Michel, Benno G. Schimmelmann, Nicole Leibundgut, Frauke T. Schultze-Lutter

157. **Different Vulnerability Indicators for Psychosis and their Neuropsychological Characteristics in the Northern Finland 1986 Birth Cohort**


158. **Flexible Object Working Memory Capacity in Schizophrenia and Healthy Participants in a Self-order Task**

Heathman S. Nichols, Jared X. Van Snellenberg, Edward E. Smith, Sohee Park

159. **Early Visual Processing in Early and Adult Onset Schizophrenia: A Source Analysis of the N80 Visual Evoked Potential**

Daniel Nunez, Andre Rupp, Matthias Weisbord, Rieke Oelkers-Ax

160. **A Cluster Approach for Determining Groups of Patients with First Psychotic Episode and their Relationship with Symptoms, Social and Neuropsychological Functioning**

Susana Ochoa, Judith Usall, Elena Huerta-Ramos, Montserrat Dolz, Ana Barajas, Iris Baños, Bernardo Sánchez, Janina Carlson, Alexandrina Foix, Trinidad Pelaez, Marta Coromina, Marta Pardo
161. Neurocognitive Profile and its Association with Psychopathology in First-degree Relatives of Patients with Schizophrenia: A Case–control Study
Silvia Scala, Antonio Lasalvia, Cristofalo Doriana, Bonetto Chiara, Ruggeri Mirella

162. Disturbed Self-agency in Schizophrenia Due to Abnormal Implicit (but not explicit) Processing of Action-outcome Information
Robert A. Renes, Lisanne Vermeulen, Rene S. Kahn, Henk Aarts, Neeltje E. van Haren

163. Neural Correlates of CBT in Patients with Positive Symptoms during a Jumping to Conclusions Task
Axel Krug, Henrik Walter, Georg Winter, Wolfgang Wölwer, Bernhard Müller, Jutta Herrlich, Georg Wiedemann, Kai Vogeley, Andreas Wittorf, Alexander Rapp, Stefan Klingberg, Maurice Cabanis, Tilo Kircher

164. Feasibility of Mindfulness Based Therapy in Patients Recovering from a First Psychotic Episode, A Pilot Study
Carin J. Meijer, Renate van der Valk, Susanna van der Waerdt, Ingrid van den Hout, Lieuwe de Haan

165. Efficacy and Safety of Deep Brain Stimulation in Patients with a Psychiatric Illness and Tardive Dyskinesia and/or Dystonia; A Systematic Review
C.L. Mentzel, D.E. Tenback, P. N. van Harten

166. Negative Schematic Beliefs about Self and Others Differentially Predict Suspiciousness in at-risk States
Hendrik Müller, Michael Wagner, Wolfgang Maier, Marion Lautenschlager, Walter de Milis, Birgit Janssen, Wolfgang Gaebel, Tanja Michel, Frank Schneider, Martin Lambert, Dieter Naber, Georg Juckel, Thomas Wobrock, Michael Riedel, Joachim Klosterkötter, Andreas Bechdolf

167. Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
Danijela Piskulic, Mariapaola Barbato, Jean Addington

168. Attention and Memory Training in Stable Schizophrenic Patients: A Double-blind, Randomized, Controlled Trial Using Simple Resources

169. Involvement of Patients and Relatives in Scientific Research Projects: Experiences from the GROUP Study
Agna A. Bartels-Velthuis

170. Coping Strategies in Carers of Patients with First Episode Psychosis
Sue M. Cotton, McCann Terence, John Gleeson, Kingsley Crisp, Catania Lisa, Daniel Lubman

171. Psychiatrists’ Perceptions of the Clinical Importance, Assessment and Management of Patient Functioning in the Treatment of Schizophrenia: Results of an EMEA-wide Survey
Philip Gorwood, Georg Juckel, Tom Burns, Alessandro Rossi, Luis San, Pierre Cherubin, Ludger Hargarter, Andreas Schreiner

172. Effects of Family Member Participation on Structural Transparency and Content of Discourse in Schizophrenia
Pertti O. Hella, Jussi Niemi, Lidia Otsa, Jani-Matti Tirkkonen

173. The Association of Insight with Self- and Clinician-Rated Side Effects and HRV Measures
Samuel S. Hwang, Jae Seung Chang, Yong Sik Kim
174. Vitamin D Levels in Severely Mentally Ill Patients and Staff Members in a Long Stay Psychiatric Unit
Tijmen Bostoen, Jan P. A. M. Rogers

175. Adjunctive Lisdexamfetamine Dimesylate Treatment of Predominant Negative Symptoms of Schizophrenia in Clinically Stable Adults Maintained on Atypical Antipsychotic Agents: A 14-Week Trial
Robert Lasser, Bryan Dirks, Henry Nasrallah, Courtney Kirsch, Joseph Gao, Mary Ann Knesevich, Jean-Pierre Lindenmayer

176. The Birth of the New Korean Term for Schizophrenia: JoHyeonByung(Attunement Disorder)
Yu Sang Lee, Jun Soo Kwon, Jae-Jin Kim, Il Ho Park, Seon-Cheol Park

177. The Australian Schizophrenia Research Biobank (ASRB): An Audit of the First Five-years of Recruitment Resource Access
Carmel M. Loughland, Kathryn McCabe, Jason Bridge, Frans Henskens, Stanley Catts, Assen Jablensky, Patricia Michie, Bryan Mowry, Christos Pantelis, Ulrich Schall, Rodney Scott, Paul Tooney, Liesl Duffy, Vaughan Carr

Frans Henskens, David Paul, Carmel Loughland, Jason Bridge, Kathryn McCabe, Stanley Catts, Assen Jablensky, Patricia Michie, Bryan Mowry, Christos Pantelis, Ulrich Schal, Paul Tooney, Liesl Duffy, Vaughan Carr

179. OPEN BOARD

180. The Role of Category Fluency in Schizophrenia Research: A Novel Approach to Answer the Question of whether Performance on this Task Reflects Executive or Semantic Deficits
Erica Neill, Susan L. Rossell

181. Body Mass Index (BMI) as a Predictor of Metabolic Syndrome (MetS) in Patients with Schizophrenia
Milawaty Nurjono, Jimmy Lee

182. The Effect of Telepsychiatric Follow-up on the Family Burden, Emotional Expression and Depression Levels in the Caregivers of Turkish Patients with Schizophrenia
Birgul Ozkan, Emine Erdem, Saliha Ozsoy, Gokmen Zararsiz

183. Cognitive Bizarreness as a Transnosographic Marker of Psychosis
Rebecca Ranieri, Anna Castelino, Matteo Mercatili, Armando D’agostino, Silvio Scarone

Dragana Bugarski-Kirola, Steven G. Potkin, George Garibaldi

185. Remission with Continued Paliperidone Palmitate Treatment in Stable Subjects with Schizophrenia
Joseph Hulihan, Cynthia A. Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, Yi-Wen Ma, Larry D. Alphs

186. Effectiveness vs Efficacy Rankings by a Modified PRECIS Tool for Schizophrenia Trials of Long-Acting Injectable vs. Daily Oral Antipsychotic Treatments
Cynthia A. Bossie, Larry Alphs, Joseph F. Hulihan
187. Midlife Progression and its Clinical Correlates in Schizophrenia: A 43-year Follow-up in the Northern Finland 1966 Birth Cohort
Matti Isohanni, Erika Jääskeläinen, Irene Isohanni, Kristiina Moilanen, Antti Alaräisänen, Jouko Miettunen

188. A Rasch Model Analysis to Assess Cross-cultural Differences among Items the Positive and Negative Syndrome Scale (PANSS) in Schizophrenia
Christian Yavorsky, Anzalee Khan, Stacy Leicht, Brian Rothman, Mark Opler, Ashleigh DeFries

189. Comparing Symptom Response among Antipsychotic Medications in CATIE

190. Some Notes of Caution on ‘Time-to-Discontinuation’ as a Primary Outcome Measurement
Patricia R.N. Nazir, Jan Pieter Maes, Chantal N. Delger, Arthur R. Van Gool

191. The Strauss and Carpenter Prognostic Scale in Subjects Clinically at High Risk of Psychosis

192. Improvement in Negative Symptoms and Functional Outcome after Group Cognitive Remediation Treatment (REHACOP program): A Randomized Controlled Trial
Natalia Ojeda, Pedro Sanchez, Javier Peña, Edorta Elizagarate, Eneritz Bengoetxea, Jesus Ezcurra, Miguel Gutierrez

193. Negative Thought Disorder and its Relationship to Schizotypy: Evidence from the New York High-Risk Project
Diane C. Gooding, Salome Ott, Simone A. Roberts, L. Erlenmeyer-Kimling

194. Depressive Symptoms are Associated with (sub) Clinical Psychosis Vulnerability in Patients with Non-affective Psychotic Disorder, Siblings and Healthy Controls
Rianne M.C. Klaassen, Manuela Heins, Nico van beveren, Bert L. Luteijn, Mark V. D. Gaag, Inez Myin-Germeys, Lieve de Haan

195. Psychometric Properties and Validity of Short Forms of the Wisconsin Schizotypy Scales in Two Large Samples
Thomas R. Kwapil, Georgina M. Gross, Paul J. Silvia, Neus Barrantes-Vidal

196. Interpersonal Appraisals and Subjective Stress Predict Psychotic Symptoms in Daily Life
Thomas R. Kwapil, Tecelli Dominguez, Erika Bedoya, Neus Barrantes-Vidal

197. Factor Structure of Schizotypy and Associations with Psychopathology and Functioning in a Group previously at Ultra-high Risk for Psychosis

198. Reliability and Validity of the Spanish Versions of AVHRS y PUHi: Two Instruments for Assessing Auditory Hallucinations from a Dimensional Perspective
Esther Lorente-Rovira, Eva Grasa, Iluminada Corripio, Susana Ochoa, Pelaez Trinidad, Victor Liaño, M. Jose Escarti, Mercedes Renovell, Julio Sanjuan, Jack Jenner
199. Rates and Time Course of Extrapyramidal Symptoms: A Comparison of Oral and Long-Acting Intramuscular (LAI) Paliperidone Randomized Controlled Studies
Srihari Gopal, Yanning Liu, Larry Alphs, Adam Savitz, Isaac Nuamah, David Hough

200. Insulin-resistance and Metabolic Disturbances Related to Second-generation Antipsychotics in a Sample of Treatment-naive Adolescents Compared to Adults
Covadonga M. Díaz-Canaja, Laura Pina-Camacho, Margarita García-Amador, Cecilia Tapia-Casellas, Pamela Rodríguez-Latorio, Pilar Sáiz, Iluminada Corripio, Bárbara Aries, Ana González-Pinto, Julio Sanjuán, Aurelio García, Miguel Ángel Jiménez-Arriero, Celso Arango

201. Improving Side Effect Monitoring in People Prescribed Long-acting Antipsychotic Injections: A UK Quality Improvement Programme
Thomas R.E. Barnes, Carol Paton

Marieke J. Begemann, Caroline F. Dekker, Mari van Lunenburg, Iris E. Sommer

203. A Randomized Controlled Trial of Allopurinol vs. Placebo Added on to Antipsychotics in Patients with Schizophrenia or Schizoaffective Disorder
Shimon Burshtein, Ari A. Gershon, Katya Rubinstein, Camelia Petcu, John M. Davis, Mark Weiser

204. Effects of Papaverine on Contextual Fear Conditioning Deficit Presented by an Animal Model of Schizophrenia: the Spontaneously Hypertensive Rats
Bianca A. Camerini, Natalia C. Zanta, Felipe M. Hungria, Claudio F. Souza, Vanessa C. Abílio, Rodrigo A. Bressan, Mariana B. Catzavara

205. IV Droperidol or Olanzapine as Adjuncts to Midazolam for the Acutely Agitated Patient: A Multi-centre, Randomised, Double-blind, Placebo-controlled, Clinical Trial
Esther Chan, David McD Taylor, David Kong, Jonathan Knott, Georgina Phillips, David Castle

206. The Pharmacokinetic Profile of CLZ might Explain the Variability in the Acute Response in Treatment Refractory Schizophrenia
Rosa Catalan, Rafael Penadés, Mireia Vázquez, Merce Torra, Guillen Masana, Alex Pons, Miquel Bernardo

207. Switching to Olanzapine Long-acting Injection from either Oral Olanzapine or any other Antipsychotic: Comparative Post-hoc Analyses
Antonio Ciudad, Marta Casillas, Alexander Schacht, Ernie Anand, Elena Perrin

208. Effectiveness of Lurasidone vs. Quetiapine XR For Relapse Prevention in Schizophrenia: A 12-Month, Double-Blind Study
Antony Loebel, Josephine Cucchiaro, Jane Xu, Kaushik Sarma, Andrei Pikalov, John M. Kane

209. Efficacy of Lurasidone in Schizophrenia: Results of a Factor Analysis of 5 Pooled Short-Term Studies
Josephine Cucchiaro, Robert Silva, Yongcai Mao, Antony Loebel, Stephen R. Marder

Giovanni Marzullo

211. Analysis of Suicidality, Stress and Treatment with Clozapine in Schizophrenia
Gina N. Polsinelli, Vincenzo De Luca, Martha McKay, Isaac Sakinofsky, Joanna Henderson
212. Results of a Phase 2a Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia
Nicholas DeMartinis, Anindita Banerjee, Vikas Kumar, Stacey Boyer, Christopher Schmidt, Santiago Arroyo

213. Discontinuing Anticholinergic Agents Prescribed for Extrapyramidal Side Effects in Schizophrenia or Schizoaffective Disorder Treated with Antipsychotics: Effects on Movement Disorders, Cognition and Psychopathology
Julie E. Desmarais, Howard C. Margolese, Linda Beauclair, Lawrence Annable, Marie-Claire Bélanger, Theodore T. Kolivakis

214. Within-Drug Benefit/Risk Evaluation of Olanzapine Long-Acting Injection at 1 and 2 Years of Treatment
Holland C. Detke, John Lauriello, John Landry, Susan B. Watson, David P. McDonnell

215. Comparison of Outcomes in Patients with Early Phase Versus Later Phase Schizophrenia
Holland C. Detke, Christoph U. Correll, Chunxu Liu, John Landry, Peter D. Feldman, David P. McDonnell

216. Is Haloperidol More Effective than Other First-generation Antipsychotics in Schizophrenia? A Meta-analysis of Randomized Controlled Trials
Markus Dold, Stefan Leucht

217. Efficacy and Acceptability of Benzodiazepine Augmentation of Antipsychotics in Schizophrenia and Schizophrenia-like Psychoses: A Meta-analysis of Randomized Controlled Trials
Markus Dold, Stefan Leucht

218. Glucagon-like Peptide-1 Analogues Against Antipsychotic-induced Overweight: Potential Physiological Benefits

219. Serotonin 5-HT2A Receptor Antagonists for Treatment of Schizophrenia
Bjørn H. Ebdrup, Hans Rasmussen, Jørn Arnt, Birte Glenthøj

220. Management of Involuntarily Admitted Patients with Schizophrenia
Beatrice Frajo-Apor, Nina Schabetsberger, Georg Kemmler, W. Wolfgang Fleischhacker

221. Exploring the Biology of the Clinical Inverse U-shape Dose-response in Schizophrenia or Cognitive Deficits Using Mechanistic Disease Modeling
Hugo Geerts, Patrick Roberts, Athan Spiros

222. Cannabidiol Attenuates the Impairments in Prepulse Inhibition Induced by Repeated Treatment with MK-801 in Mice
Felipe V. Gomes, Ana C. Issy, Elaine Del-Bel, Francisco S. Guimarães

223. Single Dose Administration of Olanzapine: Effects on Glucose Metabolism, Endocrine and Inflammatory Markers in Healthy Volunteers
Margaret K. Hahn, Tamara Arenovich, Tom Wolever, Adria Giaaca, Tony Cohn, Roger McIntyre, Celine Teo, Leigh Clarke, Valerie Powell, Araba Chintoh, Steve Mann, Sylvia Gomes, Gary Remington

224. The Putative Antipsychotic Alstonine Decreases Glutamate Uptake in Rat Hippocampal Slices
Ana P. Herrmann, Paula Lunardi, Luísa K. Pilz, Viviane M. Linck, Christopher O. Okunji, Carlos A. Gonçalves, Elaine Elisabetsky
225. Several Prescription Patterns of Antipsychotic Drugs Influence Cognitive Functions in Japanese Chronic Schizophrenia Patients
Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Atsuko Ikeouchi-Sugita, Wakako Umene-Nakano, Jun Nakamura

226. Safety, Tolerability and Pharmacokinetics of RG1678, a Novel Glycine Reuptake Inhibitor, After Multiple Doses in Healthy Volunteers
Meret Martin-Facklam, Alain Patat, Carsten Hofmann, Christophe Boetsch, Ludger Banken, Ursula Biedinger, Bruno Boutouyrie-Dumont

227. Locus of Control and Self-esteem in Patients at their First Psychotic Episode
Simone Ciufolini, Craig Morgan, Kevin D. Morgan, Paul Fearon, Peter B. Jones, Gill Doody, Robin M. Murray, Paola Dazzan

228. The Use of Social Skills Inventory in Patients with Refractory and non-Refractory Schizophrenia
Silvia Scemes, Monica Kayo, Mariangela Gentil Savoia, Bernardo Santos, Paulo Mestriner, Helio Elks

229. Longitudinal Changes In Everyday Functioning In Older Patients With Schizophrenia: The Role Of Changes In Functional Capacity
Concetta Feo, Davide Prestia, Christopher R. Bowie, Philip D. Harvey

230. Does the Schizophrenic Patient Really Improve with a Mensual Depot Treatment? A Prospective Study in an Outpatient Treatment Program; Multiprofessional View
Isabel Fernandez, Silvia Alvarez, Paloma Alvarez, Juana Morena, Sandra Garcia

231. Personality Traits of People with Severe Mental Illness Registered in Supported Employment Programs and their Relation to Baseline Motivation to Find a Job and Job Acquisition at 1-month Follow-up: Preliminary Results
Guillaume Fortin, Tania Lecomte, Marc Corbière

232. Achieving Insight: Is Good Executive Functioning Enough?
James Gilleen, Kathryn Greenwood, Anthony S. David

233. The Impact of Family Factors on the Psychosocial and Clinical Functioning of African American Consumers with Schizophrenia
Joseph M. Guada, Maanse Hoe, Reta Floyd, Jack Barbour, John Brekke

234. Relationship between ToM and Attribution in Violent Male Patients with Schizophrenia
Stephanie T. Harris, Clare Oakley, Avi Reichenberg, Declan Murphy, Marco Picchioni

235. Impact of Stress on Paranoia in Patients with Psychosis, First-degree Relatives and Healthy Controls
Maike M. Hartmann, Ulf Köther, Steffen Moritz, Tania M. Lincoln

236. Deficits and Biases of the Facial Emotion Recognition in Patients with Schizophrenia
Im hong Jeon, Seul Bi Lee, Jin Young Park, Jee In Kang, Eun Lee, Suk Kyoon An
237. *The Influence of Attachment Style on Therapeutic Alliance: A Study of Psychotic Patients and Care Workers*
   Nikie Korver-Nieberg, Simone Vriend, Patricia Tollenaar, Reinaud van de Fliert, Carin Meijer, Lieuwe de Haan

238. *The Relationship between Adult Attachment, Parental Bonding and Psychotic like Experiences, Preliminary Results*
   Nikie Korver-Nieberg, Julia Meijer, Carin Meijer, Lieuwe de Haan

239. *Randomized Trial of In-person versus Electronic Intervention for Medication Adherence*
   Natalie J. Maples, Xueying Li, Jim Mintz, Dawn I. Velligan

240. *Differential Associations between Cognition and Outcome in Early Psychosis: A Cohort Study of Early Psychosis Patients in the Netherlands*
   Luyken Stouten, Wim Veling, Mischa Van der Helm, Winfried Laan, Mark Van der Gaag

241. *Cognitive and Clinical Predictors of Functional Capacity in First Episode Schizophrenia – The Importance of Working Memory*
   Lone Vesterager, Torben Christensen, Birthe Olsen, Marianne Melau, Hysse Forchhammer, Merete Nordentoft

242. *Clinical and Morphometric Predictors of Quality of Life at Three Year Longitudinal Follow up of a First Episode Psychosis Cohort*
   Shane J. McInerney, Cathy Scanlon, John Mc Farland, Heike Schmidt, Mohamed Ahmed, Dara Cannon, Colm McDonald

243. *The Brain-Gut Connection: Constipation in Schizophrenia*
   Sudhakar Sivapalan, Thomas J. Raedler

244. *Monitoring Physical and Metabolic Parameters in a First Psychotic Episode*
   Rosa E. Rodriguez-Huesca, Carmelo Cepeda

245. *Thought Disorder in Schizophrenia: Implications for Subjective versus Objective Quality of Life*
   Eric J. Tan, Susan L. Rossell

246. *Poverty and Mental Illness*
   Cheryl Forchuk, Phyllis Montgomery, Robin Coatsworth-Puspoky, Ruth Schofield, Stewart Perry, Pam Lahey, Benita Cohen, Betty Edwards

247. *Influences of Mental Health Characteristics and Admission Experiences on Perceived Coercion*
   Seung Hyun Kim

248. *Psychotic Experiences and Help-seeking in a Representative Community Sample*
   John G. Mills, Craig Morgan, Souci Frissa, Maria Verdecchia, Robert Stewart, Nicola T. Fear, Abraham Reichenberg, Bwalya Kankulu, Jennifer Clark, Billy Gazard, Robert Medcalf, Matthew Hotopf, Stephani L. Hatch, SELCoH study team
249. Compliance in Schizophrenia Patients: The Role Of Therapeutic Alliance - Introduction Of A New Rating Instrument
Christian G. Widschwendter, Alex Hofer, Susanne Baumgartner, Georg Kemmler, Monika Edlinger, Wolfgang W. Fleischhacker, Maria A. Rettenbacher

250. Patients with their First Episode of Psychosis (FEP) Who Use Cannabis have Normal Premorbid IQ
Laura Ferraro, Di Forti Marta, La Barbera Daniele, Russo Manuela, Reichenberg Avi, Murray Robin

251. Comorbidity Action Research in Northern Adelaide, South Australia
Cherrie A. Galletly, Charlotte de Crespigny, Peter Athanasos, John Moss, Nicholas Proctor, Andris Banders, Paul Delfabbro, Imelda Cairney, Cate Rowlands, Peter Tyllis, Dennis Liu, Deb Lee, Rosie King, Bev Hissee, Miriam Posselt, Heps Francis

252. Validity of Timeline Follow-Back for Use of Cannabis and Other Illicit Substances in Patients with Psychosis
Carsten R. Hjorthøj, Anne R. Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, Mikkel Arendt, Merete Nordentoft

253. Clinical Differences in Acute-phase Non-affective Psychotic Disorders with and without Substance Use
Siri Helle, Erik Johnsen, Rolf Gjestad, Rune A. Kroken, Hugo A. Jørgensen, Else-Marie Løberg

254. Towards a Phenomenological Understanding of Psychosis: Trait Perfectionism in Persons with Psychotic Illnesses
Sabrina Hassan, Rohan Ganguli, Gordon L. Flett, Paul L. Hewitt

255. Attributional Style in Paranoid Patients: The Role of Personal Beliefs and Paranoia
M. Dolores Cantero, Almudena Duque, Carmen Valiente, Filiberto Fuentenebro, Patricia Villavicencio

256. Effect of Lurasidone on Weight and Metabolic Parameters:A Comprehensive Database Analysis
Andrei Pikalov, Josephine Cucchiaro, Masaaki Ogasa, Robert Silva, Jay Hsu, Jane Xu, Antony Loebel

257. Dysfunctional Neural Networks of Time Perception in Schizophrenia During Cognitive Task: An ALE-Meta-Analysis
Jose Antonio Gómez1, Felipe Ortuño2, Francisco Guillen-Grima2, Maria Vallejo1

258. Childhood Trauma as a Precursor of Dissociative Symptoms in Schizophrenia Spectrum Patients and Healthy Controls
Carlos Peña-Salazar1, María-José Álvarez1, Pere Roura-Poch2, Caroline Gourdier1, Helga Masramon1, Francesc X. Arrufat1

259. Phenotypically Continuous with Clinical Psychosis, Discontinuous in Need for Care: Evidence for an Extended Psychosis Phenotype
Martine M. van Nierop, Jim van Os, Nicole Gunther, Inez Myin-Germeys, Ron de Graaf4, Margreet ten Have, Saskia van Dorsselaer, Maarten Bak, Ruud van Winkel

260. Imaging-genetic Study of COMT Effect on Cortical Morphology in a Large Sample of Healthy Subjects
Arnaud Cachia, Anne Franceschini, Marie-Odile Krebs, Axel Krug, Tilo Kircher
261. A Prospective Study of Factors Associated to Readmissions in Adult Schizophrenics Patients Discharged from a Short-stay psychiatric Inpatient Unit of a University General Hospital
Fermin Mayoral, Olga Perez, Marina Romero, Javier Hernandez, Francisca Rius

262. The Effect of Asenapine on Depressive Symptoms in Patients with Acute Schizophrenia, Results from Post Hoc Analyses
John Kane, J-K Jensen

263. Cariprazine Attenuates PCP-Induced Increases in Extracellular Prefrontal Cortical Glutamate Levels and Improves PCP-Induced Deficits in Cognition and Social Behavior
Nika Adham, István Gyertyan, Béla Kiss, Nagi Idris, Samantha McLean, Ben Grayson, Takashi Yoshitake, Jan Kehr, Jo Neill

264. Cortisol Levels and Cortisol/DHEAS Ratio as Potential Predictors of Anterior Cingulate Volume Change over the first 12 Weeks of Early Psychosis
Renate LEP Reniers, Belinda Garner, Christina Phassouliotis, Lisa J. Philips, Connie Markulev, Christos Pantelis, Sarah Bendall, Patrick D McGorry, Stephen J. Wood

265. Childhood Cognitive Function and Adult Psychopathology: Associations with Psychotic and Non-psychotic Symptoms in the General Population
Jennifer H. Barnett, Fiona McDougall, Man Xu, Tim J. Croudace, Marcus Richards, Peter B. Jones

266. Investigation of Neuronal Plasticity in Response to Combination Treatment with Lurasidone and Valproic Acid in Rats
Francesca Calabrese, Alessia Luoni, Gianluigi Guidotti, Giorgio Racagni, Fabio Fumagalli, Marco A. Riva

267. Multivariate Pattern Classification of Individuals with Psychosis Proneness from Functional Imaging during Emotional Processing
Gemma Modinos, William Pettersson-Yeo, Paul Allen, Philip K. McGuire, André Aleman, Andrea Mechelli
Posters, Tuesday 17 April

12:00 PM - 2:00 PM
Cavaniglia

1. Relationship between Childhood Adversity and Clinical and Cognitive Features in Schizophrenia
Kathryn McCabe, Elizabeth Maloney, Helen Stain, Carmel Loughland, Vaughan Carr

2. Childhood Bullying and the Association with Psychosis in Nonclinical and Clinical Samples: A Review and Meta-analysis
Daniella S. van Dam, Elsje van der Ven, Eva Velthorst, Jean-Paul Selten, Craig Morgan, Lieuwe de Haan

3. Childhood Trauma, Earlier Parental Experiences and Adult Attachment in Patients with Psychosis, Nonclinical Siblings and Healthy Controls
Daniella S. van Dam, Nikie Korver-Nieberg, Eva Velthorst, Carin J. Meijer, Lieuwe de Haan

4. Parental Bonding and Beliefs about Self and Others: Differential Patterns in Depressive and Paranoid Patients
Gonzalo Hervás, Nuria Romero, Regina Espinosa, Carmen Valiente, Patricia Villavicencio

5. Understanding Possible Relationships between Experiences of Trauma and Psychosis
Covadonga Chaves, M. Dolores Cantero, Carmen Valiente, Carmelo Vázquez, Patricia Villavicencio

6. Antidepressant and neuroplastic Properties of Chronic Lurasidone Treatment in Serotonin Transporter Knockout Rats
Alessia Luoni, Sjoerd Hulsken, Giorgio Racagni, Judith Homberg, Marco A. Riva

7. Clozapine Reverses Recognition Memory but not Social Interaction Deficits in a “Dual-hit” Rat Model of Schizophrenia
Allison L. McIntosh, Theresa M. Ballard, Lucinda J. Steward, Paula M. Moran, Kevin C. Fone

8. Evidence of Mismatch Negativity (MMN) in Epidural Auditory Event-related Potentials in the Rat to Frequency and Duration Deviants: Relevance to Animal Models of Schizophrenia
Patricia T. Michie, Tamo Nakamura, William R. Fulham, Juanita Todd, Timothy W. Budd, Ulrich Schall, Michael Hunter, Deborah M. Hodgson

9. Social Isolation Rearing in Rats Induces Schizophrenia-like Behaviours that are Reversed by Sub-chronic Treatment with Clozapine or N-acetyl Cysteine
Marisa Möller, Brian H. Harvey, Robin Emsley

10. Social Isolation Rearing in Rats Alters Plasma Tryptophan Metabolism and is Reversed by Sub-chronic Clozapine Treatment
Marisa Möller, Jan L. Du Preez, Brian H. Harvey

11. The Effects of the Dopamine D1 Receptor Agonist on Attentional Set-shifting Task Performance in Rats
Agnieszka Nikiforuk

13. A Novel Semi-automated Attentional Set Shifting Task for Mice
Diego Scheggia, Audrey Bebensee, Fabio Benfenati, Daniel R. Weinberger, Francesco Papaleo

14. Differential Impact of GAD67 Downregulation in CCK+ and NPY+ Interneurons
Martin J. Schmidt, Monika Everheart, Krassimira Garbett, Szatmar Horvath, Karoly Mirnics

15. Environment-environment Interactions in a Schizophrenia-related Disease Model: Impact of Poly IC and THC on the Developing Brain
Gillian M. Stenson, Judith A. Pratt, Ros R. Brett

16. Alteration of Several Schizophrenia Candidate Genes Expression in Medial Prefrontal Cortex in Perinatal Asphyxia Rodent Model
Tomoyasu Wakuda, Keiko Iwata, Katsuaki Suzuki, Nori Takei, Norio Mori

17. Time- and Gender-dependent Effects on Response to Social and Non-social Odors in Adult Mice Exposed to Valproic Acid Prenatally
Ran Wei, Qi Li, Grainne M. McAlonan

18. Effects of Papaverine on Social Behaviors in an Animal Model of Schizophrenia: The Spontaneously Hypertensive Rats
Natalia C. Zanta, Bianca A. Camerini, Felipe M. Hungria, Cláudio F. Souza, Vanessa C. Abilio, Rodrigo A. Bressan, Mariana B. Calzavara

19. Chronic Exposure to Cigarette Smoke during Gestation Results in Altered Cholinesterase Enzyme Activity and Behavioral Deficits in Adult Rat Offspring: Potential Relevance to Schizophrenia
Alexandra I. Zugno, Daiane Fraga, Renata D. Luca, Fernando Ghedim, Pedro Deroza, Andreza Cipriano, Alexandre Silverio, Renan Souza, João Quevedo

20. Altered Default Network Resting State Functional Connectivity in Patients with a First Episode of Psychosis

21. Brain Activity during Moral Judgment Tasks in Individuals with Schizophrenia, their Unaffected Siblings, and Healthy Controls
Delfina de Achával, Mirta F. Villarreal, Elsa Y. Costanzo, Mariana N. Castro, Ramón C. Leiguarda, Charles B. Nemeroff, Salvador M. Guinjoan

22. Functional Brain Imaging Correlates of Identifying Intention to Communicate in Schizophrenia
Mary-Claire Hanlon, Gavin J. Cooper, W. Ross Fulham, Robyn Langdon, Ulrich A. Schall
23. **Neural Substrates of Empathic Accuracy in People with Schizophrenia**  
Philippe-Olivier Harvey, Jamil Zaki, Junghee Lee, Kevin Ochsner, Michael F. Green

24. **From Lab to Life: Prefrontal Dopaminergic Hyporeactivity to Psychosocial Stress Predicts Psychotic Experiences in Response to Daily Life Stress in Individuals with a Familial Risk of Psychosis**  
Dennis Hernaus, Johan Lataster, Dina Collip, Jenny Ceccarini, Linda Booij, Jim van Os, Jens Pruissner, Koen van Laere, Inez Myin-Germeys

25. **Deficit of Integrative Emotional Processing in Patient with Schizophrenia: An fMRI Study**  
Seon-Koo Lee, Ji Won Chun, Hae-Jeong Park, Jae-Jin Kim

26. **Attenuated Frontal Activations and Reduced Functional Connectivity Elicited by an Overt Semantic Verbal Fluency Task in Patients with Schizophrenia**  
Axel Krug, Heidelore Backes, Bruno Dietsche, Arne Nagels, Justus Marquetand, Mirjam Stratmann, Tilo Kircher

27. **Neural Correlates of Reality Judgment Abnormality in Patients with Schizophrenia**  
Jung Suk Lee, Ji Won Chun, Sang-hoon Lee, Dong-Il Kang, Hae-Jeong Park, Jae-Jin Kim

28. **Gender-dependent Differences in the Neural Responses to Fear Acquisition: A Voxel-based Diffusion Tensor Imaging (DTI) Study**  
Qi Li, Abby Y. Ding, Ran Wei, Wendy Kong, Sylvia Lam, Xiao F. Zhang, Siew E. Chua, Ed X. Wu, Grainne M. McAlonan

29. **Out of our Minds: The Auditory ‘Where’ Pathway Projects Hallucinated Voices into External Auditory Space**  
Jasper Looijestijn, Kelly Diederen, Rutger Goekoop, Iris Sommer, René Kahn, Jan Dirk Blom

30. **Neuroimaging Correlates of Working Memory in Postpartum Psychosis**  
Astrid M. Pauls, Mitul A. Mehta, Owen G. O’Daly, Susan Pawlby, Simone Ciufolini, Costanza Vecchio, Steven C. R. Williams, Carmine M. Pariante, Paola Dazzan

31. **Functional Connectivity in Relation to Different Genetic Risk Levels for Psychotic Disorder: A Resting State fMRI Study**  
Sanne C. T. Peeters, Vincent van de Ven, Petra Habets, Patrick Domen, Rainer Goebel, Jim van Os, Mahteld Marcelis

32. **Neural Mechanisms Supporting the Cognitive Control of Emotional Information in Schizophrenia**  
Laura M. Tully, Sarah Hope Lincoln, Todd Wright, Christine I. Hooker

33. **Schizophrenia, Social Cognition, Emotional Processing and the Role of the Left Ventrolateral Prefrontal Cortex**  
Lisette Van der Meer, Marieke Pijnenborg, Willem A. Nolen, André Aleman

34. **Brain Activity during Emotion Regulation in Individuals at Ultra-high Risk for Psychosis**  
Jorien Van der Velde, Esther Opmeer, Edith Liemburg, Roeline Nieboer, Lex Wunderink, Andre Aleman
35. Auditory Verbal Hallucinations in Non-psychotic Individuals – A Graph Theoretical Study  
Remko van Lutterveld, Wim Otte, Kelly Diederen, René Kahn, Kees Stam, Iris Sommer

36. Reduced Proactive Inhibitory Control in Schizophrenia Patients and their Unaffected Siblings  
Matthijs Vink, Bram B. Zandbelt, M. van Buuren, Rene S. Kahn

37. Neural Correlates of Physical and Social Causality Judgement in Patients with Schizophrenia  
Kim C. Wende, Arne Nagels, Mirjam Stratmann, Anjan Chatterjee, Tilo Kircher, Benjamin Straube

38. MRS Study of Glutamate, GABA, and NAAG in Schizophrenia  
Laura M. Rowland, Kimberly Kontson, Jef T. West, He Zhu, Richard A. Edden, Henry H. Holcomb, Peter B. Barker

39. Associations between Focal Brain Structural Changes, Phospholipid Metabolism and Glutamatergic Neurotransmission – A Combined 31P/1H MR Spectroscopy Investigation in Patients with First Acute Onset Schizophrenia  
Stefan Smesny, Alexander Gussew, Reinhardt Rzanny, Berko Milleit, Juergen Reichenbach, Heinrich Sauer

40. Fractional Anisotropy Reductions in Cingulum Bundle and Corpus Callosum in at Risk Mental State  
Naoyuki Katagiri, Masaaki Hori, Takahiro Nemoto, Naohisa Tsujino, Keiko Morita, Junichi Saito, Keigo Shimoji, Nobuyuki Shiraga, Shigeaki Aoki, Masafumi Mizuno

41. Longitudinal Voxel-based Morphometric Study Examining Progressive Gray Matter Changes in First-episode Schizophrenia  
Yasuhiro Kawasaki, Yukihsa Matsuda, Tsutomu Takahashi, Mikio Kido, Kazue Nakamura, Atsushi Furuichi, Michio Suzuki

42. Prefrontal Cortex and Hippocampal Volumes in Aggressive and Non-Aggressive Patients with a Psychotic Disorder  
Laura Koenders, Marise W. J. Machielsen, Jet D. Heering, Claudia Vingerhoets, Dick J. Veltman, Lieuwe de Haan

43. White Matter Abnormalities in Middle-aged Subjects with Schizophrenia - The Northern Finland 1966 Birth Cohort  
Jenni S. Koivukangas, Juha Veijola, Osmo Tervonen, Marianne Haapea, Jouko Miettunen, Matti Isohanni, Vesa Kiviniemi, Erika Jääskeläinen, Peter B. Jones, Anna Barnes, Juha Nikkinen

44. Association between Reduced Thalamo-prefrontal Integrity and Cortical Thickness Reduction in Schizophrenia  
Manabu Kubota, Jun Miyata, Akihiko Sasamoto, Hidefumi Yoshida, Ryosaku Kawada, Shinsuke Fujimoto, Yusuke Tanaka, Nobukatsu Sawamoto, Hidenao Fukuyama, Hidehiko Takahashi, Toshiya Murai

45. Differences in Structural Brain Volumes between Patients with an Early Psychotic Disorder With and Without Comorbid Cannabis Use Disorders  
Marise Machielsen, Floor van der Meer, Angelique van Gasselt, Jet Heering, Dick Veltman, Lieuwe de Haan
46. *Altered White Matter Connections in Never-medicated Patients with Schizophrenia*

René C. W. Mandl, Monica Rais, G. Caroline van Baal, Neeltje van Haren, Wiepke Cahn, René S. Kahn, Hilleke E. Hulshoff Pol

47. *White Matter Alterations in Schizophrenia: A Diffusion Tractography Study of Cingulum Bundle*

Alessia Mirigliani, Mariana Gallo, Antonino Bizzanica, Fabio Di Fabio, Marianna Frascarelli, Fabrizio Parente, Francesca Caramia, Massimo Biondi

48. *A Multimodal Study of Emotion Processing in Prodromal and First-Episode Psychosis*

Heline Mirzakhanian, Khalima Bolden, Kristin Cadenhead, Lisa Eyler, Pedro Roman, Gregory Brown

49. *Neuroanatomy of Auditory Verbal Hallucinations in Schizophrenia: A Quantitative Meta-analysis of Voxel-based Morphometry Studies*

Gemma Modinos, Sergi G. CostaFreda, van Tol Marie-José, Philip K. McGuire, André Aleman, Paul Allen

50. *Morphological Characteristics of Anterior Cingulate Cortex in Schizophrenia and Subjects at Genetic High Risk for Psychosis*

Hyeyoun Park, JaeYeon Hwang, Wi Hoon Jung, Geumsook Shim, JoonHwan Jang, JunSoo Kwon

51. *Correlates of Autobiographical Memory from Different Lifetime Periods in Patients with Chronic Schizophrenia*

Christina Herold, Lena Schmid, Marc Lässer, Ulrich Seidl, Philipp Thomann, Marco Essig, Johannes Schröder

52. *Increased Hypothalamus and Mamillary Bodies Volumes in Chronic Schizophrenia*

Stefania Tognin, Gianluca Rambaldelli, Marcella Bellani, Cinzia Perlini, Veronica Marinelli, Robert Terlevic, Michele Tansella, Paolo Brambilla

53. *Cortical Thickness and Cortical Surface in Schizophrenia: Two Distinct but Relevant Processes?*

Neeltje E. van Haren, Hugo G. Schnack, Wiepke Cahn, Hilleke E. Hulshoff Pol, Rene S. Kahn

54. *Pituitary Gland Volume in Individuals with an At-risk Mental State: A Longitudinal MRI Analysis*

Anna Walter, Anita Riecher-Rössler, Erich Studerus, Renata Smieskova, Corinne Tamagni, Charlotte Rapp, Stefan Borgwardt

55. *T2 Relaxation Times in the Superior Temporal Gyrus of Individuals at Ultra-High Risk for Psychosis and Their Association With Auditory Hallucinations*

Stephen J. Wood, Ashleigh Lin, Damian Kennedy, Barnaby Nelson, Christos Pantelis, Alison R. Yung

56. *A Diffusion Tensor Imaging (DTI) study of White Matter Integrity in Parkinson’s Disease (PD)*

Nailin Yao, Shirley Pang, Kevin Yu, Charlton Cheung, Richard Chang, Henry Mak, Grainne McAlonan, SL Ho, Siew Chua

57. *Thought and Language Disorders in Young Patients with Schizophrenia, Schizoaffective Disorder and Bipolar Disorder*

Telma Pantano, Fu I. Lee, Eliana Curatolo, Camila B. Martins, Helio Elkis
58. Direct Comparison of Memory Impairment in Youth at Familial Risk for Schizophrenia or Affective Psychosis
Silvia Scala, Andrea Pousada-Casal, Heidi W. Thermenos, Ming T. Tsuang, Stephen V. Faraone, Larry J. Seidman

59. The Outcome of Early Onset Schizophrenia based on a Systematic Meta-analysis of the Literature
Lars Clemmensen, Ditte Lammers, Hans-Christoph Steinhausen

60. The Relationship Between Childhood Trauma and Adult Onset Schizophrenia: What We Now Know
Ashley K. Storrs

61. Modified Cognitive Behavioral Therapy in Adolescents with Persistent Psychotic Symptoms- Results of a Randomized Controlled Trial
Tanja Tecic, Jörn Gütgemanns, Gerd Lehmkuhl, Katarina Mueller, Dieter Stoesser, Georg Wiedemann, Stefan Klingberg, Andreas Bechdolf

62. Copenhagen High Risk Study II: Childhood and Development. 7-year old Children of Parents with Schizophrenia
Anne A. E. Thorup, Jens R. Jepsen, Kerstin Plessen, Merete Nordentoft

63. Prevalence of Bullying Amongst First-episode Psychosis Patients and Unaffected Controls
Antonella Trotta, Marta Di Forti, Craig Morgan, Paola Dazzan, Carmine Pariante, Anthony David, Alice Mulè, Caterina La Cascia, Daniele La Barbera, Robin M. Murray, Helen L. Fisher

64. Cognitive Insight and Attenuated Positive Symptoms in At-risk Mental State
Tomohiro Uchida, Noriyuki Omuro, Masahiro Katsura, Yumiko Hamaie, Emi Sunakawa, Kazunori Matsumoto, Hiroo Matsuoka

65. Functional Impairment: Should it be an Obligate Part of Clinical Criteria for an Increased Risk of Developing Psychosis?
Stefan Ruhrmann, Frauke Schultze-Lutter, Mitja Bodatsch, Don Linszen, Raimo Salokangas, Max Birchwood, Georg Juckel, Anthony Morrison, Andreas Heinz, Shon Lewis, Heinrich von Reventlow, Joachim Klosterkötter

66. A Five Factor Solution of the Scale of Prodromal Symptoms (SOPS)
Stefan Ruhrmann, Frauke Schultze-Lutter, Mitja Bodatsch, Don Linszen, Raimo Salokangas, Max Birchwood, Georg Juckel, Anthony Morrison, Andreas Heinz, Shon Lewis, Heinrich von Reventlow, Joachim Klosterkötter

67. Prevalence of Prediabetes in Patients Treated with Antipsychotics
Pauline M. Steylen, Frank M. van der Heijden, Willem M. Verhoeven

68. A New Perspective on Anhedonia in Schizophrenia
Gregory P. Strauss, Lauren T. Catalano, James M. Gold

69. Sensitivity for Stress in Early Psychosis Patients: A Clinical Profile
Renate van der Valk, Maaike Rouwenhorst, Carin Meijer, Liewe de Haan
70. *Ethnicity and Baseline Symptomatology in Patients with an At Risk Mental State for Psychosis*
Eva Velthorst, Dorien H. Nieman, Wim Veling, Rianne M. Klaassen, Sara Dragt, Judith Riedijk, Helga Ising, Lex Wunderink, Don H. Linszen, Lieuwe de Haan, Mark van der Gaag

71. *Disability in People Clinically at High Risk of Psychosis*
Eva Velthorst, Dorien H. Nieman, Don H. Linszen, Hiske E. Becker, Lieuwe de Haan, Peter M. Dingemans, Max Birchwood, Paul Patterson, Raimo K. Salokangas, Markus Heinimaa, Andreas Heinz, Georg Juckel, Heinrich Graf von Reventlow, Paul French, Helen Stevens, Frauke Schultze-Lutter

72. *Relationship between MMN and Facial Emotion Recognition in Patients with Schizophrenia*
Sung-Hyouk Park, Chan-Hyung Kim, David Braff, Gregory Light

73. *Spatial and Temporal Properties of Affect Perception Deficits in Schizophrenia: A TMS Study*
Yuri Rassovsky, Junghee Lee, Poorang Nori, Allan D. Wu, Marco Iacoboni, Michael F. Green

74. *Mismatch Negativity Peak Latency and Negative Symptoms in Schizophrenia*
Gudrun Sartory, Christian Kärgel, Daniela Kariofillis, Bernhard Müller

75. *Cognitive and Electrophysiological Correlates of Noise Power in Schizophrenia*
Alvaro Diez, Vanessa Suazo, Pilar Casado, Manuel Martin-Loeches, Vicente Molina

76. *Noise Power as a Measure of Event Related and Spontaneous Brain Activity: A Longitudinal Study*
Vanessa Suazo, Alvaro Diez, Pilar Casado, Manuel Martin-Loeches, Vicente Molina

77. *Characterization of the Novel Procognitive Antipsychotic EGIS 11150 in the Hippocampus and Neocortex in Vitro*
Isla H. B. Thomson, Ferenc A. Antoni, Michael Spedding, Miles A. Whittington, Mark O. Cunningham

78. *High Rates of Cardiometabolic Risk Factors in People with Psychotic Disorders*
Cherrie A. Galletly, Debra L. Foley, Anna Waterreus, Gerald F. Watts, David Castle, John McGrath, Andrew Mackinnon, Vera A. Morgan

79. *Longitudinal Youth-At-Risk Study (LYRIKS): Examining the Prodrome from Another Perspective*
Jimmy Lee, Attilio Rapisarda, Mike Kraus, Siow-Ann Chong, Richard Keefe

80. *Familial and Genetic Factors in the Course and Trajectories of Serious Mental Illness: A National Population-based Twin Study*
Stephen Z. Levine, Rinat Yoffe, Inna Pugachova, Avi Reichenberg

81. *Subdomains of Negative Symptoms in Schizophrenia: A Two-factor Model Confirmed by Confirmatory Factor Analysis*
Edith J. Liemburg, Stynke Castelein, Roy Stewart, Mark van der Gaag, André Aleman, GROUP Investigators, Henderikus Knegtering
82. Comparison of Early Episode and Chronic Patients Diagnosed with Schizophrenia: Symptoms and Childhood Trauma
Wang Zheng, Xuezhi Min, Puwei Dan, Yang Bo, Li Li, Yiwen Ying, Wang Peng, Liu hang, Wuguo Wei, LiuzheNing, Robert A Rosenheck

83. At-risk Criteria of Psychosis and Help-seeking Behaviour in the General Population: Preliminary Results from a Telephone Survey
Chantal Michel, Benno G. Schimmelmann, Rebecca Wyler, Frauke Schultzze-Lutter

84. Young People at Risk for Psychosis: Case Finding and Sample Characteristics of the Oulu Brain and Mind Study

85. Temperament in Individuals with Psychotic Disorders Before and After the Onset of Illness
Jouko Miettunen, Pauliina Juola, Eka Roivainen, Juha Veijola, Antti Alaräisänen, Matti Isohanni, Erika Jääskeläinen

86. First Episode of Psychosis (FEP): An Incidence Pilot Study Using the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case Register
Jason Tsang, Charlotte Gayer-Anderson, Francois Bourque, Jennifer O’Connor, Jonathan Garabette, Alex Tulloch, Adanna Onyefika, Susana Borges, Sherifat Oduola, Grant McQueen, Chelsea Gardener, Andrea Fernandes, Matthew Hotopf, Matthew Broadbent, Robert Stewart, Craig Morgan

87. The EU-Gene Environment Interaction Study (EU-GEI): Incidence of Psychosis in 6 Countries – Rational, Methods and Progress at 12 Months
EU-GEI Work Package 2 Study Grp-C. Morgan

88. Incidence of Psychotic Disorders in Palermo: Preliminary Data
Alice Mulè, Lucia Sideli, Caterina La Cascia, Marta Di Forti, Robin MG Murray, Daniele La Barbera

89. Emergency Caesarean Section as a Risk Factor for Schizophrenia
Alessandra Paparelli, Muriel Walshe, Ilaria Tarricone, Jane Boydell, Tawaliku Akib, Gabriella Pollutri, Simona A. Stilo, Elvira Bramon, Marta Di Forti, Jhon Powell, Robin Murray

90. Migration, Ethnicity and Psychosis: Evidence for a Socio-developmental Pathway
Ulrich Reininghaus, Tom Craig, Helen Fisher, Gerard Hutchinson, Paul Fearon, Kevin Morgan, Paola Dazzan, Gillian Doody, Peter Jones, Julian Leff, Robin Murray, Craig Morgan

91. Use of Antipsychotic Medication and Suicidality – The Northern Finland Birth Cohort 1966
Ina Rissanen, Erika Jääskeläinen, Matti Isohanni, Hannu Koponen, Matti Joukamaa, Antti Alaräisänen, Jouko Miettunen

92. Psychopathological Significance of At-risk Criteria of Psychosis in the General Population: Preliminary Results from a Telephone Survey
Benno G. Schimmelmann, Chantal Michel, Frauke Schultzze-Lutter
93. At-risk Criteria of Psychosis and Quality of Life in the General Population: Preliminary Results from a Telephone Survey
Benno G. Schimmelmann, Chantal Michel, Frauke Schultze-Lutter

94. Prevalence of At-risk Criteria of Psychosis in the General Population: Preliminary Results from a Telephone Survey
Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

96. Does Exposure to Herpes Simplex Virus, Type 1 Cause Cognitive Dysfunction among Schizophrenia and Control Individuals: An Indian study

97. Childhood Abuse and Symptom Severity and Disability in First Episode Psychosis
Sophie Sowden, Susana Borges, Simona Stilo, Adanna Onyiaka, Charlotte Gayer-Anderson, Grant McQueen, Arune Keraite, Chelsea Gardener, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Craig Morgan, Rowena Handley, Paola Dazzan

98. Increased Familiarity of Intellectual Deficits in Early-Onset Schizophrenia Spectrum Disorders
Ximena Goldberg, Mar Fatjó-Vilas, María J. Muñoz, Silvia Campanera, Salvador Miret, María J. Miñano, Mari Aguilera, María L. Miralles, María E. Navarro, Luisa Lázaro, Marc Guitart, Neus Barrantes-Vidal, Lourdes Fañanás

99. Replication of Previous GWAS Studies in Schizophrenia Show Common Risk SNPs with Bipolar Disorder
Jose L. Ivorra, Jose C. Gonzalez, Javier Costas, Celso Arango-Lopez, Miguel Bernardo, Julio Bobes, Jorge Cervilla, Ana Gonzalez-Pinto, Jose M. Haro-Abad, Maria D Molto, Victor Perez-Sola, Tomas Palomo, Ana R. Saez, Jeronomo Saiz-Ruiz, Julio Sanjuan

100. Application of a Molecular Pathway Based Approach to the Study Gene-Environment Interactions
Conrad Iyegbe, Emma Knowles, Rowena Handley, Heather Taylor, Simona Stilo, Helen Fisher, Paola Dazzan, Craig Morgan, Selcoh study group, Marta DiForti, Andy Simmons, Stepheni Hatch, Matthew Hotopf, John Powell, Avi Reichenberg, Robin Murray

101. COMT Val158Met Genotype and Schizotypy Dimensions
Araceli Rosa, Artal Moreno, Agnès Ros-Morente, Thomas R. Kwapil, Neus Barrantes-Vidal

102. Family Association Study of Candidate Genes in Schizophrenia
Pawel Kapelski, Maria Skibinska, Aleksandra Szczepankiewicz, Monika Dmitrzak-Węglarz, Piotr Czerski, Joanna Hauser

103. Serotonin Transporter Gene Polymorphism (5-HTTLPR) and Depressive Symptoms in Schizophrenia
Dalibor Karlovic, Ante Silic, Ana Kovak-Mufic, Mario Stefanovic, Jelena Culej, Nada Vrkc

104. Association of Estrogen Receptor Genes and Schizophrenia: A Preliminary Study
Jung Jin Kim, Jung Ah Min, Chi Un Pae, Chang Uk Lee, Chul Lee
105. Cross-phenotype Analysis for Schizophrenia Susceptibility Genes based Upon Type II Diabetes GWASs
Kenji Kondo, Masashi Ikeda, Yusuke Kajio, Yasuhisa Fukuo, Norio Ozaki, Nakao Iwata

106. GABA Transporter SLC6A11 Gene Polymorphism Associated with Tardive Dyskinesia
Woo-Young Son, Heon-Jeong Lee, Ho-Kyoung Yoon, Seung-Gul Kang, Young-Min Park, Hee-Jung Yang, Jung-Eun Choi, Hyooggin An, Han-Kyu Seo, Leen Kim

107. Evidence of an Association between Dysbindin Gene and Age at Onset in Schizophrenia
Kyuyoung Lee, Eunjeong Joo, Yongsik Kim

108. The Influence of DISC1 Ser704Cys Polymorphism on the Cortical Thickness of Salience Network (insula and anterior cingulate) in Psychosis
Lena Palaniyappan, Vijender Balain, Molly Simmonite, Liam Carrol, Peter McGuffin, Katherine Aitchison, Peter F. Liddle

109. Historical Study of Influence of Non-genetic Factors on Twin Concordance for Schizophrenia
Edward J. Pepper

110. No Association between the Presence of Val66Met Polymorphism and Schizophrenia: A Case-control Study
Alicia Valiente, Amalia Lafuente, Patricia Gasso, Ana Mesguer, Cristina Oliveira, Miquel Bioque, Bibiana Cabrera, Alicia Duran, Clemente Garcia-Rizo, Miguel Bernardo

111. Identification of a Genetic Panel to Predict Schizophrenia Risk
Joanne Voisey, Cameron P. Hurst, Bruce R. Lawford, Ross McD. Young, Charles P. Morris

112. No Evidence that Common Genetic Risk Variants are shared between Schizophrenia and Autism
Jacob Vorstman, Richard Anney, Eske Derks, Louise Gallagher, Michael Gill, Maretha de Jonge, Herman van Engeland, René S. Kahn, Roel Ophoff, Autism Genome Project (AGP), International Schizophrenia Consortium (ISC)

113. Estrogen Receptor Alpha Genotype and Cognitive Impairment in Schizophrenia
Selena Hu, Merribel Kyaw, Ans Vercammen, Loretta Moore, Cynthia S. Weickert, Thomas W. Weickert

114. Deep Re-sequencing of DPYSL2 Exons Reveals Novel SNPs and Variation in Splicing and Exon Usage Patterns in Schizophrenia Patients and Controls
Catherine L. Winchester, Graham M. Hamilton, Brian Morris, Judy A. Pratt, Robert Hunter, Mark E.S. Bailey

115. Association Analysis Polymorphisms of the Glutamic Acid Receipt Gene with Schizophrenia
Junzhe Xu, Magan Helm, Vivian Chang, Anna Li, Daniel Li, Steven Dubovsky

Shen Yu-Chih, Chen Chia-Hsiang

117. Neuroinflammation in Temporal Cortex of Patients with Recent Onset Schizophrenia
Thalia F. van der Doef, Maqsood Yaqub, Matthijs G. Bossong, Ronald Boellaard, Neeltje E. van Haren, Albert D. Windhorst, Wipke Cahn, Adriaan A. Lammertsma, René S. Kahn, Bart N. van Berckel
118. Bone Mineral Density as a Marker of Cumulative Endogenous Estrogen Exposure: Relationship to Background Genetic Risk for Psychotic Disorder
Christine van der Leeuw, Patrick Domen, Petra Habets, Marinus van Kroonenburgh, Jim van Os, Machteld Marcelis

119. The Role of Stress in Patients with Postpartum Psychosis
Costanza Vecchio, Astrid Pauls, Patricia Zunszain, Valeria Mondelli, Simone Ciufolini, Susan Pawly, Gertrude Seneviratne, Heather Taylor, Mitul Mehta, Steven Williams, Eugenio Aguglia, Carmine Pariante, Paola Dazzan

120. Parallel Increases in [3H]Muscimol and [3H]Flumazenil Binding in the Dorsolateral Prefrontal Cortex in Schizophrenia are Linked to GABA\textsubscript{A} Receptor α4 and γ2S mRNA Subunit Levels Respectively
Mathieu Verdurand, Stu G. Fillman, Cynthia Shannon Weickert, Katerina Zavitsanou

121. Alterations in the Reward Processing Related to Dopamine D2/D3 Binding Potential in Antipsychotic Naïve Schizophrenia Patients
Sanne Wulff, Mette Ø. Nielsen, Hans Rasmussen, Lars T. Jensen, Egill Rostrup, Erik Frandsen, Lars H. Pinborg, Claus Svarer, Gitte Moos Knudsen, Birte Glenthøj

122. First Results from an Antisaccade Task and Memory-guided Saccade Task in a Neurodevelopmental Approach to Schizophrenia
Rémi Gadel, Cécilia Coen, Magali Seassau, Yannick Morvan, Raphael Gaillard, Emilie Magaud, Isabelle Amado, Marie-Odile Krebs

123. Interneuron Development in Disc1 Mutant Mice
Frankie H. F. Lee, Clement C. Zai, Sabine P. Cordes, John C. Roder, Albert H. C. Wong

124. Effect of Omega 3 Supplementation in an Animal Model Schizophrenia Induced by Ketamine
Isabelle M. Miranda, Lara Canever, Renata De Luca, Redro F. Deroza, Clarissa S. Gama, Alexandra I. Zugno

125. Self-disorders and Sensory Integration Disturbances in Schizophrenia: Do They Connect? An Integrating Model of ‘Self’-development, Sensory Integration and Schizophrenia
Lot Postmes

126. Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Schizophrenic Women during Course of Treatment
Maria Skibinska, Pawel Kapelski, Aleksandra Rajewska-Rager, Joanna Pawlak, Joanna Hauser

127. Do Neurological Soft Signs in At-risk Mental State Individuals Predict Transition to First Episode Psychosis?
Corinne Tamagni, Erich Studerus, Ute Gschwandtner, Anna Walter, Charlotte Rapp, Hilal Bugra, Anita Riecher-Rössler

128. Modeling Brain Circuitry in Schizophrenia from Interneuron Development in Mice
Ksenija Vucurovic, Tania Vitalis, Arthur Kaladjian
129. The Characteristics of People at Ultra High-risk for Psychosis on the Personality, Temperament, and Relationship Style with the Effect of 6-month Pharmacotherapy
Tae Young Lee, Geumsook Shim, Joon Hwan Jang, Sung Nyun Kim, Hye Youn Park, Min Soo Byun, Jung Hyun Yu, Jun Soo Kwon

130. OPEN BOARD

131. Neuropathology of Vitamin D Receptor and Retinoid X Receptors in Schizophrenia
Shan-Yuan Tsai, Duncan Sinclair, Cynthia S. Weickert

132. Prediction of Transition to Psychosis using Neuropsychology, Symptomatology, Environmental Factors, Premorbid Adjustment and Neurophysiology
Dorien H. Nieman, Sara Dragt, Mirjam J. van Tricht, Hiske E. Becker, Don H. Linszen, Lieuwe de Haan

133. Decreased Attention to Informative Social Cues in Schizophrenia Patients
Alexandra S. C. Nikolaides, Julia Paruch, Susanne Miess, Joachim Klosterkoetter, Stephan Ruhrmann

134. Gamma Oscillations in MEG-Data in Chronic Schizophrenia and During Ketamine Administration: Evidence for the Role of NMDA-Receptor Deficits in the Pathophysiology of Schizophrenia
Davide Rivolta, Andreas Sauer, Michael Wibral, Limin Sun, Wolf Singer, Peter J. Uhlhaas

135. Elevated Low-frequency Power Across Sensory and Cognitive Conditions in Schizophrenia
Elyse M. Sullivan, Ann Summerfelt, Patricio O’Donnell, Elliot Hong

136. Facial Affect Recognition in Patients with Schizophrenia and a History of Violence
Stephanie T. Harris, Clare Oakley, Avi Reichenberg, Declan Murphy, Simon Sugurladze, Marco Picchioni

137. A Meta-Analysis of IQ Change in Schizophrenia and Healthy Individuals
Anna M. Hedman, Neeltje E. M. van Haren, Caroline G. M. van Baal, René S. Kahn, Hilleke E. Hulshoff Pol

138. Hemispheric Asymmetry in First-episode Psychosis and Schizotypy: What’s Left for Cannabis?
Daniela A. Herzig, Sarah Sullivan, Glyn Lewis, Rhiannon Corcoran, Richard Drake, Christine Mohr

139. Sex Differences in Schizophrenia – Is there a Link to Brain Asymmetry?
Marco Hirnstein, René Westerhausen, Kenneth Hugdahl

140. Test-retest Reliability of the Danish Adaptation of the National Adult Reading Test in Patients with Psychosis and Cannabis Use Disorder
Carsten R. Hjorthøj, Lone Vesterager, Merete Nordentoft

141. Schizotypy and Genetic Loading for Schizophrenia Impact upon Neuropsychological Status in Bipolar II and Unipolar Major Depressive Disorders
Hiroaki Hori, Junko Matsuo, Toshinya Teraishi, Daimei Sasayama, Yumiko Kawamoto, Yukiko Kinoshita, Kotaro Hattori, Miyako Hashikura, Teruhiko Higuchi, Hiroshi Kunugi
142. Auditory Attention Bias to Potential Threats, and its Relationship to Positive Symptoms in Schizophrenia
Norichika Iwashiro, Noriaki Yahata, Tomoya Watanabe, Tsuyoshi Kawamura, Satoru Yuasa, Yu Kawamuro, Kiyoto Kasai, Hidenori Yamasue

143. Neurocognitive Deficits in Chronic, Young Adult Early-Onset Schizophrenia Patients
Jens Richardt M. Jepsen, Birgitte Fagerlund, Anne Katrine Pagsberg, Anne Marie R. Christensen, Merete Nordentoft, Erik L. Mortensen


145. Longitudinal Study of Cognition in Schizophrenia and Bipolar Disorder: A 5 Years Follow-up Study
Eva M. Sánchez-Morla, Ana I. Aparicio, Román Solano-Ruipérez, M. Luz Alcalde, José Luis Santos

146. Deficit and Non-deficit Schizophrenia: Longitudinal Course of Neurocognitive Impairment. A Prospective 5 Years Follow-up Study
José Luis Santos, Ana I. Aparicio, Román Solano-Ruipérez, M. Luz Alcalde, Eva M. Sánchez-Morla

Stefanie J. Schmidt, Daniel R. Mueller, Volker Roder

148. Facing the Inversion Effect: Do Schizotypal and Autistic Traits Contribute differently to the “Face(-like) Inversion Effect”?
G. Sierro, Y. Schrag, C. Mohr

149. Shared Impairment of Prospective Memory in Patients with Schizophrenia and Bipolar Disorder

150. Fragmented Perception: Slower Space-based but Faster Object-based Attention in First Psychosis
Henderikus G. Smid

151. Neurocognitive Profile in Individuals at Ultra-high Risk for Psychosis and with First-episode Psychosis: It’s Relations with Intelligence
Ja Y. Sun, Jin Y. Park, Kyung R. Kim, Eun Lee, Hyun S. Cho, Suk K. An

152. Cognitive Functioning as an Intermediate Phenotype in a Finnish Isolate with High Lifetime Risk of Schizophrenia
Minna Torniainen, Juho Wedenoja, Jaana Suvisaari, Annamari Tuulio-Henriksson

153. Neurocognitive Profiling in a Large Cohort of First Episode Patients Suggests Three Specific Subgroups
154. The Central Role of Attention and Information Processing Deficits in the Profile of Cognitive Dysfunction in Schizophrenia
Keith Wesnes, Chris Edgar, Lawrence Brownstein, Howard Hassman, Eden Evins

155. Evaluation of a Rule Switching Test Designed to Assess Executive Control
Keith Wesnes, Chris Edgar, Richard Wojciak, Alicia Craig-Rodriguez, Maria Pinho, David Kreftez, Daniel Gruener, Lawrence Brownstein, Howard Hassman

156. Action Fluency Impairment and Temporal Synchronization in Patients with Schizophrenia
Helene Wilquin, Yvonne Delevoye-Turrell, Anne Giersch

157. Spurious Signal Detection and Delusions of Reference in First-episode Schizophrenia

158. Social Skills Training with Inpatients Using a Soap-Opera TV Show: A Brazilian Experience
Juliana Emy Yokomizo, Graça Maria Ramos Oliveira, Paulo Clemente Sallet

159. Initial Testing of a Novel Social Cognitive Treatment for Schizophrenia
David L. Roberts, Petra Kleinlein, Jamie Stevens

160. Silencing Dopamine D2 Receptors by Use of siRNA in the Nucleus Accumbens Shell Reduced Impairment of Prepulse Inhibition Induced by Apomorphine in Rat
Mohammad-Reza Noori-Daloii, Ali Shahbazi, Siamak Alizadeh Zendehrood, Fatemeh Zare Mehrgerdi, Somayeh Niknazar, Mohammad Mostawfi, Hajar Hashemi Sotoobadi, Asghar Korzehbor, Majid Mojarad, Ali Rashidi Nejad

161. Towards Recovery: Empowerment and Quality of Life in Chronic Psychiatric Inpatients
A. P. M. Stiekema, L. van der Meer, P. J. Quee, F. Jörg, R. Bruggeman, H. Knegtering, A. M. Dethmers, C. M. Rietberg, A. Aleman, R. A. Schoevers

162. Effect of Sports Participation on Brain Activations during Sports Observation in Schizophrenia
Hidehiko Takahashi, Tetsuya Suhara, Yoshiro Okubo

Melissa Fisher, Coleman Garrett, Phillip Alexander, Karuna Subramaniam, Sophia Vinogradov

164. Working out First Episode Schizophrenia: Neuroanatomical, Cognitive and Clinical Changes following an Aerobic Exercise Intervention

165. How do Clinical, Social and Role Functioning of At-Risk Mental States (ARMS) and First Episode of Psychosis (FEP) Patients Relate to their Relatives’ Expressed Emotion (EE)?
Cristina Medina-Pradas, Tecelli Domínguez-Martínez, Thomas R. Kwapis, Neus Barrantes-Vidal
166. Comparison of Semantic Memory Function in Schizophrenia and Two Analogues: Schizotypy and Ketamine
Erica Neill, Susan L. Rossell

167. Difference in Sexual Dysfunction among Schizophrenic Male Patients on Comminuted Therapy
Vladica Lj. Sibinovic, Violeta M. Slavkovic, Suzana M. Tosic-Golubovic, Goran R. Selimovic

168. Additive Interaction between Lifetime Cannabis Use and Childhood Trauma in Increasing the Risk for Psychosis; A Replication Analysis on a Sample of First Episode of Psychosis Patients
Lucia Sideli, Marta Di Forti, Daniele La Barbera, Caterina La Cascia, Alice Mulè, Robin M. Murray

169. Retrieval-induced Forgetting in Schizophrenic Patients
Fiorentina Sterkaj, Trudi Edginton, Kevin Morgan, David Groome

170. Proline and Schizophrenia: A Population-based Study
Jaana M. Suvisaari, Tuulia Hyötyläinen, Matej Oresic

171. Is Aloud Allowed? Differentially Impaired Meaning Attribution in Schizophrenia
Eric J. Tan, Susan L. Rossell, Gregory W. Yelland

172. Effect of Cannabis Use on Age of Onset; Findings from a Sample of Italian First Episode Psychotic Patients
Maria Valentina Rumeo, Lucia Sideli, Alice Mulè, Marta Di Forti, Daniele La Barbera, Robin M. Murray

173. E-mental Healthcare Applications Supporting Self-management in People with a Psychotic Disorder: A Systematic Review of the Literature
Lian van der Krieke, Ando C. Emerencia, Lex Wunderink, Durk Wiersma, Sjoerd Sytema

174. The Influence of Top-down Processing in Auditory Verbal Hallucinations
Sanne Verkooijen, Kirstin Daalman, Eske M. Derks, René Kahn, André Aleman, Iris E. Sommer

175. The Impact of Speaking Out: The Voices of Schizophrenia
Emily C. Walker

176. NSA-16 Revisited: Identifying Latent Factors of Negative Symptoms in Schizophrenia
D. Popp, J. B. W. Williams, E. A. Cohen, M. J. Detke

177. The Use of the NSA-16 by Videoconferencing in a Clinical Trial

178. The Association between Thought-language Disorder and Negative Symptoms in Schizophrenia
Berna Yalınçetin, Levent Var, Banu Değirmencioğlu, Şilay Sevilmış, Elif Yavaş, Halis Ulaş, Selma Polat, Berna Binnur Akdede, Kükşal Alptekin

179. Association between Duration of Untreated Psychosis and Short- and Long-term Outcome in Schizophrenia within the Northern Finland 1966 Birth Cohort
Matti Penttilä, Jouko Miettunen, Hannu Koponen, Merja Kyllönen, Juha Veijola, Matti Isohanni, Erika Jääskeläinen
180. Changes in Endocrine Profile after Six Months of Treatment in a Canadian First Episode Psychosis Program  
Sharman Robertson, Paul Roy, Angela Stevens, Sahba Sabet-Rasekh

181. Predictors of Real-World Outcomes in Schizophrenia Patients, their Family Members and Control Subjects  
Katya Rubinstein, Abraham Reichenberg, Daniella Margalit, Michael Davidson, Mark Weiser

182. Change in Delusional Dimensions, Reasoning Biases and Emotions in the First 8 Weeks of Antipsychotic Treatment  
Suzanne H. So, Philippa A. Garety, Emmanuelle R. Peters, Shitij Kapur

183. Predictors of Disengagement from Treatment in an Early Psychosis Program  
Jacqueline Stowkowy, Donald Addington, Lu Liu, Brett Hollowell, Jean Addington

184. Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis – A Systematic Review  
Floor J. van der Meer, Eva Velthorst, Carin J. Meijer, Marise W. Machielsen, Paolo Fusar-Poli, Lieuwe de Haan

185. The Association between Thought-Language Disorder and Remission in Schizophrenia  
Levent Var, Berna Yalınçetin, Halis Ulaş, Selma Polat, Şilay Sevilmiş, Berna Binnur Akdede, Köksal Alptekin

186. Involuntary Admission in FEP and Evolution after 8 Years of Follow-up  
Sara Barbeito, Sonia Ruiz de Azua, Patricia Vega, Ixasó González, Miguel Gutiérrez, Ana González Pinto

187. The Evolution of Adherence in First-episode Psychotic Patients after 8 Years  
Patricia Vega, Sonia Ruiz de Azua, Amaia Ugarte, Miryam Fernandez, Ixasó González-Ortega, Santiago Ron, Purificación López, Ana González-Pinto

188. Long-term Impact of a Discontinuation Trial: Remission and Recovery Rates at 7 Years Follow-up of a First Episode Cohort Included in a Treatment Strategy Trial Comparing Maintenance Treatment with Discontinuation Strategy  
Lex Wunderink, Roeline Nieboer, Fokko Nienhuis, Nynke Boonstra, Durk Wiersma

189. Talking with a Psychiatric Patient: Theoretic and Pragmatic Aspects of the Psycho-diagnostic Interview  
Julie Nordgaard, Josef Parnas

190. Auditory Verbal Hallucinations in Patients with Borderline Personality Disorder are Similar to those in Schizophrenia  
Christina W. Slotema, Kirstin Daalman, Jan Dirk Blom, Kelly M. Diederen, Hans W. Hoek, Iris E. Sommer

191. Temperament and Character Dimensions in Ultra-high Risk for Psychosis and First-episode Schizophrenia  
Yun Young Song, Jee In Kang, Su Young Lee, Eun Lee, Suk Kyoong An, Jun Soo Kwon

192. From Intrusions to Obsessions to Psychosis: Mediated by Delusions?  
Frank Van Dael, Jim van Os, Roselind Lieb, Hans-Ulrich Wittchen, Inez Myin-Germeys
193. Verbal Information Disclosure/non-disclosure in Psychosis: A Preliminary Result
Jia-Qi Xu, Christy Lai-Ming Hui, Gloria Hoi-Yan Wong, May Mei-Ling Lam, Eric Yu-Hai Chen

194. Antipsychotic-mood Stabilizers Association has Limited Efficacy in Psychosis but is more Frequent in People Receiving High Doses of Antipsychotics: Results from a Real-world Naturalistic Study
Felice Iasevoli, E. Di Giovambattista, M. Marconi, M. P. Rapagnani, F. Felicetti, M. Perongini, Alessandro Valchera

195. QTc Interval Prolongation in a Naturalistic Sample of Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics
Erik Johnsen, Kristina Aanesen, Sanjeevan Sriskandarajah, Rune A. Kroken, Else-Marie Løberg, Hugo A. Jørgensen

196. High Dose D-serine in the Treatment of Schizophrenia
Joshua T. Kantrowitz, Tamara Friedman, Erin Oakman, Nayla Scaramello, Desiree Gomez, Gail Silipo, Daniel C. Javitt

197. Long-Term Treatment with Lurasidone in Schizophrenia: Results of an 8-week Double-blind Acute Study Followed by a 44-Week Open-Label Extension
Masaki Kato, Masaaki Ogasa, Hiroki Ogo, Yoko Ishige, Hiroshi Sawabe, Cynthia Siu, Antony Loebel

198. Differential Diagnosis and Treatment of Depressive Symptoms in Patients with Schizophrenia
Alexandra Kaufmann, Nadja Frei, Falko Biedermann, W. Wolfgang Fleischhacker, Alex Hofer

199. Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?
Richard S. E. Keefe, Robert W. Buchanan, Stephen R. Marder, Nina R. Schooler, Ashish Dugar, Milana Zivkov, Michelle Stewart

200. Symptom Structures of Atypical Antipsychotics-Induced Obsessive Compulsive Symptoms in Schizophrenia Patients
Joo Hyun Kim, Seunghyong Ryu, Hee Jung Nam, Meerae Lim, Ji Hyun Baek, Yeon Ho Joo, Jun Soo Kwon, Kyooseob Ha, Kyung Sue Hong

201. The Effect of Paliperidone ER on Subjective Well-being and Attitudes Toward Medication among Patients with Schizophrenia
Sung-Wan Kim, Jin-Sang Yoon, Il-Seon Shin, Jae-Min Kim, Kyung-Yeol Bae, Seok-Heon Kim, Ji-Eun Jang, Hee-Ju Kang, Yo-Han Lee, Yong-Min Ahn, Yong Sik Kim

202. Antipsychotic Polypharmacy in Schizophrenic Inpatients at a University Psychiatric Hospital in Korea: A Comparison of 2005 and 2010
Chan-Hyung Kim, Daeyoung Roh, Ghin-Goo Chang

203. The Relationship between Antipsychotic D2 Occupancy and Change in Frontal Metabolic and Cognitive Function: ADual [11C]-raclopride and [18F]-FDG Study with Aripiprazole
Euitae Kim, Oliver D. Howes, Jae Min Jeong, Federico E. Turkheimer, Shitij Kapur, Jun Soo Kwon
204. Time to Discontinuation of Antipsychotic Drugs in a Schizophrenia Cohort: Influence of Current Treatment Strategies

205. Development of a Brief Questionnaire for (un)desired Effects of Antipsychotics

206. Antipsychotic-like Effects Independent of D2 Receptors Blockade: The Case of Alstonine
Viviane M. Linck, Ana P. Herrmann, Marta C. Antonelli, Christopher O. Okunji, Elaine Elisabetsky

207. A Double-Blind, Placebo Controlled Trial of Betahistine to Ameliorate Antipsychotic Associated Weight Gain in Adolescents and Young Adults: Preliminary Safety and Efficacy Data
Allison S. Larr, Julia Vakhrusheva, Peter Marino, Lawrence Maayan

208. Plasma Clozapine and Norclozapine in Relation to Prescribed Dose and Other Factors in Patients Aged 65 Years and Over: Data from a Therapeutic Drug Monitoring Service, 1996-2010
James H. MacCabe, Sally Bowskill, Lewis Couchman, Robert J. Flanagan

209. Effects of Dopamine D3 Receptor Stimulation on Reward Learning: Implications for Adjunct Treatment of Antipsychotic-induced Motivational Impairments
Patrick N. McCormick, Paul Fletcher, Gary J. Remington

210. Olanzapine Influences Insulin Signaling Pathway Independently by its Effects on Weight and Fat Deposition
Valeria Mondelli, Christopher Anacker, Annamaria Cattaneo, Anthony Vernon, Sridhar Natesan, Mike Modo, Paola Dazzan, Shitij Kapur, Carmine M. Pariante

211. Adjunctive Lisdexamfetamine Dimesylate Treatment of Predominant Negative Symptoms of Schizophrenia: Analysis by Atypical Antipsychotic Agent
Henry A. Nasrallah, Robert Lasser, Bryan Dirks, Courtney Kirsch, Ben Adeyi, Brian Scheckner, Jean-Pierre Lindenmayer

212. Risk of Relapse and Hospitalization in the 2-Year Open-Label Treatment of Outpatients with Schizophrenia Randomized to Olanzapine Long-Acting Injection or Oral Olanzapine
Diego Novick, Haya Ascher-Svanum, Jordan Bertsch, Holland C. Detke, David McDonnell, Josep Maria Haro

213. Efficacy of an NMDA Receptor Antagonist in the Treatment of Tardive Dyskinesia: A Randomized, Double-blind, Placebo-controlled Study
Sofia Pappa, Sofia Tzouli, Venos Mavreas, Spyros Konitsiotis

214. Risperidone and Total 9-hydroxyrisperidone in Relation to Prescribed Dose and Other Factors: Data from a UK Therapeutic Drug Monitoring Service, 2002-2010
Maxine X. Patel, Sally J. V. Bowskill, Simon Handle, Danielle Fischer, Robert J. Flanagan

215. A Systematic Review of the Evidence of Clozapine’s Anti-aggressive Effects
Catherine L. Frogley, David Taylor, Marco Picchioni
216. A Retrospective Study of Clozapine in Emotionally Unstable Personality Disorder
Catherine L. Frogley, Katina Anagnostakis, Shawn Mitchell, Fiona Mason, Marco M. Picchioni

217. Predicting Dopamine D2 Receptor Occupancy following Antipsychotic Dose Reduction: A Pilot PET Study
Hiroyuki Uchida, Robert R. Bies, Takefumi Suzuki, Ariel Graff-Guerrero, Bruce G. Pollock, Benoit H. Mulsant, David C. Mamo

218. Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data
Hiroyuki Uchida, Hitoshi Sakurai, Robert R. Bies, Scott Stroup, Richard S. E. Keefe, Takefumi Suzuki, Takashi Tsuboi, Masaru Mimura, Bruce G. Pollock, David C. Mamo

219. A Post-hoc Analysis of the Negative Symptom Factor Score in a Proof-of-concept with a Glycine Reuptake Inhibitor (GRI) in Schizophrenia
Daniel Umbricht, Ellen L. Lentz, Luca Santarelli, Justine Lalonde

220. Intranasal Oxytocin Effects on Social Anxiety and Depression in Schizophrenia: Results from a Double Blind Placebo Controlled Trial
Heidi J. Wehring, Mary R. Lee, Robert P. McMahon, Alan Bellack, Jared Linthicum, Stephanie Feldman, Gopal Vyas, Charles Richardson, Robert W. Buchanan, Carlo Contoreggi, Ann Marie Kearns, Deanna L. Kelly

221. A Survey on Attitudes of Korean Psychiatrists toward Long-acting injectable Antipsychotics: An Interim Analysis
Jin-Sang Yoon, Sung-Wan Kim, Kyung-Yeol Bae, Joon-An Yoo, Seon-Young Kim, Ji-Eun Jang, Seok-Heon Kim, Yo-Han Lee

222. Delayed ‘eureka’ of Alpha 7 Nicotinic Acetylcholine Receptor Knockout Mice in a Probabilistic Reversal Learning Paradigm
Jared W. Young, Mary E. Kamenski, Mark A. Geyer

223. Gender Differences and Effects of Acute and Chronic Oxytocin on Social Interaction in Mice
Xiaofan Zhang, Qi Li, Sylvia Lam, Siew Chua, Grainne McAlonan

224. Multi-centered Research of the Effectiveness of Combined Therapies for People with Schizophrenia- A Comprehensive Psycho-educational Approach and Scheme Set (COMPASS) while using Risperidone Long-acting Injection Therapy
Yueren Zhao, Nakao Iwata

225. Specific Executive Dysfunctions as Possible Predictors of Community Functioning
Kaidi Kiis

226. The Eyes Have It: Evidence of Heightened Sensitivity to Other People’s Eye-gaze in Schizophrenia
Robyn A. Langdon, Philip B. Ward

227. Increased Social Withdrawal and Isolation in the Context of Intact Hedonic Capacity in People at Ultra-high Risk for Psychosis: An Experience Sampling Study
Tineke Lataster, Judith Drees, Margreet Oorschot, Michael Wagner, Inez Myin-Germeys
228. Personality Characteristics and its Relations with Anhedonia and Global Functioning in Individuals at Ultra-High Risk for Psychosis and Patients with First-Episode Schizophrenia  
Mikyung Lee, Ki Pyoung Kim, Suk K. An

229. The Association between Working Alliance, Compliance, Self-efficacy, and Social Function in a Cohort of 397 Patients with First-episode Psychosis  
Marianne Melau, Susanne Harder, Pia Jeppesen, Anne Thorup, Merete Nordentoft

230. Persons with Schizophrenia and Four Types of Family Involvement  
Carpentier Normand

231. Evaluating Readiness for Work in Patients with Schizophrenia: “the Readiness for Work Questionnaire” WoRQ  
Steven G. Potkin, Dragona Burgarski-Kirola, George Garibaldi

232. Psychosocial Unmet Needs and Social Functioning: Its Relationship in Persons with Severe Mental Health Disorders  
Gemma Prat, Pere Bonet, Myriam Valencia

233. Empathy Deficits are Uniquely Associated with Poor Functioning in Schizophrenia  
Matthew J. Smith, William P. Horan, Tatiana Karpouzian, Samantha Abram, Derin Cobia, John G. Csernansky

234. The Impact of Trauma in Childhood and Adulthood on Clinical and Social Functioning in First Episode Psychosis  
Helen J. Stain, Inge Joa, Tor K. Larsen, Jan Olav Johannessen, Wenche ten Velden Hegelstad, Johannes Langeveld

235. The Social Consequences for Adults Experiencing Psychosis: Findings from the Second Australian National Survey of Psychosis  
Helen J. Stain, Cherrie Galletly, Scott Clark, Jacqui Wilson, Emily Killen, Lauren Anthes, Linda Campbell, Mary-Claire Hanlon, Carol Harvey

236. Longitudinal Changes of Psychopathological Symptoms in At-risk Mental State (ARMS) Individuals without Transition to Psychosis  
Erich Studerus, Charlotte Rapp, Jacqueline Aston, Anita Riecher-Rössler

237. Effect of Supported Employment/Education on Symptom Changes in Young Adults with a First Episode Psychosis  
Manuel Tettamanti, Maryse Badan Bá, Eric Zbinden, Philippe Rey-Bellet, Marco C. G. Merlo

238. Facial and Prosodic Emotion Recognition Deficits Predict Specific Dimension of Psychotic Symptoms in Schizophrenia  
Huai-Hsuan Tseng, Yu-Lien Huang, Sue-Huei Chen, Chih-Min Liu, Ming H. Hsieh, Chen-Chung Liu, Jia-Chi Shan, Yi-Ting Lin, Hai-Gwo Hwu

239. The Effect of Cognitive Remediation Combined with a Comprehensive Psychosocial Programme for Patients with First Episode Schizophrenia: Results of the NEUROCOM Trial  
Lone Vesterager, Torben Christensen, Birthe Olsen, Marianne Melau, Gertrud Krarup, Merete Nordentoft
240. Quality of Life as an Outcome of Psychosis: Implications for Recovery
Sue M. Cotton, John F. Gleeson, Mario Alvarez-Jimenez, Lisa Henry, Meredith Harris, Simone Farrelly, Susy Harrigan, Patrick McGorry

241. Obsessive Compulsive Symptoms but not Obsessive Compulsive Disorder are Related to Lower Quality of Life in Schizophrenia
Alp Ucok, Aysu Tihan, Rasit Tukel

242. Movement Disorders in the Severely Mentally Ill
Diederik Tenback, Peter van Harten

243. Experienced and Anticipated Discrimination in First-episode Psychotic Patients: Pattern, Severity and Relationship with Clinical and Social Factors; Findings from the PICOS Project
Silvia Zoppei, Antonio Lasalvia, Chiara Bonetto, Doriana Cristofalo, Sarah Tosato, Mariaelena Bertani, Sarah Bissoli, Lorenza Lazzarotto, Gioia Zanatta, Katia De Santi, Enrico Ceccato, Rossana Riolo, Vanna Marangon, Stylianos Nicolau, Ileana Boggian, Mirella Ruggeri

244. Crucial Elements in Treatment of First-episode Psychosis Patient, Psychosocial Aspects
Merete Nordentoft, Stephen Austin, Pia Jeppesen, Marianne Melau, Anne Thorup

245. Prevalence of High Dose Antipsychotic Medication Prescription on Discharge: A Clinical Audit
Eirini Theochari, Kevin Pankhurst

246. Long- and Short-term Inpatients with Schizophrenia in China: Implications for Community-Based Service Development
Guowei Wu, Xuan Ouyang, Bo Yang, Li Li, Zheng Wang, Wenying Yi, Chang Liu, Peng Wang, Zhimin Xue, Robert Rosenheck, Zhenning Liu

247. Longitudinal Medication Adherence Instability and the Risk of Psychiatric Admission in Veterans with Schizophrenia
John E. Zeber, Eileen M. Stock, Mary Jo V. Pugh, Jack Y. Tsan, Jacqueline A. Pugh, Sandra B. Morissette, Laurel A. Copeland

248. Evaluating Patient Preferences for Early Intervention Services Using Discrete Choice Conjoint Analysis
Robert B. Zipursky, Charles E. Cunningham, Peter Bieling, Yvonne Chen, Ivana Furimsky, Lisa Jeffs, Victoria Madsen, Heather Rimas, Fiona Wilson, Bruce Christensen

249. Cognitive Performance in Cannabis-using Adolescents with a First Episode of Psychosis
Teresa Sánchez-Gutiérrez, Marta Rapado-Castro, Ana Calvo, Guadalupe Chiclana, Celso Arango

250. A Multi-centre, Randomised Controlled Trial of a Group Psychological Intervention for Psychosis with Comorbid Cannabis Dependence over the Early Course of Illness
Kevin Madigan, Elizabeth Lawlor, Daria Brennan, Niall Turner, Anthony Kinsella, John O’Connor, Vincent Russell, John Waddington, Eadbhard O’Callaghan

251. Substance Use Disorders and Conduct Disorder among Violent Patients with Schizophrenia
Clare Oakley, Stephanie Harris, Tom Fahy, Declan Murphy, Marco Picchioni

252. Effect of Cannabis Use on the Course of Schizophrenia in Male Patients: A Prospective Cohort Study
Daniel van Dijk, Maarten W. J. Koeter, Ronald Hijman, René S. Kahn, Wim van den Brink

253. Longitudinal Substance Use Trajectories for Persons with Schizophrenia
Richard A. Van Dorn, Sarah L. Desmarais, M. Scott Young, Beom Lee, Marvin S. Swartz
254. Sex Differences in Basal and Longitudinal Brain Changes in Early Onset Psychosis
Marta Rapado-Castro, Santiago Reig, Mara Parellada, Josefina Castro-Fornieles, Ana González-Pinto, Soraya Otero, Inmaculada Baesa, Joost Janssen, Montserrat Graell, Dolores Moreno, Manuel Desco, Celso Arango

255. Longitudinal Study of Neurological Soft Signs in First Episode Early Onset Psychosis
María Mayoral, Igor Bombin, Pablo Lobato, Josefina Castro-Fornieles, Ana González-Pinto, Soraya Otero, Mara Parellada, Dolores Moreno, Inmaculada Baesa, Montserrat Graell, Marta Rapado, Celso Arango

256. Social Cognitive Biases as Moderators and Mediators of Successful Cognitive – Behavioral Therapy in Schizophrenia - Results of the Positive Study
Stephanie Mehl, Martin W. Landsberg, Anna Schmidt, Andreas Wittorf, Stefan Klingberg, Michael Wagner

257. Confirmation and Validation of Apolipoprotein H as Novel Biomarker for Schizophrenia
Tze Jen Chow, Han Chern Loh

258. A Haplotype Implication Confirms Association Study of AKT1 Genes with Schizophrenia in Malaysian Population
Han Chern Loh, Tze Jen Chow, Shiu Foon Tee

259. Gender Differences in the Deficit of Insight in Psychotic Patients

260. Reduced Reward-Related Probability Learning in Schizophrenia Patients
Fatma Simsek, Alpaslan Yilmaz, Nazlı B. Ozcelik, Ali S. Gonul

261. Impact of Improving Negative Symptoms on Functioning in Patients with Schizophrenia: A Post-hoc Analysis of a Proof-of-concept Study
Thomas Blaettler

262. Specific Default Network Activity and Connectivity Patterns in Adolescent and Young Adult Relatives of Individuals with Bipolar Psychotic Disorder or Schizophrenia
Heidi W. Thermenos, Susan Whitfield-Gabrieli, Richard Juelich, Nikos M. Makris, Stephen V. Farahone, Ming T. Tsuang, John D. E. Gabrieli, Larry J. Seidman

263. Homer Expression Modulation by Antipsychotics, Alone or in Combination with Antidepressants: Role of D2-R and Serotonin Occupancy
Carmine Tomasetti, Felicelasevoli, Federica Marmo, Andrea de Bartolomeis

264. Default Node network in Young People with Familial Risk for Psychosis

265. Computational Approach to Understanding Cortical Circuit Deficits of Schizophrenia
Peter J. Seymeier, Tsung-Ung W. Wuu

266. Preliminary 6-month Outcome of a Randomized Controlled Trial of Specialized Early Intervention Treatment in Adult onset First-episode Psychosis (JCEP)

267. Evidence that the Combination of Hallucinatory Experiences and Delusional Ideation is a Crucial Indicator of the Early Transition from Vulnerability to Clinical Psychosis
Feikje Smeets, Tineke Lataster, María-De Gracia Dominguez, Ruud van Winkel, Juliëtte Hommes, Roselind Lieb, Hanss-Ullricht Wittchen, Ron de Graaf, Margreet ten Have, Jim van Os

268. Do Time Perception Networks Mediate Cognitive Dysfunctions in Schizophrenia?
Felipe Ortuño, José A. Gómez, Francisco Guillen-Grima
<table>
<thead>
<tr>
<th>Index of Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aanesen, K. 120, 126</td>
</tr>
<tr>
<td>Aaron, R. 66, 126</td>
</tr>
<tr>
<td>Aarts, H. 95, 126</td>
</tr>
<tr>
<td>Aas, M. 47, 126, 127</td>
</tr>
<tr>
<td>Abayomi, O. 80, 126</td>
</tr>
<tr>
<td>Abazyan, B. 4, 60, 126</td>
</tr>
<tr>
<td>Abazyan, S. 60, 126</td>
</tr>
<tr>
<td>Abbs, B. 4, 63, 126</td>
</tr>
<tr>
<td>Abel, K. 91, 126, 127</td>
</tr>
<tr>
<td>Abeling, N. 61, 126</td>
</tr>
<tr>
<td>Abhishekh, H. 66, 126</td>
</tr>
<tr>
<td>Abi-Dargham, A. 24, 126, 127</td>
</tr>
<tr>
<td>Abilio, V 83, 99, 105, 126</td>
</tr>
<tr>
<td>Aboutaleb, N. 87, 126</td>
</tr>
<tr>
<td>Abram, S. 126, 127</td>
</tr>
<tr>
<td>Abi-Dargham, A. 24, 126, 127</td>
</tr>
<tr>
<td>Abil, B. 121, 126</td>
</tr>
<tr>
<td>Adham, N. 126</td>
</tr>
<tr>
<td>Adres, M. 73, 87, 126, 127</td>
</tr>
<tr>
<td>Agar, I. 126, 127</td>
</tr>
<tr>
<td>Aggernais, B. 85, 126, 127</td>
</tr>
<tr>
<td>Agid, O. 46, 76, 77, 126, 127</td>
</tr>
<tr>
<td>Agrawal, A. 74</td>
</tr>
<tr>
<td>Aguglia, E. 114</td>
</tr>
<tr>
<td>Aguilar, E. 74, 126, 127</td>
</tr>
<tr>
<td>Aguilar, L. 60, 112, 126, 127</td>
</tr>
<tr>
<td>Aguvi, R. 91</td>
</tr>
<tr>
<td>Ahmad, S. 80</td>
</tr>
<tr>
<td>Ahmed, M. 63, 102, 126, 127</td>
</tr>
<tr>
<td>Ahn, Y. 120</td>
</tr>
<tr>
<td>Ainsworth, J. 88</td>
</tr>
<tr>
<td>Altchison, K. 113, 126, 127</td>
</tr>
<tr>
<td>Akedde Kivircik, B. 77</td>
</tr>
<tr>
<td>Akedde, B. 77, 93, 118, 119</td>
</tr>
<tr>
<td>Akhtar, S. 78</td>
</tr>
<tr>
<td>Akib, T. 111</td>
</tr>
<tr>
<td>Aktener, A. 4, 77, 93</td>
</tr>
<tr>
<td>Alaraisänen, A. 97, 111</td>
</tr>
<tr>
<td>Alary, M. 83</td>
</tr>
<tr>
<td>Alba-Ferrara, L. 94</td>
</tr>
<tr>
<td>Alberati, D. 51, 77</td>
</tr>
<tr>
<td>Alberich, S. 73</td>
</tr>
<tr>
<td>Alcalde, M. 116</td>
</tr>
<tr>
<td>Alemany, S. 60, 73, 83, 126, 127</td>
</tr>
<tr>
<td>Alexander, P. 117</td>
</tr>
<tr>
<td>Ali, M. 74</td>
</tr>
<tr>
<td>Alizadeh Zendehrood, S. 117</td>
</tr>
<tr>
<td>Allain, P. 94</td>
</tr>
<tr>
<td>Allegri, F. 30</td>
</tr>
<tr>
<td>Allen, P. 62, 63, 103, 108, 126, 127</td>
</tr>
<tr>
<td>Allott, K. 40, 78, 79</td>
</tr>
<tr>
<td>Almeida, V. 83</td>
</tr>
<tr>
<td>Aloj, L. 69</td>
</tr>
<tr>
<td>Alonso, C. 71</td>
</tr>
<tr>
<td>Alonso-Fernandez, A. 75</td>
</tr>
<tr>
<td>Alonso-Solis, A. 105</td>
</tr>
<tr>
<td>Alphs, L. 75, 97, 99</td>
</tr>
<tr>
<td>Alptekin, K. 4, 75, 77, 93, 118, 119, 126, 127</td>
</tr>
<tr>
<td>Altmann, D. 86, 126, 127</td>
</tr>
<tr>
<td>Al-Uzri, M. 79</td>
</tr>
<tr>
<td>Alvarez Sanchez, R. 77</td>
</tr>
<tr>
<td>Alvarez, E. 105, 126, 127</td>
</tr>
<tr>
<td>Alvarez, M. 102, 126, 127</td>
</tr>
<tr>
<td>Alvarez, P. 101</td>
</tr>
<tr>
<td>Alvarez, S. 101</td>
</tr>
<tr>
<td>Alvarez-Jimenez, M. 124, 126, 127</td>
</tr>
<tr>
<td>Amado, I. 81, 94, 114, 126, 127</td>
</tr>
<tr>
<td>Amano, N. 92</td>
</tr>
<tr>
<td>Amato, D. 126, 127</td>
</tr>
<tr>
<td>Ameller, A. 65</td>
</tr>
<tr>
<td>Ammari, N. 65</td>
</tr>
<tr>
<td>Amminger, G. 28, 67</td>
</tr>
<tr>
<td>Amminger, P. 126, 127</td>
</tr>
<tr>
<td>Amzad, S. 65</td>
</tr>
<tr>
<td>An, H. 113</td>
</tr>
<tr>
<td>An, S. 71, 85, 102, 116, 119, 123</td>
</tr>
<tr>
<td>Anacker, C. 121</td>
</tr>
<tr>
<td>Anagnostakis, K. 122</td>
</tr>
<tr>
<td>Anand, E. 75, 99</td>
</tr>
<tr>
<td>Andreas, V. 71</td>
</tr>
<tr>
<td>Andreassen, N. 50, 126, 127</td>
</tr>
<tr>
<td>Andreassen, O. 126, 127</td>
</tr>
<tr>
<td>Andreopoulos, A. 94</td>
</tr>
<tr>
<td>Andrés-Perpiñá, S. 65</td>
</tr>
<tr>
<td>Annable, L. 100</td>
</tr>
<tr>
<td>Anney, R. 113</td>
</tr>
<tr>
<td>Anthes, L. 123</td>
</tr>
<tr>
<td>Antonelli, M. 121</td>
</tr>
<tr>
<td>Antoni, F. 110</td>
</tr>
<tr>
<td>Antonio, C. 60</td>
</tr>
<tr>
<td>Antonucci, L. 84, 126, 127</td>
</tr>
<tr>
<td>Anusha, M. 66</td>
</tr>
<tr>
<td>Aoki, S. 107</td>
</tr>
<tr>
<td>Aparicio, A. 116, 126, 127</td>
</tr>
<tr>
<td>Apter, A. 73, 87, 126, 127</td>
</tr>
<tr>
<td>Aral, M. 92</td>
</tr>
<tr>
<td>Araki, T. 85</td>
</tr>
<tr>
<td>Arango, M.D., Ph.D., C. 3, 4, 36, 63, 65, 87, 99, 124, 125, 126, 127</td>
</tr>
<tr>
<td>Arango-Lopez, C. 112</td>
</tr>
<tr>
<td>Arenas-Fernandez, R. 75</td>
</tr>
<tr>
<td>Arendt, M. 103, 127</td>
</tr>
<tr>
<td>Arenovich, T. 83, 101, 127</td>
</tr>
<tr>
<td>Arias, B. 60, 91, 99, 127</td>
</tr>
<tr>
<td>Armando, M. 41, 57, 127</td>
</tr>
<tr>
<td>Arnt, J. 100, 127</td>
</tr>
<tr>
<td>Arroyo, S. 100</td>
</tr>
<tr>
<td>Arrufat, F. 103</td>
</tr>
<tr>
<td>Asabella, A. 63</td>
</tr>
<tr>
<td>Ascher-Svanum, H. 77, 78, 92, 98, 121, 127</td>
</tr>
<tr>
<td>Ash, D. 80, 127</td>
</tr>
<tr>
<td>Askenazy, F. 95</td>
</tr>
<tr>
<td>Asmal, L. 76</td>
</tr>
<tr>
<td>Aston, J. 63, 64, 123</td>
</tr>
<tr>
<td>Atakan, Z. 127</td>
</tr>
<tr>
<td>Athanasos, P. 103</td>
</tr>
<tr>
<td>Atkinson, R. 86, 127</td>
</tr>
<tr>
<td>Attard, A. 52</td>
</tr>
<tr>
<td>Atturotto, M. 72, 91, 127</td>
</tr>
<tr>
<td>Aukes, M. 68, 70, 127</td>
</tr>
<tr>
<td>Austin, S. 124</td>
</tr>
<tr>
<td>AuYang, C. 80</td>
</tr>
<tr>
<td>Averbeck, B. 56</td>
</tr>
<tr>
<td>Avvisati, L. 69</td>
</tr>
<tr>
<td>Ayan-Oshodi, M. 78</td>
</tr>
<tr>
<td>Azcárraga, M. 85</td>
</tr>
<tr>
<td>Azorin, J. 75</td>
</tr>
<tr>
<td>Baaré, W. 81, 85, 127</td>
</tr>
<tr>
<td>Bachmann, S. 63, 127</td>
</tr>
<tr>
<td>Backasch, B. 84</td>
</tr>
<tr>
<td>Backes, H. 64, 84, 86, 106</td>
</tr>
<tr>
<td>Bacon, E. 94, 127</td>
</tr>
<tr>
<td>Badan Bâ, M. 81, 123</td>
</tr>
<tr>
<td>Bader, V. 45</td>
</tr>
<tr>
<td>Badowksa, D. 60, 61</td>
</tr>
<tr>
<td>Baee, K. 120, 122, 127</td>
</tr>
<tr>
<td>Baek, J. 120</td>
</tr>
<tr>
<td>Baeza, I. 63, 65, 125, 127</td>
</tr>
<tr>
<td>Bahn, S. 49, 61</td>
</tr>
<tr>
<td>Bailey, M. 113</td>
</tr>
<tr>
<td>Bais, L. 84, 127</td>
</tr>
<tr>
<td>Baitz, H. 72</td>
</tr>
<tr>
<td>Bak, M. 102</td>
</tr>
<tr>
<td>Bak, N. 127</td>
</tr>
<tr>
<td>Baker C. 127</td>
</tr>
<tr>
<td>Baker, A. 79, 127</td>
</tr>
<tr>
<td>Baker, R. 74</td>
</tr>
<tr>
<td>Baker, S. 66</td>
</tr>
<tr>
<td>Bakker, B. 82</td>
</tr>
<tr>
<td>Bakker, R. 82 (Bakker P.R. 127)</td>
</tr>
<tr>
<td>Bakker, S. 127</td>
</tr>
<tr>
<td>Baklouti, N. 84</td>
</tr>
<tr>
<td>Balain, V. 113</td>
</tr>
<tr>
<td>Baldwin, P. 88</td>
</tr>
<tr>
<td>Ballard, T. 77, 104, 127</td>
</tr>
<tr>
<td>Ballespí, S. 60, 82</td>
</tr>
<tr>
<td>Banders, A. 103</td>
</tr>
<tr>
<td>Banerjee, A. 100, 127</td>
</tr>
<tr>
<td>Banken, L. 101</td>
</tr>
<tr>
<td>Baños, I. 76, 95</td>
</tr>
<tr>
<td>Bansal, R. 86, 127</td>
</tr>
<tr>
<td>Banzato, C. 65, 66</td>
</tr>
<tr>
<td>Báir, K. 71, 84, 127</td>
</tr>
<tr>
<td>Barajas, A. 95</td>
</tr>
<tr>
<td>Barbato, M. 94, 96</td>
</tr>
<tr>
<td>Barbeito, S. 73, 92, 119</td>
</tr>
<tr>
<td>Barbour, J. 101</td>
</tr>
<tr>
<td>Bargalló, N. 83</td>
</tr>
<tr>
<td>Barker, G. 63, 86, 127</td>
</tr>
<tr>
<td>Barker, P. 107</td>
</tr>
<tr>
<td>Barnes, A. 107, 127</td>
</tr>
<tr>
<td>Barnes, T. 86, 99, 128</td>
</tr>
<tr>
<td>Barnett, J. 93, 95, 111, 128</td>
</tr>
<tr>
<td>Barr, A. 52, 72, 128</td>
</tr>
<tr>
<td>Barrantes-Vidal, N. 60, 82, 98, 112, 117, 128</td>
</tr>
</tbody>
</table>
Index of Speakers

128

Calabrese, F. 103
Callicott, J. 69, 129
Calvo, M.Sc., A. 124
Calzavara, M. 83, 98, 105
Camerini, B. 98, 105
Campanera, S. 112, 129
Campbell, L. 123
Campbell, P. 9, 21
Cañas, F. 75
Canever, L. 114
Canneva, F. 81
Cannon, D. 63, 101, 129
Cannon, M. 3, 4, 39, 58, 82, 86, 129
Cannon, T. 36, 81, 129
Cantero, M. 102, 104
Cantor, R. 70, 129
Cappe, C. 71
Caramia, F. 108
Carceller, H. 83
Cardarelli, R. 66
Carletti, F. 85, 129
Carlsson, T. 87
Carlton, J. 94
Carr, V. 31, 64, 76, 80, 90, 91, 96, 104, 129
Carrión, R. 4, 71
Carrol, L. 113
Carson, W. 74
Carter, C. 129
Casado, P. 110
Casas-Anguera, E. 79
Casella, N. 25, 40
Casillas, M. 75, 98
Castelein, S. 110, 129
Castellani, C. 4, 47
Castellanos, F. 105
Castellano, A. 74, 77, 88, 96
Castle, D. 3, 79, 98, 110
Castro, M. 84, 105
Castro-Fornies, J. 65, 125
Catalan, R. 98, 129
Catalán, R. 98, 129
Catalano, L. 109
Cather, C. 63
Catinaud, D. 74
Cattaneo, A. 121
Catts, S. 80, 96, 129
Catts, V. 45
Ceccarini, J. 106, 129
Cecco, E. 124
Cella, M. 72
Cepeda, C. 101
Cervilla, J. 112
Ceylan, D. 77
Chaddock, C. 37, 45, 62, 129
Chafee, M. 60
Chakirova, G. 72, 85
Champagne-Lavau, M. 79, 94
Chan, C.
Chan, E. 98
Chan, G. 80
Chan, K. 76
Chan, R. 72, 116, 129
Chan, S. 76, 83, 117, 129 CI
Chanes, A. 66
Chang, G. 120
Chang, J. 93, 95, 98
Chang, V. 113
Chang, W. 76, 80, 117, 129
Chao, Y. 61
Charalambides, M. 89, 90, 129
Charest, A. 94
Chatterjee, A. 107
Chaturvedi, S. 60
Chaves, C. 104
Chen, C. 61, 69, 80, 129
Chen, E. 3, 4, 76, 80, 117, 120, 129
Chen, H. 61, 83
Chen, S. 123
Chen, Y. 80, 124
Cheng, M. 69
Cherubin, P. 95
Cheung, C. 108, 129
Cheung, E. 72, 116
Chia, T. 90, 91
Chia-Hsiang, C. 61, 69, 113
Chiara, B. 93, 95, 124
Chiclana, M.Sc., G. 124
Chiliza, B. 76, 129
Chintoh, A. 83, 99
Chiu, C. 129
Cho, H. 116, 129
Choi, C. 85, 129
Choi, J. 85, 113, 129
Chong Guan, N. 67
Chong, S. 3, 4, 110
Choo, K. 78
Chow, T. 4, 125
Christensen, A. 116
Christensen, B. 73, 124
Christensen, T. 101, 124, 129
Christofolini, D. 91
Chu, E. 86, 129
Chuang, Y. 69
Chui, W. 116
Chun, J. 85, 106, 129
Chung, C. 85
Chung, Y. 74
Cichon, S. 129
Cipriano, A. 105
Ciudad, A. 98, 129
Cifolini, S. 100, 106, 114
Claes, S. 68, 129
Clark, C. 80
Clark, J. 101
Clark, S. 123
Clark, V. 79
Clarke, G. 61
Clarke, L. 99
Clarke, M. 82, 89, 129
Clarke, N. 61
Clasen, L. 129
Clelland, C. 70
Clelland, J. 70
 Clemmensen, L. 67, 87, 109
Clow, A. 79
Coatsworth-Puspoky, R. 101
Cobia, D. 123
Cobo, J. 76, 125, 129
Coen, C. 114
Cohen, B. 101
Cohen, D. 67, 78, 82, 89, 129
Cohen, E. 118
Cohen, M. 129
Cohn, T. 99
Colagiglio, L. 72, 90
Colibazzi, T. 85
Colijn, M. 93
Colizzi, M. 84, 90, 129
Collier, D. 130
Collin, G. 61, 86
Collinson, S. 71, 73
Collip, D. 106, 130
Coltheart, M. 130
Conley, R. 11, 55, 130
Conrad, A. 76
Consilium, I. 69, 113
Contoreggi, C. 122
Conus, P. 66, 130
Cooper, G. 105
Copeland, L. 66, 80, 124
Corbera, S. 79
Corbière, M. 100, 130
Corcoran, C. 88, 130
Corcoran, R. 115
Cordeiro, S. 62
Cordes, S. 114
Cornado, A. 73
Cornblatt, B. 36, 71, 130
Coromina, M. 94
Correll, C. 36, 52, 68, 77, 87, 99, 130
Corripio, I. 97, 98, 105
Cortese, L. 80
Cortizo, R. 75
Corvin, A. 38, 91, 130
Costafreda, S. 108
Costanzo, E. 84, 105, 130
Costas, J. 112
Côté, A. 65
Cotel, M. 61
Cotton, D. 4, 28, 71, 75, 92, 130
Cotton, S. 66, 95, 124, 130
Couchman, L. 65, 82, 121
Coughlin, M. 39
Couture, S. 78
Craig, T. 111, 130
Craig-Rodriguez, A. 117
Crepon, B. 81
Crews, M. 75
Crichton, J. 80
Crippa, J. 32, 85, 130
Crisp, K. 95
Cristofalo, D. 95, 124
Critchley, H. 64
Croft, R. 64
Crossley, N. 71
Croudace, T. 103
Crow, T. 7, 71, 90, 130
Cryan, J. 61
Csernansky, J. 123
Cuccia, J. 98, 102, 130
Cuesta, M. 91, 130
Culeji, J. 112
Cumming, A. 73
Cunha, P. 85
Cunningham, M. 124
Cunningham, M. 110
Curatolo, E. 108
Curic, B. 84, 130
Curran, H. 84
Curtis, J. 86, 117
Czaja, S. 81, 94
INDEX CHAIRPERSONS

FLORENCE
14-18 APRIL 2012
Florence
14-18 April 2012

Glenthoj, B. 88, 132
Glud, C. 87, 132
Gobbi, L. 92
Gochman, P. 87
Goebel, R. 84, 106, 132
Goekoop, R. 106
Goff, D. 11, 26, 31, 55, 63, 132
Goghal, N. 87, 132
Gold, J. 109, 132
Goldberg, T. 71, 132
Goldberg, X. 73, 83, 92, 112, 132
Goldstein, J. 63, 132
Gomar, J. 90, 132
Gomes, F. 4, 99
Gomes, S. 99
Gomez, D. 120, 132
Gómez-Ansón, B. 105
Gómez, J. 102, 125
Gonçalves, C. 60, 99
Gonçalves, Ó. 88
Gonçalves, P. 73
Gong, Q. 116
Gonul, A. 125
González Pinto, A. 63, 65, 73, 92, 98, 112, 119, 125, 132
Gonzalez, B. 76
González, I. 119
Gonzalez, J. 66 (JODI), 72 (JULIO), 112 (JOSE)
Gonzalez-Burgos, G. 51
González-Oliveros, R. 73
González-Ortega, I. 73, 119
Gonzalez-Pinto, A. 63, 65, 73, 92, 98, 112, 125, 132
Gonzalez-Pinto, A. V. 3
Gooding, D. 97
Goosens, F. 65
Gopal, S. 75, 98
Gordon, P. 73
Gorely, A. 25
Gorwood, P. 75, 95
Gosselin, F. 80
Gourdie, C. 102
Grace, A. 3, 4, 13, 45, 50, 56, 132
Graell, M. 63, 65, 125, 133
Graf von Reventlow, H. 97, 110, 133
Graf-Guerrero, A. 62, 85, 122
Gramfort, A. 63
Grasa, E. 97, 105
Gray, R. 79, 133
Grayson, B. 103, 133
Grayson, D. 91, 133
Green, A. 64
Green, M. 3, 4, 10, 13, 24, 46, 106, 110 (MICHAEL) – 64, 90, 91, 133 (MELISSA)
Greenwald, D. 66
Greenstein, J. 87, 133
Greenwood, K. 100, 133
Greenwood, L. 45
Grieths, S. 74
Grignon, S. 82
Gromann, P. 65, 86
Gronenschild, E. 86, 133
Groome, D. 118
Groot, C. 93
Gross, G. 11, 55 (GERHARD) – 97 (GEORGINA)
Gruber, O. 133
Guerreiro, J. 100, 133
Güellmar, D. 87
Guada, J. 100, 133
Guadalupe, M. 83
Guerrero-Pedraza, A. 90
Güttgemanns, J. 109
Güttgemanns, J. 109
Guidotti, A. 91, 133
Guidotti, G. 103
Gulliver-Grima, F. 102, 125
Günther, D. 65
Güthierrez, M. 73, 97, 119, 133
Guermans, J. 109
Haffner, M. 83
Hallerbäck, M. 66
Halpin, S. 76, 133
Hamaie, Y. 109, 133
Hämäläinen, M. 63
Hamilton, G. 113
Hammer, T. 81, 133
Hampshire, A. 72
Handley, R. 67, 89, 90, 112, 133
Handley, S. 65, 121
Hanlon, M. 105, 123
Hannan, A. 30
Hao, X. 85
Harder, S. 123
Harper, L. 75, 95, 133
Harper, M. 80, 124
Harriman, M. 76
Hartmann, M. 100
Hartung, T. 92
Harvey, B. 104
Harvey, C. 123
Harvey, L. 83
Haro, J. 69, 77, 121, 133
Haro-Abad, J. 112
Harrigan, S. 124
Harris, A. 31, 40, 133
Harris, M. 80, 124
Harrison, D. 76
Hartmann, M. 100
Hartung, T. 92
Harvey, B. 104
Harvey, C. 123
Harvey, L. 83
Harpin, S. 76, 133
Hargreaves, A. 91
Harrison, D. 76
Harley, C. 133
Harley, M. 125
Harrold, C. 108, 133
Harvey, N. 119
Herrmann, A. 99, 121
Herrmann, E. 116
Herrmann, M. 93, 115
Hessel, B. 102
Hewitt, P. 102
Hides, L. 66
Higier, R. 38
Higuchi, T. 115, 133
Hijman, R. 125
Hirnstein, M. 93, 115
Hisse, B. 102
Hjorth, A. 102
Hjorth, C. 46, 102, 115, 133
Ho, S. 108
Hochard, C. 74
Hodgson, D. 104
Hoe, M. 100
Hoek, H. 68, 119, 133
Hoertagl, C. 79
Hofer, A. 78, 79, 80, 102, 120, 133
Hoffman, L. 116, 133
Hofmann, C. 77, 100
Hollin, T. 107
Holleran, L. 63
Hollowell, B. 119
Homburg, J. 104
Hommes, J. 125
Honer, M. 92
Honer, W. 29, 51, 52, 72, 133
Hong, E. 115
Index of Speakers

132

Iakimova, G. 94
Iacoboni, M. 110
Hwu, H. 123, 134
Hwang, J. 108
Huys, Q. 62
Hurtig, T. 111, 134
Hurtado-Casanova, A. 75
Hunter, R. 113
Hunter, M. 104, 134
Hungria, F. 98, 105
Hultman, C. 25
Hulsken, S. 104
Hundel, J. 113
Hulsken, S. 104
Hultman, C. 25
Hungria, F. 98, 105
Hunter, M. 104, 134
Hunter, R. 113
Hurst, C. 113
Hurtado-Casanova, A. 75
Hurtig, T. 111, 134
Hutchinson, G. 67, 111, 134
Huttunen, M. 3, 82, 134
Huys, Q. 62
Hwang, J. 108
Hwang, S. 93, 95, 134
Hwu, H. 123, 134
Hudiyalainen, T. 118
Iacoboni, M. 110
Iakimova, G. 94
Iasevoli, F. 69, 82, 120
Ibañez, M. 60, 91
Idris, N. 103, 134
Ikeda, M. 112, 134
Ikeouch-Sugita, A. 100
Ikezawa, S. 79
Ilonen, T. 94
Im, C. 88
Imai, N. 91
Incampo, A. 62
Interian, A. 66
Investigators, G. 80, 94, 110
Ira, E. 93
Ishige, Y. 120
Ishii, T. 83
Ishiy, P. 99
Ishif, H. 110, 134
Isa, S. 72, 95, 134
Isokan, I. 97
Isokan, M. 89, 97, 107, 111, 118
Issy, A. 99
Ito, Kawa, M. 91
Ivorra, J. 69, 112
Iwashi, N. 85, 116
Iwata, K. 92, 105, 134
Iwata, N. 112, 122, 134
Iyegbe, C. 112
Jaaskelainen, E. 89, 94, 97, 107, 111, 118, 125, 134
Jääskeläinen, E. 89, 94, 97, 107, 111, 118, 125, 134
Jabbar, G. 69, 86
Jablonsky, A. 91, 96, 134
Jackson, H. 93
Jackson, M. 58, 134
Jackson, P. 94
Jamarn, S. 91, 134
James, A. 71, 134
Jang, J. 105, 108, 115, 134
(JOON HWAN) – 120, 122
Janson, E. 70
Janssen, B. 95
Janssen, J. 63, 125, 134
Jannsens, M. 46
Jantzen, P. 87
Jardri, R. 93, 134
Jäuregui, O. 84
Javil, D. 3, 120, 134
Jeffs, L. 124
Jennner, J. 97, 134
Jensen, J. 103
Jensen, K. 87
Jensen, L. 114
Jeon, I. 71, 100
Jeong, J. 120
Jeppesen, P. 67, 87, 123, 124, 134
Jepsen, J. 87, 109, 116
Jim, J. 82
Jim, O. 80
Jiménez-Arriero, M. 98
Jin, N. 74
Jidi, A. 74
Joa, I. 123, 134
Joanna, H. 69, 70, 71, 112, 114
Joel, W. 74, 112
Joergensen, T. 87
Johannesen, J. 123
Johnsen, E. 85, 102, 120, 121, 134
Johnson, B. 75
Johnstone, E. 3, 72, 85, 134
Jones, K. 75
Jones, P. 29, 58, 67, 81, 82, 89, 92, 94, 100, 103, 107, 111, 125, 134
Joo, E. 113
Joo, Y. 81, 120, 134
Jobo, R. 68, 83, 134
Jörg, F. 117
Jorgensen, H. 102, 120, 121, 134
Joukaamaa, M. 111, 134
Jovic, S. 80
Joyce, D. 86
Joyce, E. 4, 13, 47, 86, 134
Juckel, G. 87, 95, 97, 109, 110, 134
Juellich, R. 69, 86, 125, 134
Jukuri, T. 125
Jung, H. 93, 134
Jung, W. 85, 108
Juola, P. 111
Kaakinen, M. 134
Kader, L. 70
Kaiser, S. 62, 135
Kajii, Y. 112
Kaladindi, S. 62
Kaladjian, A. 114
Kalidindi, S. 68
Kälmärken, S. 82
Kalogerakou, S. 94, 135
Kambeitz, J SE KambeitzS 135
Kamboj, S. 63
Kameskri, M. 122
Kane, F. 62, 68, 135
Kane, J. 3, 11, 20, 26, 31, 53, 55, 77, 98, 103, 135
Kang, D. 106
Kang, H. 120
Kang, J. 100, 119, 135
Kang, N. 74
Kang, S. 113, 135
Kankulu, B. 101
Kantrowitz, J. 4, 120
Kao, A. 70
Kapelski, P. 69, 70, 71, 112, 114
Kapur, S. 3, 4, 10, 23, 32, 51, 52, 56, 70, 84, 119, 120, 121, 135
Karbon, L. 69
Karahasan, S. 77
Karayiorgou, M. 10, 34, 135
Karci, O. 77
Kårgel, C. 110, 135
Karim Haidar, M. 92
Karifilis, D. 110
Karl, J. 77
Karlovic, D. 112
Karlsdon, H. 81
Karpouzian, T. 123
Kasai, K. 85, 116, 135
Kastner, P. 77
Katagiri, N. 107, 135
Kato, M. 120
Katsuki, A. 100
Katsura, M. 109, 135
Kaufmann, A. 79, 120, 135
Kawashik, S. 216
Kawada, R. 107
Kawamoto, Y. 115, 135
Kawamura, T. 116
Kawamura, Y. 116
Kawasaki, Y. 65, 107, 135
Kay-Lambkin, F. 79
Kaye, M. 72, 100, 135
Kearns, A. 122
Kebir, O. 89
Keeffe, R. 3, 4, 13, 47, 73, 93, 110, 120, 122, 135
Kehr, J. 103
Keks, N. 26
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lincoln, S.</td>
<td>106</td>
</tr>
<tr>
<td>Lindberg, P.</td>
<td>81</td>
</tr>
<tr>
<td>Lindenmayer, J.</td>
<td>116, 121</td>
</tr>
<tr>
<td>Lindholm, P.</td>
<td>111</td>
</tr>
<tr>
<td>Linscott, R.</td>
<td>58</td>
</tr>
<tr>
<td>Linszen, D.</td>
<td>61, 67, 90, 97, 109, 110, 115</td>
</tr>
<tr>
<td>Linthicum, J.N.</td>
<td>122</td>
</tr>
<tr>
<td>Lisa, C.</td>
<td>95</td>
</tr>
<tr>
<td>Liu, A.</td>
<td>116</td>
</tr>
<tr>
<td>Liu, B.</td>
<td>91</td>
</tr>
<tr>
<td>Liu, C.</td>
<td>123</td>
</tr>
<tr>
<td>Liu, D.</td>
<td>102</td>
</tr>
<tr>
<td>Liu, L.</td>
<td>119</td>
</tr>
<tr>
<td>Liu, T.</td>
<td>76</td>
</tr>
<tr>
<td>Liu, Y.</td>
<td>98</td>
</tr>
<tr>
<td>Liu, Z.</td>
<td>117</td>
</tr>
<tr>
<td>Llorca, P.</td>
<td>91</td>
</tr>
<tr>
<td>Lo Bianco, L.</td>
<td>63, 84</td>
</tr>
<tr>
<td>Lobato, P.</td>
<td>125</td>
</tr>
<tr>
<td>Leberg, E.</td>
<td>85, 120</td>
</tr>
<tr>
<td>Loebel, A.</td>
<td>98, 102, 120</td>
</tr>
<tr>
<td>Loewenstein, D.</td>
<td>81, 94</td>
</tr>
<tr>
<td>Loh, H.</td>
<td>125</td>
</tr>
<tr>
<td>Lomas, B.</td>
<td>87</td>
</tr>
<tr>
<td>Long, C.</td>
<td>112</td>
</tr>
<tr>
<td>Looijestijn, J.</td>
<td>106</td>
</tr>
<tr>
<td>López, P.</td>
<td>119</td>
</tr>
<tr>
<td>Lorente-Rovira, E.</td>
<td>97</td>
</tr>
<tr>
<td>Loughland, C.</td>
<td>96, 104</td>
</tr>
<tr>
<td>Loukkola, J.</td>
<td>94</td>
</tr>
<tr>
<td>Louzá, M.</td>
<td>73</td>
</tr>
<tr>
<td>Lublin, H.</td>
<td>99</td>
</tr>
<tr>
<td>Lubman, D.</td>
<td>95</td>
</tr>
<tr>
<td>Luca, R.</td>
<td>105</td>
</tr>
<tr>
<td>Lucacchini, A.</td>
<td>91</td>
</tr>
<tr>
<td>Lugnegård, T.</td>
<td>66</td>
</tr>
<tr>
<td>Lui, S.</td>
<td>72, 116</td>
</tr>
<tr>
<td>Lunardi, P.</td>
<td>60, 99</td>
</tr>
<tr>
<td>Lunenburg, M.</td>
<td>98</td>
</tr>
<tr>
<td>Luoni, A.</td>
<td>103, 104</td>
</tr>
<tr>
<td>Luteijn, B.</td>
<td>65, 97</td>
</tr>
<tr>
<td>Lyné, J.</td>
<td>89</td>
</tr>
<tr>
<td>Lysaker, P.</td>
<td>74, 79</td>
</tr>
<tr>
<td>Ma, T.</td>
<td>60</td>
</tr>
<tr>
<td>Ma, Y.</td>
<td>75</td>
</tr>
<tr>
<td>Maat, A.</td>
<td>80</td>
</tr>
<tr>
<td>Maayan, L.</td>
<td>121</td>
</tr>
<tr>
<td>MacCabe, J.</td>
<td>29, 38, 39, 82, 89, 92, 121</td>
</tr>
<tr>
<td>MacDonald, A.</td>
<td>86</td>
</tr>
<tr>
<td>MacDonald, M</td>
<td></td>
</tr>
<tr>
<td>MacDowell, K.</td>
<td>70</td>
</tr>
<tr>
<td>MacEwan, G.W.</td>
<td>72</td>
</tr>
<tr>
<td>Machado, M.</td>
<td>81</td>
</tr>
<tr>
<td>Machielsen, M.</td>
<td>107, 119</td>
</tr>
<tr>
<td>Machin, M.</td>
<td>88</td>
</tr>
<tr>
<td>Mackinnon, A.</td>
<td>66, 110</td>
</tr>
<tr>
<td>Maddalena, G.</td>
<td>90</td>
</tr>
<tr>
<td>Madigan, K.</td>
<td>124</td>
</tr>
<tr>
<td>Madsen, G.</td>
<td>88</td>
</tr>
<tr>
<td>Madsen, K. H.</td>
<td>60</td>
</tr>
<tr>
<td>Madsen, V.</td>
<td>124</td>
</tr>
<tr>
<td>Maes, J.</td>
<td>97</td>
</tr>
<tr>
<td>Magaud, E.</td>
<td>114</td>
</tr>
<tr>
<td>Magnussen, C.</td>
<td>89</td>
</tr>
<tr>
<td>Magro, C.</td>
<td>75</td>
</tr>
<tr>
<td>Maier, W.</td>
<td>95</td>
</tr>
<tr>
<td>Mak, H.</td>
<td>108</td>
</tr>
<tr>
<td>Makady, S.</td>
<td>81</td>
</tr>
<tr>
<td>Mäki, P.</td>
<td>48, 94, 111, 125</td>
</tr>
<tr>
<td>Makris, N.</td>
<td>63, 125</td>
</tr>
<tr>
<td>Malaspina, D.</td>
<td>25</td>
</tr>
<tr>
<td>Malherbe, P.</td>
<td>77</td>
</tr>
<tr>
<td>Malhotra, A.</td>
<td>24, 68</td>
</tr>
<tr>
<td>Malla, A.</td>
<td>68</td>
</tr>
<tr>
<td>Maller, J.</td>
<td>64</td>
</tr>
<tr>
<td>Maloney, E.</td>
<td>104</td>
</tr>
<tr>
<td>Mamo, D.</td>
<td>62, 122</td>
</tr>
<tr>
<td>Mancini, M.</td>
<td>62, 63, 72, 90</td>
</tr>
<tr>
<td>Mandl, R.</td>
<td>108</td>
</tr>
<tr>
<td>Mane, A.</td>
<td>75</td>
</tr>
<tr>
<td>Mann, S.</td>
<td>76, 99</td>
</tr>
<tr>
<td>Manschreck, T.</td>
<td>69</td>
</tr>
<tr>
<td>Mantua, V.</td>
<td>91</td>
</tr>
<tr>
<td>Manuela, R.</td>
<td>102</td>
</tr>
<tr>
<td>Manzano, J.</td>
<td>78</td>
</tr>
<tr>
<td>Mao, Y.</td>
<td>98</td>
</tr>
<tr>
<td>Maples, N.</td>
<td>23, 101</td>
</tr>
<tr>
<td>Marango, V.</td>
<td>124</td>
</tr>
<tr>
<td>Marcelis, M.</td>
<td>45, 86, 106, 114</td>
</tr>
<tr>
<td>Marconi, M.</td>
<td>120</td>
</tr>
<tr>
<td>Marcus, R.</td>
<td>11, 55</td>
</tr>
<tr>
<td>Marder, S.</td>
<td>3, 9, 21, 29, 98, 120</td>
</tr>
<tr>
<td>Margalit, D.</td>
<td>119</td>
</tr>
<tr>
<td>Margoese, H.</td>
<td>99</td>
</tr>
<tr>
<td>Marie-José, van Tol</td>
<td>108</td>
</tr>
<tr>
<td>Marinelli, V.</td>
<td>108</td>
</tr>
<tr>
<td>Marino, P.</td>
<td>121</td>
</tr>
<tr>
<td>Markulev, C.</td>
<td>103</td>
</tr>
<tr>
<td>Marmo, F.</td>
<td>82, 125</td>
</tr>
<tr>
<td>Marquetand, J.</td>
<td>106</td>
</tr>
<tr>
<td>Marsh, P.</td>
<td>40</td>
</tr>
<tr>
<td>Marti-Bonmati, L.</td>
<td>74</td>
</tr>
<tr>
<td>Martin, J.</td>
<td>79</td>
</tr>
<tr>
<td>Martinez-Cengotibangoa, M. 92</td>
<td></td>
</tr>
<tr>
<td>Martinez-Diaz, J.</td>
<td>75</td>
</tr>
<tr>
<td>Martinez-Perez, M.</td>
<td>75</td>
</tr>
<tr>
<td>Martin-Facklam, M.</td>
<td>77, 100</td>
</tr>
<tr>
<td>Martini, L.</td>
<td>93</td>
</tr>
<tr>
<td>Martin-Loeches, M.</td>
<td>110</td>
</tr>
<tr>
<td>Martin-Navarro, N.</td>
<td>75</td>
</tr>
<tr>
<td>Martins, C.</td>
<td>95, 108</td>
</tr>
<tr>
<td>Martins, P.</td>
<td>73</td>
</tr>
<tr>
<td>Martins-de-Souza, D.</td>
<td>59</td>
</tr>
<tr>
<td>Marzullo, G.</td>
<td>98</td>
</tr>
<tr>
<td>Mas, A.</td>
<td>83</td>
</tr>
<tr>
<td>Masana, G.</td>
<td>98</td>
</tr>
<tr>
<td>Masellis, R.</td>
<td>63, 72, 90</td>
</tr>
<tr>
<td>Mason, F.</td>
<td>122</td>
</tr>
<tr>
<td>Masramon, H.</td>
<td>102</td>
</tr>
<tr>
<td>Mathalon, D.</td>
<td>36</td>
</tr>
<tr>
<td>Matheson, S.</td>
<td>64</td>
</tr>
<tr>
<td>Matroos, G.</td>
<td>68</td>
</tr>
<tr>
<td>Matsuda, Y.</td>
<td>107</td>
</tr>
<tr>
<td>Matsumoto, K.</td>
<td>109</td>
</tr>
<tr>
<td>Matsu, J.</td>
<td>115</td>
</tr>
<tr>
<td>Matsuoka, H.</td>
<td>109</td>
</tr>
<tr>
<td>Matsuzaki, H.</td>
<td>92</td>
</tr>
<tr>
<td>Mauri, M.</td>
<td>91</td>
</tr>
<tr>
<td>Mavreas, V.</td>
<td>121</td>
</tr>
<tr>
<td>Mayoral, F.</td>
<td>103</td>
</tr>
<tr>
<td>Mayoral, M.</td>
<td>65, 125</td>
</tr>
<tr>
<td>Mazzoncini, R.</td>
<td>93</td>
</tr>
<tr>
<td>Mc Farland, J.</td>
<td>101</td>
</tr>
<tr>
<td>Mc Inerney, S.</td>
<td>101</td>
</tr>
<tr>
<td>McAlonan, G.</td>
<td>30, 74, 83, 105, 106, 108, 122</td>
</tr>
<tr>
<td>McCabe, K.</td>
<td>96, 104</td>
</tr>
<tr>
<td>McCarley, R.</td>
<td>9, 21, 47, 50, 64, 85, 88, 92</td>
</tr>
<tr>
<td>McCarthy, J.</td>
<td>66</td>
</tr>
<tr>
<td>McCarthy, P.</td>
<td>63</td>
</tr>
<tr>
<td>McCarthy, S.</td>
<td>38</td>
</tr>
<tr>
<td>McCombie, D.</td>
<td>38</td>
</tr>
<tr>
<td>McCormick, P.</td>
<td>121</td>
</tr>
<tr>
<td>McDonald, C.</td>
<td>63, 101</td>
</tr>
<tr>
<td>McDonald, G.</td>
<td>63</td>
</tr>
<tr>
<td>McDonnell, D.</td>
<td>77, 99, 121</td>
</tr>
<tr>
<td>McDougall, F.</td>
<td>103</td>
</tr>
<tr>
<td>McFarland, J.</td>
<td>63</td>
</tr>
<tr>
<td>McFarlane, A</td>
<td></td>
</tr>
<tr>
<td>McGorry, P.</td>
<td>3, 23, 27, 66, 67, 103, 124</td>
</tr>
<tr>
<td>Speaker</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>O'Toole, B.</td>
<td>80</td>
</tr>
<tr>
<td>O'Hanlon, E.</td>
<td>86</td>
</tr>
<tr>
<td>O'Donovan, M.</td>
<td>27, 50, 139</td>
</tr>
<tr>
<td>O'Donoghue, B.</td>
<td>89, 139</td>
</tr>
<tr>
<td>O'Connor, J.</td>
<td>111, 124, 139</td>
</tr>
<tr>
<td>O'Callaghan, E.</td>
<td>89, 90, 124</td>
</tr>
<tr>
<td>O'Callaghan, E.</td>
<td>88</td>
</tr>
<tr>
<td>Nutche, J.</td>
<td>64</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nuechterlein, K.</td>
<td>29, 81, 139</td>
</tr>
<tr>
<td>Nunez, D.</td>
<td>94</td>
</tr>
<tr>
<td>Nunez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nutche, J.</td>
<td>64</td>
</tr>
<tr>
<td>O'Callaghan, E.</td>
<td>89, 90, 124</td>
</tr>
<tr>
<td>O'Callaghan, E.</td>
<td>88</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nunez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>O'Callaghan, E.</td>
<td>89, 90, 124</td>
</tr>
<tr>
<td>O'Callaghan, E.</td>
<td>88</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nunez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nunez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nunez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nunez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nurjono, M.</td>
<td>96</td>
</tr>
<tr>
<td>Nunez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Nuñez-Marín, F.</td>
<td>105</td>
</tr>
<tr>
<td>Index of Speakers</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>Santos, S. 91</td>
<td></td>
</tr>
<tr>
<td>Santos, B. 100</td>
<td></td>
</tr>
<tr>
<td>Santos, C. 105</td>
<td></td>
</tr>
<tr>
<td>Santos, J. 116</td>
<td></td>
</tr>
<tr>
<td>Santos, S. 91</td>
<td></td>
</tr>
<tr>
<td>Sarappa, C. 82</td>
<td></td>
</tr>
<tr>
<td>Sarma, K. 98</td>
<td></td>
</tr>
<tr>
<td>Sarret, P. 82</td>
<td></td>
</tr>
<tr>
<td>Sarro, S. 90</td>
<td></td>
</tr>
<tr>
<td>Sartory, G. 110</td>
<td></td>
</tr>
<tr>
<td>Sasamoto, A. 107</td>
<td></td>
</tr>
<tr>
<td>Sasayama, D. 70, 92, 115</td>
<td></td>
</tr>
<tr>
<td>Sato, Y. 81</td>
<td></td>
</tr>
<tr>
<td>Satomura, Y. 85</td>
<td></td>
</tr>
<tr>
<td>Sauer, A. 115</td>
<td></td>
</tr>
<tr>
<td>Sauer, H. 64, 87, 107</td>
<td></td>
</tr>
<tr>
<td>Saunders, J. 75</td>
<td></td>
</tr>
<tr>
<td>Savitz, A. 98</td>
<td></td>
</tr>
<tr>
<td>Savoia, M. 100</td>
<td></td>
</tr>
<tr>
<td>Saw, A. 25, 39, 60, 66</td>
<td></td>
</tr>
<tr>
<td>Sawabe, H. 120</td>
<td></td>
</tr>
<tr>
<td>Sawamoto, N. 107</td>
<td></td>
</tr>
<tr>
<td>Scala, S. 95, 109</td>
<td></td>
</tr>
<tr>
<td>Scanlon, C. 63, 101</td>
<td></td>
</tr>
<tr>
<td>Scaramello, N. 120</td>
<td></td>
</tr>
<tr>
<td>Scarone, S. 74, 77, 88, 96</td>
<td></td>
</tr>
<tr>
<td>Scazufoa, M. 85</td>
<td></td>
</tr>
<tr>
<td>Scemes, S. 100</td>
<td></td>
</tr>
<tr>
<td>Schabetsberger, N. 99</td>
<td></td>
</tr>
<tr>
<td>Schacht, A. 98</td>
<td></td>
</tr>
<tr>
<td>Schachtzabel, C. 64, 87</td>
<td></td>
</tr>
<tr>
<td>Schaefer, A. 66</td>
<td></td>
</tr>
<tr>
<td>Schafer, D. 25</td>
<td></td>
</tr>
<tr>
<td>Schaffhauser, H. 77, 92</td>
<td></td>
</tr>
<tr>
<td>Schal, U. 96</td>
<td></td>
</tr>
<tr>
<td>Schall, U. 76, 86, 96, 104, 105</td>
<td></td>
</tr>
<tr>
<td>Schalling, M. 90</td>
<td></td>
</tr>
<tr>
<td>Schaufelbeger, M. 85</td>
<td></td>
</tr>
<tr>
<td>Schaufelberger, M. 85</td>
<td></td>
</tr>
<tr>
<td>Scheckner, B. 121</td>
<td></td>
</tr>
<tr>
<td>Schedowski, M. 61</td>
<td></td>
</tr>
<tr>
<td>Schewe, T. 48</td>
<td></td>
</tr>
<tr>
<td>Scheggi, D. 105</td>
<td></td>
</tr>
<tr>
<td>Scheyer, R. 73, 87</td>
<td></td>
</tr>
<tr>
<td>Schimmelmann, B. 66, 76, 90, 94, 111, 112</td>
<td></td>
</tr>
<tr>
<td>Schizophrenia Consortium (ISC), I. 113</td>
<td></td>
</tr>
<tr>
<td>Schlagenhauf, F. 62, 85</td>
<td></td>
</tr>
<tr>
<td>Schlatter, D. 77</td>
<td></td>
</tr>
<tr>
<td>Schlösser, R. 64, 87</td>
<td></td>
</tr>
<tr>
<td>Schmid, L. 108</td>
<td></td>
</tr>
<tr>
<td>Schmidt-Kastner, R. 69</td>
<td></td>
</tr>
<tr>
<td>Schmidt, A. 125</td>
<td></td>
</tr>
<tr>
<td>Schmidt, C. 99</td>
<td></td>
</tr>
<tr>
<td>Schmidt, H. 63, 101</td>
<td></td>
</tr>
<tr>
<td>Schmidt, M. 105, 116</td>
<td></td>
</tr>
<tr>
<td>Schmitz, N. 61</td>
<td></td>
</tr>
<tr>
<td>Schnack, H. 86, 108</td>
<td></td>
</tr>
<tr>
<td>Schneider, F. 95</td>
<td></td>
</tr>
<tr>
<td>Schnyder, N. 90</td>
<td></td>
</tr>
<tr>
<td>Schobel, S. 88</td>
<td></td>
</tr>
<tr>
<td>Schoevers, R. 117</td>
<td></td>
</tr>
<tr>
<td>Schofield, R. 101</td>
<td></td>
</tr>
<tr>
<td>Schooler, N. 26, 120</td>
<td></td>
</tr>
<tr>
<td>Schrag, Y. 116</td>
<td></td>
</tr>
<tr>
<td>Schreiner, A. 75, 95</td>
<td></td>
</tr>
<tr>
<td>Schroeder, J. 63</td>
<td></td>
</tr>
<tr>
<td>Schruers, K. 86</td>
<td></td>
</tr>
<tr>
<td>Schröder, J. 108</td>
<td></td>
</tr>
<tr>
<td>Schubart, C. 65</td>
<td></td>
</tr>
<tr>
<td>Schulte, P. 78, 82</td>
<td></td>
</tr>
<tr>
<td>Schultz, C. 64, 87</td>
<td></td>
</tr>
<tr>
<td>Schultze-Lutter, F. 66, 76, 87, 90, 94, 97, 109, 110, 111, 112</td>
<td></td>
</tr>
<tr>
<td>Schulz, C. 50, 62</td>
<td></td>
</tr>
<tr>
<td>Schulz, S. 71</td>
<td></td>
</tr>
<tr>
<td>Schulze, K. 68</td>
<td></td>
</tr>
<tr>
<td>Schwab, S. 3, 4, 69</td>
<td></td>
</tr>
<tr>
<td>Scott, J. 58, 68</td>
<td></td>
</tr>
<tr>
<td>Scott, R. 86, 91, 96</td>
<td></td>
</tr>
<tr>
<td>Scully, P. 88</td>
<td></td>
</tr>
<tr>
<td>Seassau, M. 114</td>
<td></td>
</tr>
<tr>
<td>Seidl, U. 108</td>
<td></td>
</tr>
<tr>
<td>Seidman, L. 36, 47, 63, 69, 73, 86, 109, 125</td>
<td></td>
</tr>
<tr>
<td>Selimovic, G. 118</td>
<td></td>
</tr>
<tr>
<td>Selten, J. 49, 56, 65, 68, 104</td>
<td></td>
</tr>
<tr>
<td>Selvaggi, P. 83</td>
<td></td>
</tr>
<tr>
<td>Seneviratne, G. 114</td>
<td></td>
</tr>
<tr>
<td>Seo, H. 113</td>
<td></td>
</tr>
<tr>
<td>serra, c. 65</td>
<td></td>
</tr>
<tr>
<td>Serret, S. 94</td>
<td></td>
</tr>
<tr>
<td>Seto, H. 65</td>
<td></td>
</tr>
<tr>
<td>Sevimlig, &amp;. 118, 119</td>
<td></td>
</tr>
<tr>
<td>Shah, G. 74</td>
<td></td>
</tr>
<tr>
<td>Shahbazi, A. 78, 117</td>
<td></td>
</tr>
<tr>
<td>Sharm, P. 74, 83</td>
<td></td>
</tr>
<tr>
<td>Shan, B. 63</td>
<td></td>
</tr>
<tr>
<td>Shan, J. 123</td>
<td></td>
</tr>
<tr>
<td>Shannnon Weickert, C. 3, 4, 49, 114</td>
<td></td>
</tr>
<tr>
<td>Sharma, M. 68</td>
<td></td>
</tr>
<tr>
<td>Shatapathy, C. 75</td>
<td></td>
</tr>
<tr>
<td>Shazad, A. 94</td>
<td></td>
</tr>
<tr>
<td>Sheinbaum, T. 60, 82</td>
<td></td>
</tr>
<tr>
<td>Shen, T. 78</td>
<td></td>
</tr>
<tr>
<td>Shenton, M. 3, 4, 64, 69, 86</td>
<td></td>
</tr>
<tr>
<td>Shepherd, A. 64, 88</td>
<td></td>
</tr>
<tr>
<td>Shergill, S. 64, 86</td>
<td></td>
</tr>
<tr>
<td>Sherin, J. 81</td>
<td></td>
</tr>
<tr>
<td>Shim, G. 108, 115</td>
<td></td>
</tr>
<tr>
<td>Shimoji, K. 107</td>
<td></td>
</tr>
<tr>
<td>Shimozaki, S. 79</td>
<td></td>
</tr>
<tr>
<td>Shin, I. 120</td>
<td></td>
</tr>
<tr>
<td>Shiraga, N. 107</td>
<td></td>
</tr>
<tr>
<td>Shirai, Y. 83</td>
<td></td>
</tr>
<tr>
<td>Shotbolt, P. 58</td>
<td></td>
</tr>
<tr>
<td>Shum, D. 72, 116</td>
<td></td>
</tr>
<tr>
<td>Sibinovic, V. 118</td>
<td></td>
</tr>
<tr>
<td>Sidel, L. 30, 11, 118</td>
<td></td>
</tr>
<tr>
<td>Siebner, H. 84</td>
<td></td>
</tr>
<tr>
<td>Siegwart, M. 66</td>
<td></td>
</tr>
<tr>
<td>Sierro, G. 116</td>
<td></td>
</tr>
<tr>
<td>Silic, A. 112</td>
<td></td>
</tr>
<tr>
<td>Silipo, G. 120</td>
<td></td>
</tr>
<tr>
<td>Silk, S. 75</td>
<td></td>
</tr>
<tr>
<td>Silva, R. 98, 102</td>
<td></td>
</tr>
<tr>
<td>Silverio, A. 105</td>
<td></td>
</tr>
<tr>
<td>Silvia, P. 97</td>
<td></td>
</tr>
<tr>
<td>Simmonite, M. 113</td>
<td></td>
</tr>
<tr>
<td>Simmons, A. 112</td>
<td></td>
</tr>
<tr>
<td>Simmons, M.</td>
<td></td>
</tr>
<tr>
<td>Simon, A. 64</td>
<td></td>
</tr>
<tr>
<td>Simon, G. 93</td>
<td></td>
</tr>
<tr>
<td>Simon, J. 62</td>
<td></td>
</tr>
<tr>
<td>Simons, C. 70</td>
<td></td>
</tr>
<tr>
<td>Sinclair, D. 115</td>
<td></td>
</tr>
<tr>
<td>Singer, W. 84, 115</td>
<td></td>
</tr>
<tr>
<td>Sinibaldi, L. 63, 83, 84, 90</td>
<td></td>
</tr>
<tr>
<td>Siriani, M. 80</td>
<td></td>
</tr>
<tr>
<td>Stinikova, T. 63</td>
<td></td>
</tr>
<tr>
<td>Siu, C. 77, 78, 83, 120</td>
<td></td>
</tr>
<tr>
<td>Sivapalan, S. 101</td>
<td></td>
</tr>
<tr>
<td>Skibinska, M. 69, 70, 71, 112, 114</td>
<td></td>
</tr>
<tr>
<td>Skilleter, A. 63</td>
<td></td>
</tr>
<tr>
<td>Skimminge, A. 81</td>
<td></td>
</tr>
<tr>
<td>Skovgaard, A. 67, 87</td>
<td></td>
</tr>
<tr>
<td>Slachyevsky, A. 73</td>
<td></td>
</tr>
<tr>
<td>Slavkovic, V. 118</td>
<td></td>
</tr>
<tr>
<td>Slooff, C. 121</td>
<td></td>
</tr>
<tr>
<td>Slotema, C. 119</td>
<td></td>
</tr>
<tr>
<td>Sly, K. 76</td>
<td></td>
</tr>
<tr>
<td>Smeets, H. 67, 68</td>
<td></td>
</tr>
<tr>
<td>Smeets, F. 125</td>
<td></td>
</tr>
<tr>
<td>Smesny, S. 107</td>
<td></td>
</tr>
<tr>
<td>Smid, H. 116</td>
<td></td>
</tr>
<tr>
<td>Smieskova, R. 64, 108</td>
<td></td>
</tr>
<tr>
<td>Smith, E. 94</td>
<td></td>
</tr>
<tr>
<td>Smith, M. 91, 105, 123</td>
<td></td>
</tr>
</tbody>
</table>
Smith, S. 52, 75
Smyth, N. 79
Snyder, S. 60
Soek Mun Yuen, E. 78
Sofocleous, C. 94
Segaard, L. 60
Solano-Ruipérez, R. 116
Solomon, M. 60
Solowij, N. 70
Somers, M. 70
Sommer, I. 3, 31, 44, 57, 58, 68, 70, 76, 98, 106, 107, 118, 119
Sommer, J. 64, 86
Son, W. 113
Song, L. 72
Song, Y. 119
Sørensen, M. 88
Soutullo, C. 105
Souza, C. 98, 105
Souza, R. 105
Sowden, S. 67, 89, 112
Soygur, H. 77
Spang, J. 72
Specht, K. 85
Spedding, M. 110
Sperner-Unterweger, B. 11, 43
Spindola, L. 105
Spiros, A. 99
Sponheim, S. 86
Sporns, O. 35
Sridhar, N. 121
Srivastavaradajah, S. 120
Stain, H. 86, 104, 123
Stam, K. 107
Stanfield, A. 85
Stauffer, V. 78, 91
Stefanovic, M. 112
Steinberg, T. 87
Steinbusch, H. 69
Steiner, J. 59
Steinhause, H. 65, 109
Stenson, M. 105
Stentebjerg-Olesen, M. 87
Stephano, S. 85
Sterk, B. 66
Sterkjaer, F. 118
Stevens, A. 119
Stevens, H. 110
Stevens, J. 117
Stevens, K. 78
Steward, L. 104
Stewart, M. 120
Stewart, R. 101, 110, 111
Steylen, P. 109
Stieglitz, R. 64
Stiekema, A. 117
Stilo, S. 67, 80, 89, 111, 112
Stock, E. 124
Stoesser, D. 109
Storrs, A. 109
Stouten, L. 101
Stowers, C. 79
Stowkowy, J. 80, 119
Stratmann, M. 64, 84, 86, 106, 107
Stratta, P. 78
Straube, B. 84, 107
Strauss, G. 4, 97, 109
Stroup, S. 122
Studerus, E. 63, 64, 108, 114, 123
Study Group-Presenter Craig
Suazo, V. 110
Subotnik, K. 81
Subramaniam, K. 117
Suckling, C. 70
Suckow, R. 70
Suga, M. 85
Sugihara, G. 64
Sugurladze, S. 115
Suhara, T. 117
Sullivan, E. 115
Suzuki, M. 65, 107
Takahashi, H. 107, 117
Takahashi, T. 65, 107
Takaki, M. 91
Takano, Y. 85
Takei, N. 3, 92, 105
Takizawa, R. 85
Tamagni, C. 64, 108, 114
Tamminga, C. 3, 11, 43, 50
Tan, E. 81, 101
Tanaka, H. 92
Tanaka, M. 40
Tanaka, Y. 107
Tang, J. 76
Tansella, M. 93, 108
Tanskehan, A. 82
Tao, H. 117
Tapia-Casellas, C. 87, 98
Taricone, I. 20
Tarragó, J. 71
Tarricone, I. 19, 20, 30, 111
Tarrier, N. 74
Tas, C. 79
Taurisano, P. 62, 63, 72, 83, 84
Taxis, K. 121
Taylor, D. 98, 121
Taylor, H. 112, 114
Taylor, L. 66, 76, 93, 117
Tecic, T. 109
Tee, S. 125
Tempelaar, W. 65
ten Have, M. 102, 125
ten Velden Hegelstad, W. 123
Tenback, D. 82, 95, 124
Teo, C. 76, 83, 99
Teraishi, T. 70, 92, 115
Terence, M. 95
Terlevic, R. 108
Termorshuizen, F. 67
Tervonen, O. 107
Terwisscha van Scheltinga, A. 47
Tettamanti, M. 123
Thak, J. 81
Thakkar, K. 62
Thanju, A. 116
Theochari, E. 94, 124
Thermenos, H. 69, 86, 109, 125
Thirthalli, J. 66
Thomann, P. 63, 108
Thomas, N. 66, 93
Thomas, P. 62, 65, 75, 112
Thompson, A. 4, 67, 79
Thomson, D. 61, 70
Thomson, I. 110
Thornton, A. 72
Thorup, A. 109, 123, 124
Tiedt, L. 86
Tighe, O. 61
Tihan, A. 124
Tijssen, M. 82
Tirkkonen, J. 95
Todd, J. 73, 86, 104, 106
Toognin, S. 108
Tollenaar, P. 101
Tomasetti, C. 69, 125
Tooney, P. 70, 90, 91, 96
Tomialen, M. 116
Torra, M. 98
Tosato, S. 19, 39, 93, 124
Tosic-Golubovic, S. 118
Toulopoulou, T. 62, 85
Towell, T. 79
Trabaj-Vega, P. 75
Trapp, E. 117
triас, g. 65
Tricklebank, M. 61
Trinidad, P. 94, 97
Trotta, A. 4, 30, 92, 109
Tsai, S. 115
Tsalatsas, E. 94
Tsan, J. 124
Tsang, J. 111
Tseng, H. 63, 123
Toussoutsolaski, C.
Touss, M. 109, 125
Tsuboi, T. 122
Tszuino, N. 107
Tukel, R. 124
Tulloch, A. 111
Tully, L. 4, 106
Tundia, N. 70
Turkheimer, F. 120
Turkington, D. 10, 23, 24, 37, 74
Turner, K. 71
Turner, N. 89, 124
Tuulio-Henriksson, A. 116
Tyllis, P. 102
Tzouli, S. 121
Uchida, H. 4, 122
Uchida, T. 109
Uchitomi, Y. 91
<table>
<thead>
<tr>
<th>Speakers</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>van der Valk, R.</td>
<td>95, 109</td>
</tr>
<tr>
<td>van der Veld, J.</td>
<td>106</td>
</tr>
<tr>
<td>van der Ven, E.</td>
<td>65, 68, 104</td>
</tr>
<tr>
<td>van der Waerdt, S.</td>
<td>95</td>
</tr>
<tr>
<td>van Dijk, D.</td>
<td>82, 116, 125</td>
</tr>
<tr>
<td>Van Dorn, R.</td>
<td>124</td>
</tr>
<tr>
<td>van Dorselaer, S.</td>
<td>102, 116</td>
</tr>
<tr>
<td>Van Duin, E.</td>
<td>90</td>
</tr>
<tr>
<td>van Eijk, K.</td>
<td>68, 70, 116</td>
</tr>
<tr>
<td>van Engeland, H.</td>
<td>113, 116</td>
</tr>
<tr>
<td>Van Erp, T.</td>
<td>81</td>
</tr>
<tr>
<td>van Es, F.</td>
<td>116</td>
</tr>
<tr>
<td>van Gasselt, A.</td>
<td>107</td>
</tr>
<tr>
<td>van Gastel, W.</td>
<td>65</td>
</tr>
<tr>
<td>Van Gool, A.</td>
<td>97, 119</td>
</tr>
<tr>
<td>van Haelst, I.</td>
<td>78</td>
</tr>
<tr>
<td>van Haren, N.</td>
<td>68, 86, 87, 95, 108, 113, 115</td>
</tr>
<tr>
<td>van Harten, P.</td>
<td>68, 82, 95, 124</td>
</tr>
<tr>
<td>van Kroonenburgh, M.</td>
<td>114</td>
</tr>
<tr>
<td>van Laere, K.</td>
<td>106</td>
</tr>
<tr>
<td>van Lutterveld, R.</td>
<td>76, 107</td>
</tr>
<tr>
<td>van Nierop, M.</td>
<td>102</td>
</tr>
<tr>
<td>Van Os, J.</td>
<td>3, 9, 10, 21, 27, 28, 32, 34, 56, 59, 65, 66, 67, 68, 69, 81, 86, 87, 90, 97, 102, 106, 114, 115, 119, 125</td>
</tr>
<tr>
<td>Van Snellenberg, J.</td>
<td>94</td>
</tr>
<tr>
<td>van Tricht, M.</td>
<td>115</td>
</tr>
<tr>
<td>van Winkel, R.</td>
<td>35, 66, 68, 70, 90, 102, 125</td>
</tr>
<tr>
<td>Vancampfort, D.</td>
<td>48</td>
</tr>
<tr>
<td>Vanover, K.</td>
<td>11</td>
</tr>
<tr>
<td>van Brink, W.</td>
<td>125</td>
</tr>
<tr>
<td>van Buuren, M.</td>
<td>107</td>
</tr>
<tr>
<td>van den Brink, W.</td>
<td>125</td>
</tr>
<tr>
<td>van den Buuse, M.</td>
<td>26</td>
</tr>
<tr>
<td>van den Heuvel, E.</td>
<td>35, 61, 86, 116, 121</td>
</tr>
<tr>
<td>Van den Heuvel, M.</td>
<td>35, 61, 86</td>
</tr>
<tr>
<td>van den Hout, I.</td>
<td>95</td>
</tr>
<tr>
<td>van der Doef, T.</td>
<td>113</td>
</tr>
<tr>
<td>Van der Gaag, M.</td>
<td>27, 74, 101, 110</td>
</tr>
<tr>
<td>van der Heijden, F.</td>
<td>108</td>
</tr>
<tr>
<td>van der Helm, M.</td>
<td>101</td>
</tr>
<tr>
<td>van der Helm, F.</td>
<td>109</td>
</tr>
<tr>
<td>van der Krieke, L.</td>
<td>118</td>
</tr>
<tr>
<td>van der Leeuw, C.</td>
<td>114</td>
</tr>
<tr>
<td>van der Meulen, L.</td>
<td>95</td>
</tr>
<tr>
<td>Van der Helm, M.</td>
<td>101</td>
</tr>
<tr>
<td>van der Meulen, L.</td>
<td>95</td>
</tr>
<tr>
<td>van der Meulen, L.</td>
<td>95</td>
</tr>
<tr>
<td>van der Meer, J.</td>
<td>61</td>
</tr>
<tr>
<td>Van der Meer, L.</td>
<td>61, 62, 84, 106, 117</td>
</tr>
<tr>
<td>van der Meer, L.</td>
<td>62, 84, 106, 117</td>
</tr>
<tr>
<td>Velthorst, E.</td>
<td>4, 97, 104, 110, 119</td>
</tr>
<tr>
<td>Veltman, D.</td>
<td>107</td>
</tr>
<tr>
<td>Vendramini, A.</td>
<td>83</td>
</tr>
<tr>
<td>Ventura, J.</td>
<td>81</td>
</tr>
<tr>
<td>Vercammen, A.</td>
<td>63, 84, 113</td>
</tr>
<tr>
<td>Verdyczia, M.</td>
<td>101</td>
</tr>
<tr>
<td>Verduran, M.</td>
<td>114</td>
</tr>
<tr>
<td>Verhoeven, W.</td>
<td>109</td>
</tr>
<tr>
<td>Verkooijen, S.</td>
<td>118</td>
</tr>
<tr>
<td>Vermeulen, L.</td>
<td>95</td>
</tr>
<tr>
<td>Vernon, A.</td>
<td>121</td>
</tr>
<tr>
<td>Verwij, K.</td>
<td>67</td>
</tr>
<tr>
<td>Vesterager, L.</td>
<td>101, 105, 124</td>
</tr>
<tr>
<td>Viana, A.</td>
<td>60</td>
</tr>
<tr>
<td>Viechtbauer, W.</td>
<td>66</td>
</tr>
<tr>
<td>Viertioti, S.</td>
<td>68</td>
</tr>
<tr>
<td>Vilamala, S.</td>
<td>79</td>
</tr>
<tr>
<td>Vila-Rodriguez, F.</td>
<td>72</td>
</tr>
<tr>
<td>Villa, H.</td>
<td>60</td>
</tr>
<tr>
<td>Villarreal, M.</td>
<td>83, 105</td>
</tr>
<tr>
<td>Villavicencio, P.</td>
<td>102, 104</td>
</tr>
<tr>
<td>Villella, G.</td>
<td>80</td>
</tr>
<tr>
<td>Villeneuve, K.</td>
<td>75</td>
</tr>
<tr>
<td>Vingerhoets, C.</td>
<td>107</td>
</tr>
<tr>
<td>Vink, M.</td>
<td>61, 107</td>
</tr>
<tr>
<td>Vinogradov, S.</td>
<td>36, 117</td>
</tr>
<tr>
<td>Vita, A.</td>
<td>3, 4, 19, 44</td>
</tr>
<tr>
<td>Vitalis, T.</td>
<td>114</td>
</tr>
<tr>
<td>Vizzotto, A.</td>
<td>95</td>
</tr>
<tr>
<td>Vogele, K.</td>
<td>61, 95</td>
</tr>
<tr>
<td>Vogt, A.</td>
<td>77</td>
</tr>
<tr>
<td>Voisey, J.</td>
<td>113</td>
</tr>
<tr>
<td>Vollebergh, W.</td>
<td>97</td>
</tr>
<tr>
<td>von Hörsten, S.</td>
<td>81</td>
</tr>
<tr>
<td>von Kienlin, M.</td>
<td>84</td>
</tr>
<tr>
<td>von Reventlow, H.</td>
<td>87, 97, 109, 110, 133</td>
</tr>
<tr>
<td>Vorstman, J.</td>
<td>113</td>
</tr>
<tr>
<td>Vosse, R.</td>
<td>92</td>
</tr>
<tr>
<td>Vosloo, V.</td>
<td>113</td>
</tr>
<tr>
<td>von Horsten, S.</td>
<td>81</td>
</tr>
<tr>
<td>von Kienlin, M.</td>
<td>84</td>
</tr>
<tr>
<td>von Reventlow, H.</td>
<td>87, 97, 109, 110, 133</td>
</tr>
<tr>
<td>Vorstman, J.</td>
<td>113</td>
</tr>
<tr>
<td>Vosse, R.</td>
<td>92</td>
</tr>
<tr>
<td>Vosloo, V.</td>
<td>113</td>
</tr>
<tr>
<td>von Horsten, S.</td>
<td>81</td>
</tr>
<tr>
<td>von Kienlin, M.</td>
<td>84</td>
</tr>
<tr>
<td>von Reventlow, H.</td>
<td>87, 97, 109, 110, 133</td>
</tr>
<tr>
<td>Vorstman, J.</td>
<td>113</td>
</tr>
<tr>
<td>Vosse, R.</td>
<td>92</td>
</tr>
<tr>
<td>Vosloo, V.</td>
<td>113</td>
</tr>
<tr>
<td>von Horsten, S.</td>
<td>81</td>
</tr>
<tr>
<td>von Kienlin, M.</td>
<td>84</td>
</tr>
<tr>
<td>von Reventlow, H.</td>
<td>87, 97, 109, 110, 133</td>
</tr>
<tr>
<td>Vorstman, J.</td>
<td>113</td>
</tr>
<tr>
<td>Vosse, R.</td>
<td>92</td>
</tr>
<tr>
<td>Vosloo, V.</td>
<td>113</td>
</tr>
<tr>
<td>von Horsten, S.</td>
<td>81</td>
</tr>
<tr>
<td>von Kienlin, M.</td>
<td>84</td>
</tr>
<tr>
<td>von Reventlow, H.</td>
<td>87, 97, 109, 110, 133</td>
</tr>
<tr>
<td>Wicks, S.</td>
<td>Wykes, T. 3, 4, 13, 23, 37, 46, 72, 74, 93</td>
</tr>
<tr>
<td>Widenschwendter, C.</td>
<td>Wyl, R.</td>
</tr>
<tr>
<td>Wiedemann, G.</td>
<td>Wynne, K. 75</td>
</tr>
<tr>
<td>Wiersma, D.</td>
<td>Xue, Z. 117, 124</td>
</tr>
<tr>
<td>Wiggers, M.</td>
<td>Xue, M. 103</td>
</tr>
<tr>
<td>Wicks, S.</td>
<td>Xue, M. 113</td>
</tr>
<tr>
<td>Widschwendter, C.</td>
<td>Yang, B. 124</td>
</tr>
<tr>
<td>Wiedemann, G.</td>
<td>Yang, H. 113</td>
</tr>
<tr>
<td>Wiersma, D.</td>
<td>Yang, S. 81</td>
</tr>
<tr>
<td>Wiggers, M.</td>
<td>Yang, S.</td>
</tr>
<tr>
<td>Widdershuis, G.</td>
<td>Yang, X. 62</td>
</tr>
<tr>
<td>Wickers, M.</td>
<td>Yao, N. 108</td>
</tr>
<tr>
<td>Wilkinson, I.</td>
<td>Yaqub, M. 113</td>
</tr>
<tr>
<td>Wills, S.</td>
<td>Yağçıoğlu, A. 77</td>
</tr>
<tr>
<td>Wilkins, L.</td>
<td>Yağçıoğlu, S. 77</td>
</tr>
<tr>
<td>Wilkinson, I.</td>
<td>Yahata, N. 116</td>
</tr>
<tr>
<td>Williams, G.</td>
<td>Yalcin, N. 78, 79, 80</td>
</tr>
<tr>
<td>Williams, J.</td>
<td>Yalınçetin, B. 118, 119</td>
</tr>
<tr>
<td>Williams, S.</td>
<td>Yamasue, H. 116</td>
</tr>
<tr>
<td>Wilmers, H.</td>
<td>Yang, B. 124</td>
</tr>
<tr>
<td>Wilson, F.</td>
<td>Yang, H. 113</td>
</tr>
<tr>
<td>Wilson, J.</td>
<td>Yang, J. 74</td>
</tr>
<tr>
<td>Winchester, C.</td>
<td>Yang, S. 81</td>
</tr>
<tr>
<td>Windhorst, A.</td>
<td>Yang, X. 62</td>
</tr>
<tr>
<td>Winkler, A.</td>
<td>Yao, N. 108</td>
</tr>
<tr>
<td>Winter, G.</td>
<td>Yaqub, M. 113</td>
</tr>
<tr>
<td>Winterer, G.</td>
<td>Yavaş, E. 118</td>
</tr>
<tr>
<td>Witcher, J.</td>
<td>Yavorsky, C. 80, 97</td>
</tr>
<tr>
<td>Wittchen, H.</td>
<td>Yazıcı, M. 77</td>
</tr>
<tr>
<td>Wittorf, A.</td>
<td>Yelland, G. 118</td>
</tr>
<tr>
<td>Wobrock, T.</td>
<td>Yi, J. 88</td>
</tr>
<tr>
<td>Wojciak, R.</td>
<td>Yi, W. 75, 96</td>
</tr>
<tr>
<td>Wolever, T.</td>
<td>Yilmaz, A. 125</td>
</tr>
<tr>
<td>Wolf, R.</td>
<td>Yoffe, R. 110</td>
</tr>
</tbody>
</table>
Clinical trials are the most important way to evaluate the safety and efficacy of new medicines. We also know that ethnicity, lifestyle and genetics affect how medicines work in individual patients. But only 17% of participants in trials today represent minority populations.\(^1\) This is especially challenging because many trials focus specifically on health conditions that impact minority groups at higher rates.

It's our responsibility to help close the gap. By 2050, minorities will make up 42% of the U.S. population.\(^2\) We need more diverse representation in clinical trials to ensure treatments are safe and effective for all the people who use them. And we need your help.

For more information, or to learn about becoming an investigator, call 1-877-CTLILLY. Or, visit impact.nmanet.org.

---


Clinical trials are the most important way to evaluate the safety and efficacy of new medicines. We also know that ethnicity, lifestyle and genetics affect how medicines work in individual patients. But only 17% of participants in trials today represent minority populations. This is especially challenging because many trials focus specifically on health conditions that impact minority groups at higher rates.

It's our responsibility to help close the gap. By 2050, minorities will make up 42% of the U.S. population. We need more diverse representation in clinical trials to ensure treatments are safe and effective for all the people who use them. And we need your help.

For more information, or to learn about becoming an investigator, call 1-877-CTLILLY. Or, visit impact.nmanet.org.
The name “Otsuka” translates to “major milestone”. And indeed, for over 85 years, Otsuka’s people have achieved major milestones in their quest to create new products for better health. Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal, and central nervous systems, and to treat cancer and ophthalmic disorders. We’ve funded new research, supported new clinical trials, and pursued the development of new medications – an unfaltering commitment of energy and resources with one goal in mind – to create new products for better health worldwide.